
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY
I Background Information:
A 510(k) Number
K211748
B Applicant
Selux Diagnostics, Inc
C Proprietary and Established Names
Selux AST System; Model AST Gen 1.0
D Regulatory Information
Product Regulation
Classification Panel
Code(s) Section
21 CFR 866.1645 - Fully
Automated Short-Term
LON Class II Incubation Cycle MI - Microbiology
Antimicrobial
Susceptibility System
21 CFR 866.1640 -
LTT Class II Antimicrobial MI - Microbiology
susceptibility test powder
21 CFR 866.1640 -
LTW Class II Antimicrobial MI - Microbiology
susceptibility test powder
II Submission/Device Overview:
A Purpose for Submission:
To obtain substantial equivalence determination for Gram-negative organisms tested with the
Selux AST System to determine the minimum inhibitory concentration of specific antimicrobials
with specific Gram-negative organisms.
B Measurand:
Antimicrobial Reportable Range
Amikacin ≤0.12 to ≥256 μg/mL
Amoxicillin-Clavulanate ≤0.5 to ≥128 μg/mL
Ampicillin ≤0.25 to ≥128 μg/mL
Ampicillin-Sulbactam ≤0.5 to ≥128 μg/mL
Food and Drug Administration Updated: 5/30/2023
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
www.fda.gov

[Table 1 on page 1]
	Product		Classification		Regulation		Panel
	Code(s)				Section		
LON			Class II	21 CFR 866.1645 - Fully
Automated Short-Term
Incubation Cycle
Antimicrobial
Susceptibility System			MI - Microbiology
LTT			Class II	21 CFR 866.1640 -
Antimicrobial
susceptibility test powder			MI - Microbiology
LTW			Class II	21 CFR 866.1640 -
Antimicrobial
susceptibility test powder			MI - Microbiology

[Table 2 on page 1]
	Amikacin			≤0.12 to ≥256 μg/mL	
	Amoxicillin-Clavulanate			≤0.5 to ≥128 μg/mL	
	Ampicillin			≤0.25 to ≥128 μg/mL	
	Ampicillin-Sulbactam			≤0.5 to ≥128 μg/mL	

--- Page 2 ---
Antimicrobial Reportable Range
Aztreonam ≤0.03 to ≥128 μg/mL
Cefazolin ≤0.12 to ≥128 μg/mL
Cefepime ≤0.25 to ≥128 μg/mL
Cefoxitin ≤1 to ≥128 μg/mL
Ceftazidime ≤0.25 to ≥64 μg/mL
Ceftazidime-Avibactam ≤0.12 to ≥64 μg/mL
Ceftriaxone ≤0.25 to ≥32 μg/mL
Ciprofloxacin ≤0.03 to ≥16 μg/mL
Eravacycline ≤0.016 to ≥4 μg/mL
Ertapenem ≤0.03 to ≥16 μg/mL
Gentamicin ≤0.06 to ≥64 μg/mL
Imipenem-Relebactam ≤0.03 to ≥128 μg/mL
Levofloxacin ≤0.06 to ≥32 μg/mL
Meropenem ≤0.12 to ≥64 μg/mL
Meropenem-Vaborbactam ≤0.06 to ≥64 μg/mL
Minocycline ≤0.25 to ≥64 μg/mL
Piperacillin-Tazobactam ≤0.25 to ≥512 μg/mL
Tobramycin ≤0.12 to ≥128 μg/mL
Trimethoprim-Sulfamethoxazole ≤0.12 to ≥32 μg/mL
C Type of Test:
Quantitative antimicrobial susceptibility test (AST) system that utilizes colorimetric, oxidation-
reduction and growth-based strategies to determine the minimum inhibitory concentration (MIC)
of specific antimicrobial-organism combinations.
III Intended Use/Indications for Use:
A Intended Use(s):
The Selux AST System is intended to be used for the automated quantitative or qualitative
susceptibility testing for most clinically significant aerobic microorganisms. The Selux AST
System does not provide organism identification.
B Indication(s) for Use:
The Selux Gram-Negative Panel is intended for use with the Selux AST System as an in vitro
test to determine the susceptibility of isolated colonies of specific gram-negative bacilli to
specific antimicrobial agents when used as instructed.
The Selux Gram-Negative Panel is a quantitative test for the following antimicrobial agents with
the specific organisms identified below:
• Amikacin: Pseudomonas aeruginosa
• Amoxicillin-Clavulanate: Escherichia coli, Klebsiella species (including K. oxytoca, K.
pneumoniae), Proteus mirabilis
• Ampicillin: Escherichia coli, Proteus mirabilis
• Ampicillin-Sulbactam: Acinetobacter baumannii complex, Escherichia coli, Klebsiella
species (including K. oxytoca, K. pneumoniae), Proteus mirabilis, Proteus vulgaris
• Aztreonam: Escherichia coli
K211748 - Page 2 of 43

[Table 1 on page 2]
	Aztreonam			≤0.03 to ≥128 μg/mL	
	Cefazolin			≤0.12 to ≥128 μg/mL	
	Cefepime			≤0.25 to ≥128 μg/mL	
	Cefoxitin			≤1 to ≥128 μg/mL	
	Ceftazidime			≤0.25 to ≥64 μg/mL	
	Ceftazidime-Avibactam			≤0.12 to ≥64 μg/mL	
	Ceftriaxone			≤0.25 to ≥32 μg/mL	
	Ciprofloxacin			≤0.03 to ≥16 μg/mL	
	Eravacycline			≤0.016 to ≥4 μg/mL	
	Ertapenem			≤0.03 to ≥16 μg/mL	
	Gentamicin			≤0.06 to ≥64 μg/mL	
	Imipenem-Relebactam			≤0.03 to ≥128 μg/mL	
	Levofloxacin			≤0.06 to ≥32 μg/mL	
	Meropenem			≤0.12 to ≥64 μg/mL	
	Meropenem-Vaborbactam			≤0.06 to ≥64 μg/mL	
	Minocycline			≤0.25 to ≥64 μg/mL	
	Piperacillin-Tazobactam			≤0.25 to ≥512 μg/mL	
	Tobramycin			≤0.12 to ≥128 μg/mL	
	Trimethoprim-Sulfamethoxazole			≤0.12 to ≥32 μg/mL	

--- Page 3 ---
• Cefazolin: Escherichia coli, Klebsiella pneumoniae
• Cefepime: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae complex,
Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae,
Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens
• Cefoxitin: Escherichia coli, Klebsiella species (including K. oxytoca, K. pneumoniae),
Morganella morganii
• Ceftazidime: Citrobacter species (including C. freundii complex, C. koseri), Enterobacter
cloacae complex, Escherichia coli, Klebsiella species (including K. aerogenes, K. oxytoca,
K. pneumoniae), Proteus mirabilis, Proteus vulgaris, Serratia marcescens
• Ceftazidime-Avibactam: Citrobacter freundii complex, Citrobacter koseri, Enterobacter
cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella
pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Pseudomonas
aeruginosa, Serratia marcescens
• Ceftriaxone: Citrobacter freundii complex, Citrobacter koseri, Escherichia coli, Klebsiella
aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis
• Ciprofloxacin: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae
complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae,
Morganella morganii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa
• Eravacycline: Citrobacter freundii complex, Enterobacter cloacae complex, Escherichia
coli, Klebsiella oxytoca
• Ertapenem: Citrobacter freundii complex, Citrobacter koseri, Escherichia coli, Klebsiella
oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris,
Serratia marcescens
• Gentamicin: Citrobacter species (including C. freundii complex, C. koseri), Enterobacter
cloacae complex, Escherichia coli, Klebsiella species (including K. aerogenes, K. oxytoca,
K. pneumoniae), Proteus species (including P. mirabilis, P. vulgaris), Pseudomonas
aeruginosa, Serratia marcescens
• Imipenem-Relebactam: Citrobacter freundii complex, Citrobacter koseri, Escherichia coli,
Klebsiella oxytoca, Pseudomonas aeruginosa
• Levofloxacin: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae
complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae,
Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens
• Meropenem: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae
complex, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii,
Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens
• Meropenem-Vaborbactam: Citrobacter freundii complex, Citrobacter koseri, Enterobacter
cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella
pneumoniae, Morganella morganii, Serratia marcescens
• Minocycline: Escherichia coli, Klebsiella species (including K. aerogenes, K. oxytoca, K.
pneumoniae)
• Piperacillin-Tazobactam: Citrobacter koseri, Escherichia coli, Klebsiella pneumoniae,
Morganella morganii, Proteus mirabilis, Proteus vulgaris
• Tobramycin: Pseudomonas aeruginosa
• Trimethoprim-Sulfamethoxazole: Enterobacter cloacae complex, Klebsiella species
(including K. aerogenes, K. oxytoca, K. pneumoniae)
K211748 - Page 3 of 43

--- Page 4 ---
C Special Conditions for Use Statement(s):
• Rx - For Prescription Use Only
The following limitations were added to the device labeling based on performance demonstrated
in the current submission:
• The ability of the Selux AST system to detect resistance in the following
antimicrobial/organism combinations is unknown because an insufficient number of resistant
isolates were available at the time of comparative testing:
• Ampicillin-Sulbactam: Proteus vulgaris
• Cefepime: Klebsiella aerogenes, Morganella morganii, Proteus vulgaris, Serratia
marcescens
• Cefoxitin: Klebsiella oxytoca
• Ceftazidime-avibactam: Citrobacter koseri, Klebsiella aerogenes, Klebsiella oxytoca,
Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens
• Ciprofloxacin: Citrobacter koseri, Proteus vulgaris
• Eravacycline: Escherichia coli, Klebsiella oxytoca
• Ertapenem: Citrobacter koseri, Klebsiella oxytoca, Morganella morganii, Proteus
mirabilis, Proteus vulgaris
• Gentamicin: Klebsiella aerogenes, Morganella morganii, Proteus vulgaris, Serratia
marcescens
• Imipenem-Relebactam: Citrobacter koseri, Klebsiella aerogenes, Klebsiella oxytoca
• Levofloxacin: Citrobacter koseri
• Meropenem: Citrobacter koseri, Klebsiella oxytoca, Morganella morganii, Proteus
vulgaris
• Meropenem-vaborbactam: Citrobacter koseri, Klebsiella aerogenes, Klebsiella oxytoca,
Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens
• Minocycline: Klebsiella oxytoca
• Piperacillin-tazobactam: Citrobacter koseri, Proteus mirabilis, Proteus vulgaris
• Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Amikacin: Acinetobacter baumannii
• Ampicillin: Proteus mirabilis when the Selux MIC is 2 μg/mL due to one very major
error
• Ampicillin-Sulbactam: Proteus vulgaris when the Selux MIC is 32 μg/mL due to 3 major
errors
• Aztreonam: Pseudomonas aeruginosa
• Cefazolin: Proteus mirabilis
• Cefepime: Klebsiella aerogenes when the Selux MIC is ≥64 μg/mL due to 2 major errors,
Pseudomonas aeruginosa
• Cefoxitin: Proteus mirabilis, Proteus vulgaris
• Ceftazidime: Acinetobacter baumannii, Pseudomonas aeruginosa
• Ceftriaxone: Enterobacter cloacae, Serratia marcescens
• Ciprofloxacin: Serratia marcescens
• Eravacycline: Klebsiella pneumoniae
• Ertapenem: Citrobacter freundii complex when the Selux MIC is 2, 4, or 8 μg/mL due to
3 major errors, Enterobacter cloacae, Klebsiella aerogenes
• Gentamicin: Pseudomonas aeruginosa when the Selux MIC is ≤0.06 μg/mL
K211748 - Page 4 of 43

--- Page 5 ---
• Imipenem: Acinetobacter baumannii
• Imipenem-Relebactam: Klebsiella oxytoca when the Selux MIC is 4 µg/mL due to one
major error, Klebsiella aerogenes, Klebsiella pneumoniae
• Levofloxacin: Citrobacter freundii complex when the Selux MIC is 2 μg/mL due to 2
major errors, Klebsiella aerogenes when the Selux MIC is 2 μg/mL due to one major
error, Pseudomonas aeruginosa
• Meropenem: Acinetobacter baumannii, Citrobacter freundii complex when the Selux
MIC is 16 or 32 μg/mL due to 3 major errors, Serratia marcescens when the Selux MIC
is 16 or 32 μg/mL due to 4 major errors
• Meropenem-Vaborbactam: Proteus mirabilis, Proteus vulgaris
• Minocycline: Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae when
the Selux MIC is 4 μg/mL due to 2 very major errors
• Piperacillin-Tazobactam: Acinetobacter baumannii, Citrobacter freundii, Enterobacter
cloacae, Klebsiella aerogenes, Pseudomonas aeruginosa, Serratia marcescens
• Trimethoprim-Sulfamethoxazole: Citrobacter freundii, Escherichia coli
D Special Instrument Requirements:
Selux AST System, Software version 1, subversion 8.168
IV Device/System Characteristics:
A Device Description:
The Selux AST System is an antimicrobial susceptibility test (AST) system that consists of a
Sample Prep Station, an Inoculator, an Analyzer, a computer workstation, and the reagents and
consumables required to perform AST testing. The system is operated via software that guides
users through the manual sample preparation process and operates the automated Inoculator and
Analyzer. The software includes an algorithm that enables the system to determine the
susceptibility of an organism to the variety of antimicrobials provided in the Selux AST panels.
The system is designed so that only Gram stain information is required to initiate testing to select
the gram-negative or gram-positive antimicrobial panel. While complete system testing can be
performed without species-level identification, this information is required for the system to
report susceptibility results. Species identification information can be either manually input to
the Selux system or automatically downloaded from the laboratory information system (LIS) at
any time, once the sample ID is entered into the LIS.
The Selux AST Systems provides the following consumables: AST panels, panel lids, tubes and
caps for sample prep, troughs for inoculator, McFarland Standards for densitometer performance
checks, inoculator pipette tips, inoculator waste bins, inoculator growth media, inoculator
cleaning solution, analyzer reagent packs, analyzer liquid waste disinfectant tablets, analyzer
absorbent waste pads, and an analyzer solid waste bag.
The Selux AST System is divided into three primary AST steps performed at three different
stations: workbench (for sample preparation), panel inoculator (for inoculation), and AST
analyzer (for antimicrobial susceptibility testing), as described in detail in the Device Description
section of K211759.
The Selux AST System with the Gram-Negative Panel can determine the MIC of various
antimicrobials when tested against specific organisms Table 1.
K211748 - Page 5 of 43

--- Page 6 ---
Table 1. Reportable MIC Ranges and Organism-Specific Breakpoints for Antimicrobials included in the Selux AST
System, Gram-Negative Panel
Selux AST System FDA-Recognized/
Antimicrobial Organism Group Reportable Range Approved Breakpoints (μg/mL)
(μg/mL) S I R
Amikacin Pseudomonas aeruginosa ≤0.12 to ≥256 ≤16 32 ≥64
Amoxicillin-
Enterobacterales ≤0.5 to ≥128 ≤8 16 ≥32
Clavulanate
Ampicillin Enterobacterales ≤0.25 to ≥128 ≤8 16 ≥32
Ampicillin- Acinetobacter baumannii complex
≤0.5 to ≥128 ≤8 16 ≥32
Sulbactam Enterobacterales
Aztreonam Enterobacterales ≤0.03 to ≥128 ≤4 8 ≥16
Cefazolin Enterobacterales ≤0.12 to ≥128 ≤1 2 ≥4
Cefepime Enterobacterales ≤0.25 to ≥128 ≤2 4-8 ≥16
Cefoxitin Enterobacterales ≤1 to ≥128 ≤4 8 ≥16
Ceftazidime Enterobacterales ≤0.25 to ≥64 ≤4 8 ≥16
Ceftazidime- Enterobacterales
≤0.12 to ≥64 ≤8 - ≥16
Avibactam Pseudomonas aeruginosa
Ceftriaxone Enterobacterales ≤0.25 to ≥32 ≤1 2 ≥4
Enterobacterales ≤0.25 0.5 ≥1
Ciprofloxacin ≤0.03 to ≥16
Pseudomonas aeruginosa ≤0.5 1 ≥2
Eravacycline Enterobacterales ≤0.016 to ≥4 ≤0.5 - -
Ertapenem Enterobacterales ≤0.03 to ≥16 ≤0.5 1 ≥2
Enterobacterales
Gentamicin ≤0.06 to ≥64 ≤4 8 ≥16
Pseudomonas aeruginosa
Imipenem- Enterobacterales ≤1 2 ≥4
≤0.03 to ≥128
Relebactam Pseudomonas aeruginosa ≤2 4 ≥8
Levofloxacin Enterobacterales ≤0.06 to ≥32 ≤0.5 1 ≥2
Enterobacterales ≤1 2 ≥4
Meropenem ≤0.12 to ≥64
Pseudomonas aeruginosa ≤2 4 ≥8
Meropenem-
Enterobacterales ≤0.06 to ≥64 ≤4 8 ≥16
Vaborbactam
Minocycline Enterobacterales ≤0.25 to ≥64 ≤4 8 ≥16
Piperacillin-
Enterobacterales ≤0.25 to ≥512 ≤16 32-64 ≥128
Tazobactam
Tobramycin Pseudomonas aeruginosa ≤0.12 to ≥128 ≤4 8 ≥16
Trimethoprim-
Enterobacterales ≤0.12 to ≥32 ≤2 - ≥4
Sulfamethoxazole
S, Susceptible; I, Intermediate; R, Resistant; -, no breakpoint (interpretive criterion) recognized
B Principle of Operation:
The Selux AST test requires that the Gram type of the organism be known prior to testing as the
information is necessary to select the proper AST panel to use (i.e., gram-positive or gram-
negative). The organism identification (ID) is not needed for Selux AST processing to be
performed; however, the organism ID is necessary for a final result to be reported.
K211748 - Page 6 of 43

[Table 1 on page 6]
Antimicrobial			Organism Group				Selux AST System			FDA-Recognized/							
							Reportable Range			Approved Breakpoints (μg/mL)							
							(μg/mL)			S			I			R	
	Amikacin			Pseudomonas aeruginosa			≤0.12 to ≥256			≤16			32			≥64	
	Amoxicillin-		Enterobacterales			≤0.5 to ≥128			≤8			16			≥32		
	Clavulanate																
	Ampicillin			Enterobacterales			≤0.25 to ≥128			≤8			16			≥32	
	Ampicillin-			Acinetobacter baumannii complex		≤0.5 to ≥128			≤8			16			≥32		
	Sulbactam			Enterobacterales													
	Aztreonam			Enterobacterales			≤0.03 to ≥128			≤4			8			≥16	
	Cefazolin			Enterobacterales			≤0.12 to ≥128			≤1			2			≥4	
	Cefepime			Enterobacterales			≤0.25 to ≥128			≤2			4-8			≥16	
	Cefoxitin			Enterobacterales			≤1 to ≥128			≤4			8			≥16	
	Ceftazidime			Enterobacterales			≤0.25 to ≥64			≤4			8			≥16	
	Ceftazidime-			Enterobacterales		≤0.12 to ≥64			≤8			-			≥16		
	Avibactam			Pseudomonas aeruginosa													
	Ceftriaxone			Enterobacterales			≤0.25 to ≥32			≤1			2			≥4	
Ciprofloxacin				Enterobacterales		≤0.03 to ≥16				≤0.25			0.5			≥1	
				Pseudomonas aeruginosa						≤0.5			1			≥2	
	Eravacycline			Enterobacterales			≤0.016 to ≥4			≤0.5			-			-	
	Ertapenem			Enterobacterales			≤0.03 to ≥16			≤0.5			1			≥2	
Gentamicin				Enterobacterales		≤0.06 to ≥64			≤4			8			≥16		
				Pseudomonas aeruginosa													
	Imipenem-			Enterobacterales		≤0.03 to ≥128				≤1			2			≥4	
	Relebactam			Pseudomonas aeruginosa						≤2			4			≥8	
	Levofloxacin			Enterobacterales			≤0.06 to ≥32			≤0.5			1			≥2	
Meropenem				Enterobacterales		≤0.12 to ≥64				≤1			2			≥4	
				Pseudomonas aeruginosa						≤2			4			≥8	
	Meropenem-		Enterobacterales			≤0.06 to ≥64			≤4			8			≥16		
	Vaborbactam																
	Minocycline			Enterobacterales			≤0.25 to ≥64			≤4			8			≥16	
	Piperacillin-		Enterobacterales			≤0.25 to ≥512			≤16			32-64			≥128		
	Tazobactam																
	Tobramycin			Pseudomonas aeruginosa			≤0.12 to ≥128			≤4			8			≥16	
	Trimethoprim-		Enterobacterales			≤0.12 to ≥32			≤2			-			≥4		
	Sulfamethoxazole																

--- Page 7 ---
The Selux AST System performs antimicrobial susceptibility testing similar to the gold-standard
broth microdilution method. To get an accurate reading of microbial growth, the sufficient
growth assay monitors growth in dedicated AST panel wells that contain organisms and cation-
adjusted Mueller-Hinton Broth but no antimicrobials or probes. Sufficient growth assay wells are
monitored by fluorescence to those wells which the standard metabolism-based viability assay
pair resazurin/methylene blue have been added and/or by optical absorbance. Two probe-based
assays commence across all wells in the panel after the threshold in the sufficient growth well
has been met. The “viability assay” uses a fluorescent metabolic probe as an indicator of cellular
activity and the “surface area assay” uses a fluorescent cationic probe that binds microorganism
surfaces as a proxy for cellular surface area. The viability and surface area assays are performed
in each AST panel well, providing two complementary datasets for each well. These data are
input to an MIC-determining algorithm that provides results when organism IDs are available.
Refer to the K211759 Decision Summary for additional information on the Selux AST System.
V Substantial Equivalence Information:
A Predicate Device Name(s):
BD Phoenix Automated Microbiology System - GN Ceftaroline (0.0156-4 µg/mL)
B Predicate 510(k) Number(s):
K190905
C Comparison with Predicate(s):
Device &
Device: Predicate:
Predicate
K211748 K190905
Device(s):
BD Phoenix Automated
Device Trade
Selux AST System Microbiology System – GN
Name
Ceftaroline (0.0156-4 µg/mL)
General Device Characteristic Similarities
The BD Phoenix Automated Microbiology
The Selux AST System is intended to be used for the
System is intended for in vitro quantitative
automated quantitative or qualitative susceptibility
determination of antimicrobial
testing for most clinically significant aerobic
susceptibility by minimal inhibitory
microorganisms. The Selux AST System does not
concentration (MIC) of most Gram-
Intended
provide organism identification.
negative aerobic and facultative anaerobic
Use/Indications For
bacteria isolates from pure culture for
Use The Selux Gram-Negative Panel is intended for use Enterobacteriaceae and Non-
with the Selux AST System as an in vitro test to
Enterobacteriaceae and most Gram-
determine the susceptibility of isolated colonies of
positive bacteria isolates from pure culture
specific gram-negative bacilli to specific antimicrobial
belonging to the genera Staphylococcus,
agents when used as instructed.*
Enterococcus and Streptococcus.
Source of
Bacterial colonies isolated from culture Same
Microorganisms
Automated growth based enhanced by use
Automated growth-based detection using metabolic
Technology of a redox indicator (colorimetric oxidation-
indicators to detect organism growth
reduction) to detect organism growth
Panel Type Gram-negative Same
K211748 - Page 7 of 43

[Table 1 on page 7]
	Device &		Device:
K211748	Predicate:
K190905	
	Predicate				
	Device(s):				
Device Trade
Name			Selux AST System	BD Phoenix Automated
Microbiology System – GN
Ceftaroline (0.0156-4 µg/mL)	
	General Device Characteristic Similarities				
Intended
Use/Indications For
Use			The Selux AST System is intended to be used for the
automated quantitative or qualitative susceptibility
testing for most clinically significant aerobic
microorganisms. The Selux AST System does not
provide organism identification.
The Selux Gram-Negative Panel is intended for use
with the Selux AST System as an in vitro test to
determine the susceptibility of isolated colonies of
specific gram-negative bacilli to specific antimicrobial
agents when used as instructed.*	The BD Phoenix Automated Microbiology
System is intended for in vitro quantitative
determination of antimicrobial
susceptibility by minimal inhibitory
concentration (MIC) of most Gram-
negative aerobic and facultative anaerobic
bacteria isolates from pure culture for
Enterobacteriaceae and Non-
Enterobacteriaceae and most Gram-
positive bacteria isolates from pure culture
belonging to the genera Staphylococcus,
Enterococcus and Streptococcus.	
Source of
Microorganisms			Bacterial colonies isolated from culture	Same	
Technology			Automated growth-based detection using metabolic
indicators to detect organism growth	Automated growth based enhanced by use
of a redox indicator (colorimetric oxidation-
reduction) to detect organism growth	
Panel Type			Gram-negative	Same	

[Table 2 on page 7]
Device:
K211748

[Table 3 on page 7]
Predicate:
K190905

--- Page 8 ---
Device &
Device: Predicate:
Predicate
K211748 K190905
Device(s):
Read Method Automated Same
Inoculation Method Automated Same
Report results as minimum inhibitory
Report results as minimum inhibitory concentration
Result Reported concentration (MIC) and categorical
(MIC) and categorical interpretation (S, I, R, NS)
interpretation (S, I, R)
Acinetobacter baumannii complex, specific
Indicated Species Specific Enterobacterales species
Enterobacterales species, and Pseudomonas aeruginosa
General Device Characteristic Differences
Amikacin ≤0.12 to ≥256 μg/mL
Amoxicillin-Clavulanate ≤0.5 to ≥128 μg/mL
Ampicillin ≤0.25 to ≥128 μg/mL
Ampicillin-Sulbactam ≤0.5 to ≥128 μg/mL
Aztreonam ≤0.03 to ≥128 μg/mL
Cefazolin ≤0.12 to ≥128 μg/mL
Cefepime ≤0.25 to ≥128 μg/mL
Cefoxitin ≤1 to ≥128 μg/mL
Ceftazidime ≤0.25 to ≥64 μg/mL
Ceftazidime-Avibactam ≤0.12 to ≥64 μg/mL
Antimicrobial Ceftriaxone ≤0.25 to ≥32 μg/mL
Ciprofloxacin ≤0.03 to ≥16 μg/mL
Agent and Ceftaroline 0.0156-4 µg/mL
Eravacycline ≤0.016 to ≥4 μg/mL
Reporting Range
Ertapenem ≤0.03 to ≥16 μg/mL
Gentamicin ≤0.06 to ≥64 μg/mL
Imipenem ≤0.016 to ≥64 μg/mL
Imipenem-Relebactam ≤0.03 to ≥128 μg/mL
Levofloxacin ≤0.06 to ≥32 μg/mL
Meropenem ≤0.12 to ≥64 μg/mL
Meropenem-Vaborbactam ≤0.06 to ≥64 μg/mL
Minocycline ≤0.25 to ≥64 μg/mL
Piperacillin-Tazobactam ≤0.25 to ≥512 μg/mL
Tobramycin ≤0.12 to ≥128 μg/mL
Trimethoprim-Sulfamethoxazole ≤0.12 to ≥32 μg/mL
IVD Functions AST ID and AST
BD Phoenix Automated Microbiology
Instrument Selux AST System
System
* The Selux Gram-Negative Panel is a quantitative test for the antimicrobial agents with the specific organisms listed in section
III.B (Indications for Use Statement).
VI Standards/Guidance Documents Referenced:
• FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST)
Systems; Guidance for Industry and FDA (Issued August 28, 2009)
• CLSI M100-M30, “Performance Standards for Antimicrobial Susceptibility Testing”;
Thirtieth Edition (January 2020)
VII Performance Characteristics (if/when applicable):
A Analytical Performance:
1. Precision/Reproducibility:
K211748 - Page 8 of 43

[Table 1 on page 8]
	Device &		Device:
K211748	Predicate:
K190905	
	Predicate				
	Device(s):				
Read Method			Automated	Same	
Inoculation Method			Automated	Same	
Result Reported			Report results as minimum inhibitory concentration
(MIC) and categorical interpretation (S, I, R, NS)	Report results as minimum inhibitory
concentration (MIC) and categorical
interpretation (S, I, R)	
Indicated Species			Acinetobacter baumannii complex, specific
Enterobacterales species, and Pseudomonas aeruginosa	Specific Enterobacterales species	
	General Device Characteristic Differences				
Antimicrobial
Agent and
Reporting Range			Amikacin ≤0.12 to ≥256 μg/mL
Amoxicillin-Clavulanate ≤0.5 to ≥128 μg/mL
Ampicillin ≤0.25 to ≥128 μg/mL
Ampicillin-Sulbactam ≤0.5 to ≥128 μg/mL
Aztreonam ≤0.03 to ≥128 μg/mL
Cefazolin ≤0.12 to ≥128 μg/mL
Cefepime ≤0.25 to ≥128 μg/mL
Cefoxitin ≤1 to ≥128 μg/mL
Ceftazidime ≤0.25 to ≥64 μg/mL
Ceftazidime-Avibactam ≤0.12 to ≥64 μg/mL
Ceftriaxone ≤0.25 to ≥32 μg/mL
Ciprofloxacin ≤0.03 to ≥16 μg/mL
Eravacycline ≤0.016 to ≥4 μg/mL
Ertapenem ≤0.03 to ≥16 μg/mL
Gentamicin ≤0.06 to ≥64 μg/mL
Imipenem ≤0.016 to ≥64 μg/mL
Imipenem-Relebactam ≤0.03 to ≥128 μg/mL
Levofloxacin ≤0.06 to ≥32 μg/mL
Meropenem ≤0.12 to ≥64 μg/mL
Meropenem-Vaborbactam ≤0.06 to ≥64 μg/mL
Minocycline ≤0.25 to ≥64 μg/mL
Piperacillin-Tazobactam ≤0.25 to ≥512 μg/mL
Tobramycin ≤0.12 to ≥128 μg/mL
Trimethoprim-Sulfamethoxazole ≤0.12 to ≥32 μg/mL	Ceftaroline 0.0156-4 µg/mL	
IVD Functions			AST	ID and AST	
Instrument			Selux AST System	BD Phoenix Automated Microbiology
System	

[Table 2 on page 8]
Device:
K211748

[Table 3 on page 8]
Predicate:
K190905

--- Page 9 ---
Reproducibility testing for the Selux AST System with the Gram-Negative Panel was
conducted at 3 testing sites (2 external and 1 internal site). Panel members generally
consisted of species indicated for use with each respective antimicrobial. To accommodate
the numerous antimicrobial/organism combinations being tested concurrently, up to three
non-indicated species, within an indicated genus or family, were considered acceptable for
testing. Reproducibility was determined from the total number (and percent) of results that
fell within one dilution (+/- one doubling dilution) of the modal MIC result for quantitative
assays divided by the total number of results. Reproducibility was evaluated between sites
(inter-site) and within sites (intra-site). Both best-case (assumes that off-scale results are
within one dilution of the mode) and worst-case (assumes that off-scale results are more than
one dilution of the mode) performance was determined for each antimicrobial, as outlined in
the AST Special Controls Guidance.
In the initial study, inter-site reproducibility was evaluated at three sites by testing at least 25
isolates with on-scale MIC values for each antimicrobial, for a minimum of 75 results per
antimicrobial (25 isolates x 3 sites = 75 results/antimicrobial). In general, best-case inter-site
reproducibility was acceptable (≥95%) and a sufficient number of results obtained (≥75
results). However, antimicrobials with inter-site worst-case reproducibility of <89% or an
insufficient number of results generated (i.e., <75) in the initial study were further evaluated
in a supplemental study in which testing was performed with three instruments. Data from
both studies are collated and summarized in Table 2. Performance is summarized for each
antimicrobial tested with all organisms as well as indicated organisms only. Inter-site
reproducibility was determined to be acceptable.
Table 2. Inter-site Reproducibility of Selux AST System (Gram Negative Panel)
All organisms (combined) Indicated organisms only
Antimicrobial Best-case (%) Worst-case (%) Best-case (%) Worst-case (%)
Amikacin 98/104 (94.2%) 98/104 (94.2%) 92/98 (93.9%) 92/98 (93.9%)
Amoxicillin-Clavulanate 77/78 (98.7%) 76/78 (97.4%) 71/72 (98.6%) 70/72 (97.2%)
Ampicillin 72/75 (96%) 72/75 (96%) 68/69 (98.6%) 68/69 (98.6%)
Ampicillin-Sulbactam 74/75 (98.7%) 74/75 (98.7%) 69/69 (100%) 69/69 (100%)
Aztreonam 77/78 (98.7%) 75/78 (96.2%) 77/78 (98.7%) 75/78 (96.2%)
Cefazolina 77/81 (95.1%) 76/81 (93.8%) 68/72 (94.4%) 67/72 (93.1%)
Cefepime 77/78 (98.7%) 76/78 (97.4%) 77/78 (98.7%) 76/78 (97.4%)
Cefoxitin 73/75 (97.3%) 72/75 (96.0%) 70/72 (97.2%) 69/72 (95.8%)
Ceftazidime 77/81 (95.1%) 76/81 (93.8%) 77/81 (95.1%) 76/81 (93.8%)
Ceftazidime-Avibactam 140/144 (97.2%) 139/144 (96.5%) 140/144 (97.2%) 139/144 (96.5%)
Ceftriaxone 140/141 (99.3%) 140/141 (99.3%) 140/141 (99.3%) 140/141 (99.3%)
Ciprofloxacina 74/75 (98.7%) 71/75 (94.7%) 74/75 (98.7%) 71/75 (94.7%)
Eravacycline 78/78 (100%) 78/78 (100%) 78/78 (100%) 78/78 (100%)
Ertapenem 143/145 (98.6%) 143/145 (98.6%) 143/145 (98.6%) 143/145 (98.6%)
Gentamicina 77/80 (96.3%) 77/80 (96.3%) 77/80 (96.3%) 77/80 (96.3%)
Imipenem 145/149 (97.3%) 140/149 (94.0%) 145/149 (97.3%) 140/149 (94.0%)
Imipenem-Relebactam 71/75 (94.7%) 71/75 (94.7%) 71/75 (94.7%) 71/75 (94.7%)
Levofloxacin 76/78 (97.4%) 76/78 (97.4%) 73/75 (97.3%) 73/75 (97.3%)
Meropenem 75/78 (96.2%) 73/78 (93.6%) 70/72 (97.2%) 68/72 (94.4%)
Meropenem-Vaborbactam 142/145 (97.9%) 132/145 (91.0%) 142/145 (97.9%) 132/145 (91.0%)
K211748 - Page 9 of 43

[Table 1 on page 9]
				All organisms (combined)						Indicated organisms only				
	Antimicrobial			Best-case (%)			Worst-case (%)			Best-case (%)			Worst-case (%)	
Amikacin			98/104 (94.2%)			98/104 (94.2%)			92/98 (93.9%)			92/98 (93.9%)		
Amoxicillin-Clavulanate			77/78 (98.7%)			76/78 (97.4%)			71/72 (98.6%)			70/72 (97.2%)		
Ampicillin			72/75 (96%)			72/75 (96%)			68/69 (98.6%)			68/69 (98.6%)		
Ampicillin-Sulbactam			74/75 (98.7%)			74/75 (98.7%)			69/69 (100%)			69/69 (100%)		
Aztreonam			77/78 (98.7%)			75/78 (96.2%)			77/78 (98.7%)			75/78 (96.2%)		
Cefazolina			77/81 (95.1%)			76/81 (93.8%)			68/72 (94.4%)			67/72 (93.1%)		
Cefepime			77/78 (98.7%)			76/78 (97.4%)			77/78 (98.7%)			76/78 (97.4%)		
Cefoxitin			73/75 (97.3%)			72/75 (96.0%)			70/72 (97.2%)			69/72 (95.8%)		
Ceftazidime			77/81 (95.1%)			76/81 (93.8%)			77/81 (95.1%)			76/81 (93.8%)		
Ceftazidime-Avibactam			140/144 (97.2%)			139/144 (96.5%)			140/144 (97.2%)			139/144 (96.5%)		
Ceftriaxone			140/141 (99.3%)			140/141 (99.3%)			140/141 (99.3%)			140/141 (99.3%)		
Ciprofloxacina			74/75 (98.7%)			71/75 (94.7%)			74/75 (98.7%)			71/75 (94.7%)		
Eravacycline			78/78 (100%)			78/78 (100%)			78/78 (100%)			78/78 (100%)		
Ertapenem			143/145 (98.6%)			143/145 (98.6%)			143/145 (98.6%)			143/145 (98.6%)		
Gentamicina			77/80 (96.3%)			77/80 (96.3%)			77/80 (96.3%)			77/80 (96.3%)		
Imipenem			145/149 (97.3%)			140/149 (94.0%)			145/149 (97.3%)			140/149 (94.0%)		
Imipenem-Relebactam			71/75 (94.7%)			71/75 (94.7%)			71/75 (94.7%)			71/75 (94.7%)		
Levofloxacin			76/78 (97.4%)			76/78 (97.4%)			73/75 (97.3%)			73/75 (97.3%)		
Meropenem			75/78 (96.2%)			73/78 (93.6%)			70/72 (97.2%)			68/72 (94.4%)		
Meropenem-Vaborbactam			142/145 (97.9%)			132/145 (91.0%)			142/145 (97.9%)			132/145 (91.0%)		

--- Page 10 ---
All organisms (combined) Indicated organisms only
Antimicrobial Best-case (%) Worst-case (%) Best-case (%) Worst-case (%)
Minocyclinea 73/75 (97.3%) 73/75 (97.3%) 64/66 (97.3%) 64/66 (97.3%)
Piperacillin-Tazobactama 72/75 (96.0%) 69/75 (92.0%) 63/66 (95.5%) 60/66 (90.9%)
Tobramycin 74/78 (94.9%) 73/78 (93.6%) 74/78 (94.9%) 73/78 (93.6%)
Trimethoprim-
143/148 (96.6%) 142/148 (95.9%) 143/148 (96.6%) 142/148 (95.9%)
Sulfamethoxazole
a In instances where the original study had lower than the required number, supplemental testing was conducted and data
collated with original data.
Intra-site reproducibility was evaluated by testing a minimum of five isolates in triplicate on
three days at one internal site for each antimicrobial to generate a minimum of 45 results per
antimicrobial (5 isolates x 3 replicates x 3 days = 45 results/antimicrobial). In general, best-
case intra-site reproducibility was acceptable (≥95%) and a sufficient number of results
obtained (≥45 results). However, antimicrobials with worst-case reproducibility <89% or an
insufficient number of results generated (i.e., <45) in the initial study were further evaluated
in a supplemental study. Data from both studies are collated and summarized in Table 3.
Performance is summarized for each antimicrobial tested with all organisms as well as
indicated organisms only. Intra-site reproducibility was determined to be acceptable.
Table 3. Intra-site Reproducibility of Selux AST System (Gram Negative Panel)
All organisms (combined) Indicated organisms only
Antimicrobial Best-case (%) Worst-case (%) Best-case (%) Worst-case (%)
Amoxicillin-
63/63 (100%) 63/63 (100%) 63/63 (100%) 63/63 (100%)
Clavulanate
Ampicillin 45/45 (100%) 45/45 (100%) 45/45 (100%) 45/45 (100%)
Ampicillin-Sulbactam 72/72 (100%) 72/72 (100%) 72/72 (100%) 72/72 (100%)
Aztreonam 71/74 (95.9%) 68/74 (91.9%) 71/74 (95.9%) 68/74 (91.9%)
Cefazolin 61/63 (96.8%) 61/63 (96.8%) 61/63 (96.8%) 61/63 (96.8%)
Cefepime 45/47 (95.7%) 45/47 (95.7%) 45/47 (95.7%) 45/47 (95.7%)
Cefoxitin 54/54 (100%) 54/54 (100%) 54/54 (100%) 54/54 (100%)
Ceftazidime 92/93 (98.9%) 91/93 (97.8%) 92/93 (98.9%) 91/93 (97.8%)
Ceftazidime-
47/47 (100%) 43/47 (91.5%) 47/47 (100%) 43/47 (91.5%)
Avibactam
Eravacycline 103/103 (100%) 99/103 (96.1%) 103/103 (100%) 99/103 (96.1%)
Gentamicin 116/121 (95.9%) 116/121 (95.9%) 116/121 (95.9%) 116/121 (95.9%)
Imipenem-Relebactam 72/76 (94.7%) 72/76 (94.7%) 72/76 (94.7%) 72/76 (94.7%)
Levofloxacin 179/181 (98.9%) 174/181 (96.1%) 179/181 (98.9%) 174/181 (96.1%)
Meropenem 57/58 (98.3%) 56/58 (96.6%) 57/58 (98.3%) 56/58 (96.6%)
Meropenem-
45/47 (95.7%) 43/47 (91.5%) 45/47 (95.7%) 43/47 (91.5%)
Vaborbactam
Piperacillin-
54/56 (96.4%) 54/56 (96.4%) 54/56 (96.4%) 54/56 (96.4%)
Tazobactam
Trimethoprim-
62/65 (95.4%) 61/65 (93.8%) 62/65 (95.4%) 61/65 (93.8%)
Sulfamethoxazole
a In instances where the original study had lower than the required number, supplemental testing was conducted and data
collated with original data.
K211748 - Page 10 of 43

[Table 1 on page 10]
				All organisms (combined)						Indicated organisms only		
	Antimicrobial			Best-case (%)			Worst-case (%)			Best-case (%)	Worst-case (%)	
Minocyclinea			73/75 (97.3%)			73/75 (97.3%)			64/66 (97.3%)		64/66 (97.3%)	
Piperacillin-Tazobactama			72/75 (96.0%)			69/75 (92.0%)			63/66 (95.5%)		60/66 (90.9%)	
Tobramycin			74/78 (94.9%)			73/78 (93.6%)			74/78 (94.9%)		73/78 (93.6%)	
Trimethoprim-
Sulfamethoxazole			143/148 (96.6%)			142/148 (95.9%)			143/148 (96.6%)		142/148 (95.9%)	

[Table 2 on page 10]
				All organisms (combined)						Indicated organisms only		
	Antimicrobial			Best-case (%)			Worst-case (%)			Best-case (%)	Worst-case (%)	
Amoxicillin-
Clavulanate			63/63 (100%)			63/63 (100%)			63/63 (100%)		63/63 (100%)	
Ampicillin			45/45 (100%)			45/45 (100%)			45/45 (100%)		45/45 (100%)	
Ampicillin-Sulbactam			72/72 (100%)			72/72 (100%)			72/72 (100%)		72/72 (100%)	
Aztreonam			71/74 (95.9%)			68/74 (91.9%)			71/74 (95.9%)		68/74 (91.9%)	
Cefazolin			61/63 (96.8%)			61/63 (96.8%)			61/63 (96.8%)		61/63 (96.8%)	
Cefepime			45/47 (95.7%)			45/47 (95.7%)			45/47 (95.7%)		45/47 (95.7%)	
Cefoxitin			54/54 (100%)			54/54 (100%)			54/54 (100%)		54/54 (100%)	
Ceftazidime			92/93 (98.9%)			91/93 (97.8%)			92/93 (98.9%)		91/93 (97.8%)	
Ceftazidime-
Avibactam			47/47 (100%)			43/47 (91.5%)			47/47 (100%)		43/47 (91.5%)	
Eravacycline			103/103 (100%)			99/103 (96.1%)			103/103 (100%)		99/103 (96.1%)	
Gentamicin			116/121 (95.9%)			116/121 (95.9%)			116/121 (95.9%)		116/121 (95.9%)	
Imipenem-Relebactam			72/76 (94.7%)			72/76 (94.7%)			72/76 (94.7%)		72/76 (94.7%)	
Levofloxacin			179/181 (98.9%)			174/181 (96.1%)			179/181 (98.9%)		174/181 (96.1%)	
Meropenem			57/58 (98.3%)			56/58 (96.6%)			57/58 (98.3%)		56/58 (96.6%)	
Meropenem-
Vaborbactam			45/47 (95.7%)			43/47 (91.5%)			45/47 (95.7%)		43/47 (91.5%)	
Piperacillin-
Tazobactam			54/56 (96.4%)			54/56 (96.4%)			54/56 (96.4%)		54/56 (96.4%)	
Trimethoprim-
Sulfamethoxazole			62/65 (95.4%)			61/65 (93.8%)			62/65 (95.4%)		61/65 (93.8%)	

--- Page 11 ---
2. Linearity:
Not applicable
3. Analytical Specificity/Interference:
Not Applicable
4. Assay Reportable Range:
Not applicable
5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):
Quality Control Testing. The Selux AST System software contains QC Sets (A, B, C) such
that when the Gram-Negative Panel is selected, the system will indicate the appropriate QC
strains to be prepared for testing. CLSI-recommended QC strains and expected QC ranges for
use with the Gram-Negative Panel are summarized in Table 4, which also includes the
designation of the QC set as appropriate for each antimicrobial. Notably, QC Set A
comprises gram-positive ATCC QC organisms which is acceptable to use for QC testing of
the Gram-Negative Panel provided that QC is run concurrently with Set B and/or C, which
comprise gram-negative ATCC QC organisms. This is necessary because the metabolic assay
in the Selux AST System utilizes an additional biochemical reagent, an electron transfer
agent, exclusively with gram-negative organisms. The following QC reporting scheme is
included in the device labeling (and is supported by software information) to ensure that
gram-negative organisms will be processed correctly by the Selux AST System:
• Gram-Negative Panel QC failure when testing gram-positive QC organisms: clinical
results should not be reported for the antimicrobial(s) in which QC failed but may be
reported for the antimicrobials for which QC passed.
• Gram-Negative Panel QC failure when testing gram-negative QC organisms:
If all gram-negative organisms fail QC: all QC results (including those when
o
testing gram-positive organisms) should be considered failed and clinical results
should not be reported for any antimicrobial.
If one (or fewer than all) gram-negative organisms fail QC: clinical results should
o
not be reported for the antimicrobial(s) in which QC failed but may be reported
for the antimicrobials for which QC passed (including those when testing gram-
positive organisms).
Table 4. CLSI-Recommended QC Organisms for Gram-Negative Panel
Expected QC Range
Antimicrobial Abbreviation QC Set QC Strain
(µg/mL)
Amikacin AMK A ATCC 29213 a 1-4
Amoxicillin-Clavulanate AMC B ATCC 700603 4-16
Ampicillin AMP C ATCC 25922 2-8
Ampicillin-Sulbactam SAM B ATCC 700603 8-32
Aztreonam ATM C ATCC 25922 0.06-0.25
Cefazolin CFZ C ATCC 25922 1-4
Cefepime FEP A ATCC 29213 a 1-4
Cefoxitin FOX C ATCC 25922 2-8
Ceftazidime CAZ A ATCC 29213 a 4-16
Ceftazidime-Avibactam CZA B ATCC 700603 0.25-2
K211748 - Page 11 of 43

[Table 1 on page 11]
Antimicrobial			Abbreviation			QC Set			QC Strain				Expected QC Range	
													(µg/mL)	
	Amikacin			AMK			A			ATCC 29213 a			1-4	
	Amoxicillin-Clavulanate			AMC			B			ATCC 700603			4-16	
	Ampicillin			AMP			C			ATCC 25922			2-8	
	Ampicillin-Sulbactam			SAM			B			ATCC 700603			8-32	
	Aztreonam			ATM			C			ATCC 25922			0.06-0.25	
	Cefazolin			CFZ			C			ATCC 25922			1-4	
	Cefepime			FEP			A			ATCC 29213 a			1-4	
	Cefoxitin			FOX			C			ATCC 25922			2-8	
	Ceftazidime			CAZ			A			ATCC 29213 a			4-16	
	Ceftazidime-Avibactam			CZA			B			ATCC 700603			0.25-2	

--- Page 12 ---
Expected QC Range
Antimicrobial Abbreviation QC Set QC Strain
(µg/mL)
Ceftriaxone CRO A ATCC 29213 a 1-8
Ciprofloxacin CIP A ATCC 29213 a 0.12-0.5
Eravacycline ERV C ATCC 25922 0.016-0.12
Ertapenem ETP A ATCC 29213 a 0.06-0.25
Gentamicin GEN A ATCC 29212 a 4-16
Imipenem IMP B ATCC 700603 0.06-0.5
Imipenem-Relebactam IMR C ATCC BAA-2814 0.06-0.5
Levofloxacin LVX A ATCC 29212 a 0.25-2
Meropenem MEM A ATCC 29212 a 2-8
Meropenem-Vaborbactam MEV C ATCC BAA-2814 0.12-0.5
Minocycline MIN A ATCC 29212 a 1-4
Piperacillin-Tazobactam TZP B ATCC 700603 8-32
Tobramycin TOB A ATCC 29212 a 8-32
Trimethoprim-Sulfamethoxazole SXT C ATCC 25922 0.12-0.5b
a Set A comprises gram-positive ATCC QC organisms which is acceptable to use for QC testing of the Gram-Negative
Comprehensive panel provided that QC is run concurrently with Set B and/or C, which comprise gram-negative ATCC QC
organisms. This is necessary because the metabolic assay in the Selux AST System utilizes an additional biochemical reagent, an
electron transfer agent, exclusively with gram-negative organisms. This ensures that gram-negative organisms will be processed
correctly by the Selux AST System.
b Expected QC range for SXT in CLSI M100 is ≤0.5; Selux AST reporting range for SXT is ≤0.12 to ≥32 μg/mL. Selux MIC results
of ≤0.5 μg/mL were considered acceptable.
Quality control testing was performed each day that testing was conducted. CLSI-
recommended QC strains for each antimicrobial (described in Table 4) were tested a
sufficient number of times (i.e., at least 20 times/site) at each testing site using the Selux
AST System. QC testing of the broth microdilution reference method was performed at a
single, central site. In some cases, the site used CLSI-recommended QC organisms that were
different from QC organisms tested with the Selux AST System. This is noted in Table 5.
QC expected ranges and results for the Selux AST System with Gram-Negative panel are
summarized in Table 5. For all antimicrobials, greater than 95% of results were within the
expected range, which is acceptable.
Due to an administrative error, reference data for minocycline and tobramycin was not
previously included in Table 5. This data is included in the updated table for both
minocycline and tobramycin testing of E. coli ATCC 25922.
Table 5. QC Results for the Selux AST System Assay with Gram Negative Panel
Expected No. in Range (%)
Antimicrobial QC Strain
Range (µg/mL) Reference Selux
Amikacin S. aureus ATCC 29213 1-4 56/56 (100) 218/219 (99.5)
Amoxicillin K. pneumoniae ATCC 700603a ≥128c 4747 (100) 219/221 (99.1)
Amoxicillin-Clavulanate K. pneumoniae ATCC 700603 4-16 49/50 (98.0) 211/221 (95.5)
E. coli ATCC 25922 2-8 47/48 (97.9) 210/210 (100)
Ampicillin
K. pneumoniae ATCC 700603a ≥128c 50/50 (100) 219/221 (99.1)
Ampicillin-Sulbactam K. pneumoniae ATCC 700603 8-32 46/47 (97.9) 221/221 (100)
Aztreonam E. coli ATCC 25922 0.06-0.25 56/57 (98.2) 210/210 (100)
K211748 - Page 12 of 43

[Table 1 on page 12]
Antimicrobial			Abbreviation			QC Set			QC Strain				Expected QC Range	
													(µg/mL)	
	Ceftriaxone			CRO			A			ATCC 29213 a			1-8	
	Ciprofloxacin			CIP			A			ATCC 29213 a			0.12-0.5	
	Eravacycline			ERV			C			ATCC 25922			0.016-0.12	
	Ertapenem			ETP			A			ATCC 29213 a			0.06-0.25	
	Gentamicin			GEN			A			ATCC 29212 a			4-16	
	Imipenem			IMP			B			ATCC 700603			0.06-0.5	
	Imipenem-Relebactam			IMR			C			ATCC BAA-2814			0.06-0.5	
	Levofloxacin			LVX			A			ATCC 29212 a			0.25-2	
	Meropenem			MEM			A			ATCC 29212 a			2-8	
	Meropenem-Vaborbactam			MEV			C			ATCC BAA-2814			0.12-0.5	
	Minocycline			MIN			A			ATCC 29212 a			1-4	
	Piperacillin-Tazobactam			TZP			B			ATCC 700603			8-32	
	Tobramycin			TOB			A			ATCC 29212 a			8-32	
	Trimethoprim-Sulfamethoxazole			SXT			C			ATCC 25922			0.12-0.5b	

[Table 2 on page 12]
Antimicrobial			QC Strain				Expected			No. in Range (%)				
							Range (µg/mL)			Reference			Selux	
	Amikacin			S. aureus ATCC 29213			1-4			56/56 (100)			218/219 (99.5)	
	Amoxicillin			K. pneumoniae ATCC 700603a			≥128c			4747 (100)			219/221 (99.1)	
	Amoxicillin-Clavulanate			K. pneumoniae ATCC 700603			4-16			49/50 (98.0)			211/221 (95.5)	
Ampicillin				E. coli ATCC 25922			2-8			47/48 (97.9)			210/210 (100)	
				K. pneumoniae ATCC 700603a			≥128c			50/50 (100)			219/221 (99.1)	
	Ampicillin-Sulbactam			K. pneumoniae ATCC 700603			8-32			46/47 (97.9)			221/221 (100)	
	Aztreonam			E. coli ATCC 25922			0.06-0.25			56/57 (98.2)			210/210 (100)	

--- Page 13 ---
Expected No. in Range (%)
Antimicrobial QC Strain
Range (µg/mL) Reference Selux
Cefazolin E. coli ATCC 25922 1-4 53/53 (100) 210/210 (100)
Cefepime S. aureus ATCC 29213 1-4 54/55 (98.2) 218/219 (99.5)
Cefoxitin E. coli ATCC 25922 2-8 45/46 (97.8) 209/210 (99.5)
S. aureus ATCC 29213 4-16 NT 217/219 (99.1)
Ceftazidime E. coli ATCC 25922b 0.06-0.5 56/57 (98.2) NT
K. pneumoniae ATCC 700603a 16-64 66/66 (100) 218/221 (98.6)
Ceftazidime-Avibactam K. pneumoniae ATCC 700603 0.25-2 59/59 (100) 221/221 (100)
Ceftriaxone S. aureus ATCC 29213 1-8 45/49 (97.8) 218/219 (99.5)
Ciprofloxacin S. aureus ATCC 29213 0.12-0.5 57/58 (98.3) 218/219 (99.5)
Eravacycline E. coli ATCC 25922 0.016-0.12 49/49 (100) 210/210 (100)
Ertapenem S. aureus ATCC 29213 0.06-0.25 51/51 (100) 217/219 (99.1)
Gentamicin E. faecalis ATCC 29212 4-16 51/53 (96.2) 216/217 (99.5)
K. pneumoniae ATCC 700603 0.06-0.5 64/64 (100) 221/221 (100)
Imipenem
K. pneumoniae ATCC BAA-2814a 16-64 65/65 (100) 210/210 (100)
Imipenem-Relebactam K. pneumoniae ATCC BAA-2814 0.06-0.5 65/65 (100) 207/210 (98.6)
Levofloxacin E. faecalis ATCC 29212 0.25-2 38/40 (95.0) 89/90 (98.9)
Meropenem E. faecalis ATCC 29212 2-8 55/56 (98.2) 217/217 (100)
Meropenem-Vaborbactam K. pneumoniae ATCC BAA-2814 0.12-0.5 48/49 (98.0) 204/210 (97.1)
E. faecalis ATCC 29212 1-4 NT 216/217 (99.5)
Minocycline
E. coli ATCC 25922b 0.25-1 43/44 (97.7) NT
Piperacillin-Tazobactam K. pneumoniae ATCC 700603 8-32 66/66 (100) 221/221 (100)
E. faecalis ATCC 29212 8-32 NT 211/217 (97.2)
Tobramycin
E. coli ATCC 25922b 0.25-1 52/53 (98.1) NT
Trimethoprim-
E. coli ATCC 25922 0.12-0.5b 44/100 (100) 208/210 (99.0)
Sulfamethoxazole
NT: Not tested
a Tested to confirm the integrity of the QC strain for testing with the beta-lactam/beta-lactam-inhibitor combination antimicrobial.
b BMD reference method testing was performed at a single, central site which utilized their standard, CLSI-recommended QC organisms.
c Expected QC range in CLSI M100 is >128; highest concentration of Amoxicillin and Ampicillin on the Selux AST result panel is 128
μg/mL. Selux MIC results of ≥128 μg/mL were considered acceptable.
Inoculum Density Check: Refer to the K211759 decision summary for description and
results since studies were performed concurrently.
Device Failure: Refer to the K211759 decision summary for description and results since
studies were performed concurrently.
Growth Failure Rate: There were 13 growth failures (13/1401 tests = 0.93%) when using
the Gram-Negative Panel on the Selux AST System. All samples that generated Selux results
also generated reference method results.
Purity Check: Purity plates were prepared from the inoculum suspensions of every sample
tested. AST results were only reported for pure isolates; data generated from plates that
generated multiple colony morphologies was excluded from analyses.
6. Detection Limit:
K211748 - Page 13 of 43

[Table 1 on page 13]
Antimicrobial			QC Strain				Expected			No. in Range (%)				
							Range (µg/mL)			Reference			Selux	
	Cefazolin			E. coli ATCC 25922			1-4			53/53 (100)			210/210 (100)	
	Cefepime			S. aureus ATCC 29213			1-4			54/55 (98.2)			218/219 (99.5)	
	Cefoxitin			E. coli ATCC 25922			2-8			45/46 (97.8)			209/210 (99.5)	
Ceftazidime				S. aureus ATCC 29213			4-16			NT			217/219 (99.1)	
				E. coli ATCC 25922b			0.06-0.5			56/57 (98.2)			NT	
				K. pneumoniae ATCC 700603a			16-64			66/66 (100)			218/221 (98.6)	
	Ceftazidime-Avibactam			K. pneumoniae ATCC 700603			0.25-2			59/59 (100)			221/221 (100)	
	Ceftriaxone			S. aureus ATCC 29213			1-8			45/49 (97.8)			218/219 (99.5)	
	Ciprofloxacin			S. aureus ATCC 29213			0.12-0.5			57/58 (98.3)			218/219 (99.5)	
	Eravacycline			E. coli ATCC 25922			0.016-0.12			49/49 (100)			210/210 (100)	
	Ertapenem			S. aureus ATCC 29213			0.06-0.25			51/51 (100)			217/219 (99.1)	
	Gentamicin			E. faecalis ATCC 29212			4-16			51/53 (96.2)			216/217 (99.5)	
Imipenem				K. pneumoniae ATCC 700603			0.06-0.5			64/64 (100)			221/221 (100)	
				K. pneumoniae ATCC BAA-2814a			16-64			65/65 (100)			210/210 (100)	
	Imipenem-Relebactam			K. pneumoniae ATCC BAA-2814			0.06-0.5			65/65 (100)			207/210 (98.6)	
	Levofloxacin			E. faecalis ATCC 29212			0.25-2			38/40 (95.0)			89/90 (98.9)	
	Meropenem			E. faecalis ATCC 29212			2-8			55/56 (98.2)			217/217 (100)	
	Meropenem-Vaborbactam			K. pneumoniae ATCC BAA-2814			0.12-0.5			48/49 (98.0)			204/210 (97.1)	
Minocycline				E. faecalis ATCC 29212			1-4			NT			216/217 (99.5)	
				E. coli ATCC 25922b			0.25-1			43/44 (97.7)			NT	
	Piperacillin-Tazobactam			K. pneumoniae ATCC 700603			8-32			66/66 (100)			221/221 (100)	
Tobramycin				E. faecalis ATCC 29212			8-32			NT			211/217 (97.2)	
				E. coli ATCC 25922b			0.25-1			52/53 (98.1)			NT	
	Trimethoprim-		E. coli ATCC 25922			0.12-0.5b			44/100 (100)			208/210 (99.0)		
	Sulfamethoxazole													

--- Page 14 ---
Not Applicable
7. Assay Cut-Off:
Not Applicable
B Comparison Studies:
1. Method Comparison with Predicate Device:
Clinical performance testing on the Selux AST System was initially performed at three U.S.
test sites (2 external, 1 internal). For instances in which testing was required to supplement
existing data from the original study and support specific claims, testing was performed on
three Selux AST System instruments at two testing sites.
Performance was evaluated using contemporary and stock frozen clinical isolates as well as
challenge isolates, which were selected for their resistance profiles. Clinical isolates of non-
fastidious bacteria were recovered from cultures of clinical specimens (e.g., blood, stool,
urine, respiratory, wound, aspirates) from diverse geographic locations across the U.S.
Contemporary frozen isolates were defined as isolates that had been collected and frozen
within six months of testing while stock frozen isolates were tested six or more months after
collection.
A total of 1401 clinical (426 contemporary and 975 stock) and 222 challenge isolates from
12 Enterobacterales species, Acinetobacter baumannii complex, and Pseudomonas
aeruginosa were tested to evaluate the Selux AST System performance for 24 antimicrobials
using the Selux Gram-Negative panel. Depending on the spectrum of activity, breakpoints
and the claimed organisms (species/group) for each antimicrobial on the panel, the number of
datapoints for the various antimicrobial-organisms tested varied and ranged from 165 (e.g. P.
aeruginosa/Imipenem-Relebactam) to 977 (e.g. Enterobacterales/Ertapenem). Selux results
were compared to the modal value of triplicate broth microdilution reference results
performed at an independent reference laboratory.
Performance was determined generally based on criteria outlined in the Class II Special
Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems including
essential agreement (EA), categorical agreement (CA), and categorical errors (minor, major
and very major errors). EA was calculated as the percentage of Selux MIC results that were
within plus or minus one serial two-fold dilution of the reference result. CA was calculated as
the percentage of Selux interpretive results (S/I/R) that were identical to the interpretive
results of the reference result. EA of evaluable results (on-scale Selux and reference results
or results in which an off-scale result was at least two doubling dilutions from the on-scale
result) were also calculated. Performance was considered acceptable if the EA and CA were
≥90%, major error rate was ≤3%, and very major error rate was ≤2%.
A trending analysis using combined clinical and challenge isolate results was also conducted
to evaluate antimicrobial-organism combinations for which Selux MIC results were
determined to be one or more doubling dilutions lower or higher than the reference result.
MIC results that were off-scale for both the reference and Selux were not considered in the
trending analysis. Antimicrobial-organism combinations for which the difference between
the percentage of isolates with higher or lower MIC values was ≥ 30% with a statistically
K211748 - Page 14 of 43

--- Page 15 ---
significant confidence interval were considered to have evidence of trending and is addressed
in the labeling.
A high-level summary of the Selux AST System performance using the Gram-Negative
Panel is described below for each antimicrobial and indicated species. Complete details and
results including EA, CA and error rate analyses are summarized in Table 6 and trending
analyses are summarized in Table 7.
Amikacin. A total of 111 A. baumannii isolates were evaluated with amikacin. The
combined results from clinical and challenge isolate testing demonstrated an EA of 55.0%
and CA of 86.5%, which is not acceptable. There were 6 minor, 8 major (8/80 = 10%) and 1
very major (1/25 = 4%) errors, which is not acceptable. Due to the unacceptable performance
for A. baumannii, this drug/organism combination is not indicated for use with the Selux
AST System. The following limitation is included in the device labeling to restrict reporting
of A. baumannii due to unacceptable performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Amikacin: Acinetobacter baumannii
A total of 165 P. aeruginosa isolates were evaluated with amikacin. The combined results
from clinical and challenge isolate testing demonstrated an EA of 90.9% and CA of 98.2%.
There were 3 minor, 0 major and 0 very major errors. Overall, performance is acceptable.
Analysis of trending indicated that MIC values for P. aeruginosa tended to be one doubling
dilution lower than the reference MIC value. The following statement is included in the
device labeling as a footnote to the AST performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution lower than the reference MIC value:
• Amikacin: Pseudomonas aeruginosa
Amoxicillin-Clavulanate. A total of 593 Enterobacterales isolates (indicated species: 179 E.
coli, 48 K. oxytoca, 142 K. pneumoniae, 88 P. mirabilis; non-indicated species: 74 C. koseri,
62 P. vulgaris) were evaluated with amoxicillin-clavulanate. The combined results from
clinical and challenge isolate testing demonstrated an EA of 93.3% and CA of 92.8%. There
were 37 minor, 5 major and 1 very major errors. When evaluating results by individual
species, E. coli had a CA of 88.7% due to 17 minor, 1 major and 0 very major errors which
was determined to be acceptable since the majority of categorical errors were minor and the
EA of evaluable results was good (96.5%). P. mirabilis had one very major error (1/8 =
16.7%), which was considered a random error due to the limited number of resistant isolates
tested.
Analysis of trending indicated that MIC values for K. pneumoniae tended to be one doubling
dilution lower than the reference MIC value. The following statement is included as a
footnote to the AST performance table:
K211748 - Page 15 of 43

--- Page 16 ---
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution lower than the reference MIC value:
• Amoxicillin-Clavulanate: Klebsiella pneumoniae
Ampicillin. A total of 254 Enterobacterales isolates (165 E. coli, 89 P. mirabilis) were
evaluated with ampicillin. The combined results from clinical and challenge isolate testing
demonstrated an EA of 94.9% and CA of 98.8%. There was 1 minor, 1 major and 1 very
major error. When evaluating results by individual species, P. mirabilis had 1 major error
(1/60 = 1.7%) and 1 very major error (1/26 = 3.8%) at a Selux MIC value of 2 μg/mL which
represents 4.5% (4/89) of results with this drug/organism combination. The following
limitation is included in the device labeling to address the very major error:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Ampicillin: Proteus mirabilis when the Selux MIC is 2 µg/mL due to one very
major error
Analysis of trending indicated that MIC values for E. coli tended to be one doubling dilution
lower than the reference MIC value. The following statement is included as a footnote to the
AST performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution lower than the reference MIC value:
• Ampicillin: Escherichia coli
Ampicillin-Sulbactam. A total of 123 A. baumannii isolates were evaluated with ampicillin-
sulbactam. The combined results from clinical and challenge isolate testing demonstrated an
EA of 91.9% and CA of 92.7%. There were 6 minor, 2 major and 1 very major error. Overall,
performance is acceptable.
A total of 574 Enterobacterales isolates (204 E. coli, 29 K. oxytoca, 116 K. pneumoniae, 75
M. morganii, 88 P. mirabilis, 62 P. vulgaris) were evaluated with ampicillin-sulbactam. The
combined results from clinical and challenge isolate testing demonstrated an EA of 96.9%
and CA of 83.5%. There were 90 minor, 5 major and 0 very major errors. When evaluating
results by individual species, K. oxytoca and P. mirabilis each had CA <90% which was
considered acceptable since all of the categorical errors were minor and the EA of evaluable
results was good (>95%). P. vulgaris had a CA of 45.2% due to 31 minor errors as well as 3
major errors (3/43 = 7.0%) at a Selux MIC value of 32 µg/mL which represents 9.7% (6/62)
of results with this drug/organism combination. M. morganii had a CA of 72% due to 19
minor and 2 major errors (2/4 = 50%), which is not acceptable. Due to the unacceptable
performance for M. morganii, this drug/organism combination is not indicated for use with
the Selux AST System. The following limitation is included in the device labeling address
the P. vulgaris major errors and restrict reporting of M. morganii due to unacceptable
performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
K211748 - Page 16 of 43

--- Page 17 ---
• Ampicillin-Sulbactam: Morganella morganii; Proteus vulgaris when the Selux
MIC is 32 µg/mL due to 3 major errors
A limitation statement is included in the device labeling to address the lack of testing with
resistant P. vulgaris isolates.
Analysis of trending indicated that MIC values for K. oxytoca tended to be one doubling
dilution lower than the reference MIC value while MIC values for P. vulgaris tended to be
one doubling dilution higher than the reference MIC value. The following statements are
included as a footnote to the AST performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution lower than the reference MIC value:
• Ampicillin-Sulbactam: Klebsiella oxytoca
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution higher than the reference MIC value:
• Ampicillin-Sulbactam: Proteus vulgaris
Aztreonam. A total of 183 Enterobacterales isolates (183 E. coli) were evaluated with
aztreonam. The combined results from clinical and challenge isolate testing demonstrated an
EA of 97.8% and CA of 97.3%. There were 5 minor, 0 major and 0 very major errors.
Overall, performance is acceptable.
A total of 219 P. aeruginosa isolates were evaluated with aztreonam. The combined results
from clinical and challenge isolate testing demonstrated an EA of 91.3% and CA of 87.7%.
There were 20 minor, 3 major (3/158 = 1.9%) and 4 very major (4/48 = 8.3%) errors. Due to
the unacceptable performance for P. aeruginosa, this drug/organism combination is not
indicated for use with the Selux AST System. The following limitation is included in the
device labeling to restrict reporting of P. aeruginosa due to unacceptable performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Aztreonam: Pseudomonas aeruginosa
Cefazolin. A total of 412 Enterobacterales isolates (indicated species: 177 E. coli, 115 K.
pneumoniae, 66 P. mirabilis; non-indicated species: 54 C. koseri) were evaluated with
cefazolin. The combined results from clinical and challenge isolate testing demonstrated an
EA of 94.2% and CA of 74.8%. There were 102 minor, 1 major and 1 very major errors.
When evaluating results by individual species, E. coli and K. pneumoniae each had CA
<90% which was considered acceptable since most of the categorical errors were minor and
the EA of evaluable results was good (>90%). P. mirabilis had an EA of 86.4% and an EA of
evaluable results of 84.8% (50/59), which is not acceptable. Due to the unacceptable
performance for P. mirabilis, this drug/organism combination is not indicated for use with
the Selux AST System. The following limitation statement is included in the device labeling
to restrict reporting of P. mirabilis due to unacceptable performance:
K211748 - Page 17 of 43

--- Page 18 ---
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combinations:
• Cefazolin: Proteus mirabilis
Analysis of trending indicated that MIC values for C. koseri, E. coli and K. pneumoniae
tended to be one doubling dilution lower than the reference MIC value. The following
statement is included as a footnote to the AST performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution lower than the reference MIC value:
• Cefazolin: Citrobacter koseri, Escherichia coli, Klebsiella pneumoniae
Cefepime. A total of 956 Enterobacterales isolates (77 C. freundii complex, 74 C. koseri, 77
E. cloacae complex, 170 E. coli, 52 K. aerogenes, 29 K. oxytoca, 111 K. pneumoniae, 75 M.
morganii, 88 P. mirabilis, 100 P. vulgaris, 103 S. marcescens) were evaluated with cefepime.
The combined results from clinical and challenge isolate testing demonstrated an EA of
94.8% and CA of 96.0%. There were 26 minor, 10 major and 2 very major errors. When
evaluating results by individual species, M. morganii had 1 very major error (1/1 = 100%)
and P. vulgaris had 1 very major error (1/2 = 50%), which were considered random errors
due to the insufficient number of resistant isolates tested. K. aerogenes had 2 major errors
(2/51 = 3.9%) at Selux MIC values of ≥64 µg/mL which represents 5.8% (3/52) of results
with this drug/organism combination. The following limitation is included in the device
labeling to address the major errors:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Cefepime: Klebsiella aerogenes when the Selux MIC is to ≥64 µg/mL due to two
major errors
A total of 215 P. aeruginosa isolates were evaluated with cefepime. The combined results
from clinical and challenge isolate testing demonstrated an EA of 87.4% and CA of 86.8%.
There were 0 minor, 13 major (13/178 = 7.3%) and 7 very major (7/37 = 18.9%) errors. Due
to the lack of an intermediate interpretive criterion, further analysis of the errors was
performed and adjustments were made by considering the MIC values of the errors compared
to the reference MIC value. Nine of the 13 major errors and 6 of the 7 very major errors had
an MIC value that was in essential agreement with the reference MIC value. Therefore, the
adjusted major error rate is 2.2% (4/178), which is acceptable. However, the adjusted very
major error rate is 2.7% (1/37) which is not acceptable. Due to the unacceptable performance
for P. aeruginosa, this drug/organism combination is not indicated for use with the Selux
AST System. The following limitation is included in the device labeling to restrict reporting
of P. aeruginosa due to unacceptable performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Cefepime: Pseudomonas aeruginosa
A limitation statement is included in the device labeling to address the lack of testing with
resistant K. aerogenes, M. morganii, P. vulgaris and S. marcescens isolates.
K211748 - Page 18 of 43

--- Page 19 ---
Analysis of trending indicated that MIC values for C. freundii, C. koseri, E. cloacae, E. coli,
K. aerogenes, K. oxytoca, M. morganii, P. mirabilis, P. vulgaris, S. marcescens tended to be
one doubling dilution higher than the reference MIC value. The following statement is
included as a footnote to the AST performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution higher than the reference MIC value:
• Cefepime: Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae
complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Morganella
morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens
Cefoxitin. A total of 637 Enterobacterales isolates (indicated species:168 E. coli, 29 K.
oxytoca, 133 K. pneumoniae, 64 M. morganii, 89 P. mirabilis, 100 P. vulgaris; non-indicated
species: 54 C. koseri) were evaluated with cefoxitin. The combined results from clinical and
challenge isolate testing demonstrated an EA of 92.3% and CA of 80.2%. There were 114
minor, 9 major and 3 very major errors. When evaluating results by individual species, K.
oxytoca and M. morganii had CA of <90% which was considered acceptable since most of
the categorical errors were minor and the EA of evaluable results was good (>90%). P.
mirabilis had a CA of 88.8% due to 6 minor, 2 major (2/75 = 2.7%) and 2 very major (2/7 =
28.6%) errors, which is not acceptable. P. vulgaris had an EA of 86% and a CA of 53% due
to 46 minor errors and 1 major error (1/53 = 1.9%), which is not acceptable. Due to the
unacceptable performance for P. mirabilis and P. vulgaris, these drug/organism
combinations are not indicated for use with the Selux AST System. The following limitation
is included in the device labeling to restrict reporting of P. mirabilis and P. vulgaris due to
unacceptable performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Cefoxitin: Proteus mirabilis, Proteus vulgaris
A limitation statement is included in the device labeling to address the lack of testing with
resistant K. oxytoca and P. vulgaris isolates.
There was no evidence of trending observed with any indicated species with cefoxitin.
Ceftazidime. A total of 127 A. baumannii isolates were evaluated with ceftazidime. The
combined results from clinical and challenge isolate testing demonstrated an EA of 86.6%
and CA of 94.5%. There were 7 minor, 0 major and 0 very major error. In addition, the EA of
evaluable results was 81.5% (75/92). Due to the unacceptable performance for A. baumannii,
this drug/organism combination is not indicated for use with the Selux AST System. The
following limitation is included in the device labeling to restrict reporting of A. baumannii
due to unacceptable performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Ceftazidime: Acinetobacter baumannii
K211748 - Page 19 of 43

--- Page 20 ---
A total of 787 Enterobacterales isolates (64 C. freundii, 55 C. koseri, 84 E. cloacae, 186 E.
coli, 36 K. aerogenes, 29 K. oxytoca, 145 K. pneumoniae, 66 P. mirabilis, 55 P. vulgaris, 67
S. marcescens) were evaluated with ceftazidime. The combined results from clinical and
challenge isolate testing demonstrated an EA of 95.6% and CA of 96.4%. There were 26
minor, 1 major and 1 very major errors. Overall, performance is acceptable.
A total of 224 P. aeruginosa isolates were evaluated with ceftazidime. The combined results
from clinical and challenge isolate testing demonstrated an EA of 88.0% and CA of 93.3%.
There were 9 major (9/178 = 5.1%) and 6 very major (6/46 = 13%) errors. Due to the lack of
an intermediate interpretive criterion, further analysis of the errors was performed and
adjustments were made by considering the MIC values of the errors compared to the
reference MIC value. One of the 9 major errors and 1 of the 6 very major errors had an MIC
value that was in essential agreement with the reference MIC value. Therefore, the adjusted
major error rate is 4.5% (8/177) and the adjusted very major error rate is 10.9% (5/46), which
is not acceptable. Due to the unacceptable performance for P. aeruginosa, this drug/organism
combination is not indicated for use with the Selux AST System. The following limitation is
included in the device labeling to restrict reporting of P. aeruginosa due to unacceptable
performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Ceftazidime: Pseudomonas aeruginosa
Analysis of trending indicated that MIC values for C. freundii complex, C. koseri, E.
cloacae, K. aerogenes, K. oxytoca, K. pneumoniae, P. mirabilis, P. vulgaris, and S.
marcescens tended to be one doubling dilution higher than the reference MIC value. The
following statement is included as a footnote to the AST performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution higher than the reference MIC value:
• Ceftazidime: Citrobacter freundii complex, Citrobacter koseri, Enterobacter
cloacae, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae,
Proteus mirabilis, Proteus vulgaris, Serratia marcescens
Ceftazidime-avibactam. A total of 815 Enterobacterales isolates (61 C. freundii, 54 C.
koseri, 75 E. cloacae, 170 E. coli, 52 K. aerogenes, 28 K. oxytoca, 126 K. pneumoniae, 62 M.
morganii, 66 P. mirabilis, 55 P. vulgaris, 66 S. marcescens) were evaluated with
ceftazidime-avibactam. The combined results from clinical and challenge isolate testing
demonstrated an EA of 97.3% and CA of 99.4%. There were 5 major and 0 very major
errors. Overall, performance is acceptable.
A total of 163 P. aeruginosa isolates were evaluated with ceftazidime-avibactam. The
combined results from clinical and challenge isolate testing demonstrated an EA of 89.6%
and CA of 96.9%. There were 4 major errors (4/153 = 2.6%) and 1 very major error (1/10 =
10%). Due to the lack of an intermediate interpretive criterion, further analysis of the errors
was performed and adjustments were made by considering the MIC values of the errors
compared to the reference MIC value. Two of the 4 major errors and 1 of the 1 very major
errors had an MIC value that was in essential agreement with the reference MIC value.
K211748 - Page 20 of 43

--- Page 21 ---
Therefore, the adjusted major error rate is 1.3% (2/153) and the adjusted very major error
rate is 0% (0/10), which is acceptable.
A limitation statement is included in the device labeling to address the lack of testing with
resistant C. koseri, K. aerogenes, K. oxytoca, M. morganii, P. mirabilis, P. vulgaris and S.
marcescens isolates.
Analysis of trending indicated that MIC values for C. freundii, C. koseri, E. coli, K.
aerogenes, K. oxytoca, M. morganii, P. mirabilis, and P. vulgaris tended to be one doubling
dilution higher than the reference MIC value. The following statement is included as a
footnote to the AST performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution higher than the reference MIC value:
• Ceftazidime-avibactam: Citrobacter freundii, Citrobacter koseri, Escherichia
coli, Klebsiella aerogenes, Klebsiella oxytoca, Morganella morganii, Proteus
mirabilis, Proteus vulgaris
Ceftriaxone. A total of 722 Enterobacterales isolates (64 C. freundii, 54 C. koseri, 84 E.
cloacae, 175 E. coli, 35 K. aerogenes, 29 K. oxytoca, 109 K. pneumoniae, 67 P. mirabilis,
105 S. marcescens) were evaluated with ceftriaxone. The combined results from clinical and
challenge isolate testing demonstrated an EA of 97.5% and CA of 98.5%. There were 3
minor, 4 major and 4 very major errors. When evaluating results by individual species, E.
cloacae had 3 very major errors (3/34 = 8.8%) and S. marcescens had 1 very major error
(1/12 = 8.3%), which are not acceptable. Due to the unacceptable performance for E. cloacae
and S. marcescens, these drug/organism combinations are not indicated for use with the
Selux AST System. The following limitation is included in the device labeling to restrict
reporting of E. cloacae and S. marcescens due to unacceptable performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Ceftriaxone: Enterobacter cloacae, Serratia marcescens
Analysis of trending indicated that MIC values for C. freundii, C. koseri, E. coli, K.
aerogenes, K. oxytoca, and P. mirabilis tended to be one doubling dilution higher than the
reference MIC value. The following statement is included as a footnote to the AST
performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution higher than the reference MIC value:
• Ceftriaxone: Citrobacter freundii, Citrobacter koseri, Escherichia coli, Klebsiella
aerogenes, Klebsiella oxytoca, Proteus mirabilis
Ciprofloxacin. A total of 818 Enterobacterales isolates (62 C. freundii, 55 C. koseri, 76 E.
cloacae, 170 E. coli, 32 K. aerogenes, 29 K. oxytoca, 105 K. pneumoniae, 63 M. morganii,
67 P. mirabilis, 55 P. vulgaris, 104 S. marcescens) were evaluated with ciprofloxacin. The
combined results from clinical and challenge isolate testing demonstrated an EA of 96.7%
and CA of 96.2%. There were 26 minor, 3 major and 2 very major errors. When evaluating
K211748 - Page 21 of 43

--- Page 22 ---
results by individual species, S. marcescens had 2 very major errors (2/12 = 16.7%), which is
not acceptable. Due to the unacceptable performance for S. marcescens, this drug/organism
combination is not indicated for use with the Selux AST System.The following limitation is
included in the device labeling to restrict reporting of S. marcescens due to unacceptable
performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Ciprofloxacin: Serratia marcescens
A total of 169 P. aeruginosa isolates were evaluated with ciprofloxacin. The combined
results from clinical and challenge isolate testing demonstrated an EA of 95.9% and CA of
94.7%. There were 5 minor, 4 major and 0 very major errors. Overall, performance is
acceptable.
A limitation statement is included in the device labeling to address the lack of testing with
resistant C. koseri and P. vulgaris isolates.
Analysis of trending indicated that MIC values for P. aeruginosa tended to be one doubling
dilution lower than the reference MIC value while MIC values for C. freundii, C. koseri, E.
cloacae, E. coli, K. aerogenes, K. oxytoca, M. morganii, and P. vulgaris tended to be one
doubling dilution higher than the reference MIC value. The following statements are
included as a footnote to the AST performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution lower than the reference MIC value:
• Ciprofloxacin: Pseudomonas aeruginosa
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution higher than the reference MIC value:
• Ciprofloxacin: Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae,
Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Morganella morganii,
Proteus vulgaris
Eravacycline. A total of 487 Enterobacterales isolates (62 C. freundii, 78 E. cloacae, 167 E.
coli, 47 K. oxytoca, 133 K. pneumoniae) were evaluated with eravacycline. The combined
results from clinical and challenge isolate testing demonstrated an EA of 98.2% and CA of
98.6%. There were 4 major and 3 very major errors. When evaluating results by individual
species, E. cloacae had 3 major errors (3/59 = 5.1%), K. oxytoca had 1 very major error (1/1
=100%), and K. pneumoniae had 2 very major errors (2/30 = 6.7%). Due to the lack of an
intermediate interpretive criterion (eravacycline only has a “susceptible” category), further
analysis of the errors was performed and adjustments were made by considering the MIC
values of the errors compared to the reference MIC value. Two of the 3 E. cloacae major
errors and 1 of the 1 K. oxytoca very major errors had an MIC value that was in essential
agreement with the reference MIC value. Therefore, the adjusted major error rate for E.
cloacae is 1.7% (1/59) and the adjusted very major error rate for K. oxytoca is 0% (0/1),
which is acceptable. None of the 2 K. pneumoniae very major errors were in essential
agreement resulting in an unacceptable very major error rate. Due to the unacceptable
K211748 - Page 22 of 43

--- Page 23 ---
performance for K. pneumoniae, this drug/organism combination is not indicated for use with
the Selux AST System. The following limitation is included in the device labeling to restrict
reporting of K. pneumoniae due to unacceptable performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Eravacycline: Klebsiella pneumoniae
A limitation statement is included in the device labeling to address the lack of testing with
resistant E. coli and K. oxytoca isolates.
Analysis of trending indicated that MIC values for C. freundii tended to be one doubling
dilution higher than the reference MIC value. The following statement is included as a
footnote to the AST performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution higher than the reference MIC value:
• Eravacycline: Citrobacter freundii
Ertapenem. A total of 977 Enterobacterales isolates (56 C. freundii, 74 C. koseri, 95 E.
cloacae, 210 E. coli, 55 K. aerogenes, 28 K. oxytoca, 141 K. pneumoniae, 62 M. morganii,
88 P. mirabilis, 100 P. vulgaris, 68 S. marcescens) were evaluated with ertapenem. The
combined results from clinical and challenge isolate testing demonstrated an EA of 94.7%
and CA of 97.4%. There were 11 minor, 14 major and 0 very major errors. When evaluating
results by individual species, C. freundii had 3 major errors (3/53 = 5.7%) at Selux MIC
values of 2, 4 and 8 μg/mL which represent 5.4% (3/56) of results from this drug/organism
combination. E. cloacae had an EA of 80%, a CA of 88.4%, and 6 major errors (6/70 =
8.6%), which is not acceptable. K. aerogenes had an EA of 80% and 2 major errors (2/50 =
4%), which is not acceptable. Due to the unacceptable performance for E. cloacae and K.
aerogenes, these drug/organism combinations are not indicated for use with the Selux AST
System. The following limitation is included in the device labeling to address the C. freundii
major errors and restrict reporting of E. cloacae and K. aerogenes due to unacceptable
performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Ertapenem: Citrobacter freundii when the Selux MIC is 2, 4 or 8 µg/mL due to 3
major errors, Enterobacter cloacae, Klebsiella aerogenes
A limitation statement is included in the device labeling to address the lack of testing with
resistant C. koseri, K. oxytoca, M. morganii, P. mirabilis, and P. vulgaris isolates.
Analysis of trending indicated that MIC values for M. morganii tended to be one doubling
dilution lower than the reference MIC value while MIC values for C. freundii, C. koseri, E.
coli, P. mirabilis, P. vulgaris and S. marcescens tended to be one doubling dilution higher
than the reference MIC value. The following statements are included as footnotes to the AST
performance table:
K211748 - Page 23 of 43

--- Page 24 ---
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution lower than the reference MIC value:
• Ertapenem: Morganella morganii
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution higher than the reference MIC value:
• Ertapenem: Citrobacter freundii, Citrobacter koseri, Escherichia coli, Proteus
mirabilis, Proteus vulgaris, Serratia marcescens
Gentamicin. A total of 817 Enterobacterales isolates (indicated species: 56 C. freundii, 74 C.
koseri, 95 E. cloacae, 210 E. coli, 55 K. aerogenes, 28 K. oxytoca, 141 K. pneumoniae, 88 P.
mirabilis, 100 P. vulgaris, 68 S. marcescens; non-indicated species: 62 M. morganii) were
evaluated with gentamicin. The combined results from clinical and challenge isolate testing
demonstrated an EA of 96.0% and CA of 98.8%. There were 7 minor, 1 major and 2 very
major errors. When evaluating results by individual species, M. morganii had 1 very major
error (1/8 = 12.5%) and P. mirabilis had 1 very major error (1/6 = 16.7%), which were
considered random errors due to the limited number of resistant isolates tested.
A total of 218 P. aeruginosa were evaluated with gentamicin. The combined results from
clinical and challenge isolate testing demonstrated an EA of 88.5% and CA of 97.3%. There
were 6 minor, 0 major and 0 very major errors. Restriction of reporting MIC values of ≤ 0.06
µg/mL (lowest reportable MIC value that represents 4.1% (9/218) of results from this
drug/organism combination) improved the EA to 90.4%, which is acceptable. The following
limitation statement is included in the device labeling to restrict reporting of P. aeruginosa
due to the low EA:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combinations:
• Gentamicin: Pseudomonas aeruginosa when the Selux MIC is ≤ 0.06 µg/mL
A limitation statement is included in the device labeling to address the lack of testing with
resistant K. aerogenes, M. morganii, P. vulgaris, and S. marcescens isolates.
Analysis of trending indicated that MIC values for C. freundii, E. cloacae complex, E. coli,
K. oxytoca, and K. pneumoniae tended to be one doubling dilution lower than the reference
MIC value while MIC values for S. marcescens tended to be one doubling dilution higher
than the reference MIC value. The following statements are included as footnotes to the AST
performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution lower than the reference MIC value:
• Gentamicin: Citrobacter freundii, Enterobacter cloacae, Escherichia coli,
Klebsiella oxytoca, Klebsiella pneumoniae
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution higher than the reference MIC value:
• Gentamicin: Serratia marcescens
K211748 - Page 24 of 43

--- Page 25 ---
Imipenem. A total of 126 A. baumannii isolates were evaluated with imipenem. The
combined results from clinical and challenge isolate testing demonstrated an EA of 88.9%
and CA of 98.4%. There were 0 minor, 0 major and 2 very major errors (2/62 = 3.2%), which
is not acceptable. Due to the unacceptable performance for A. baumannii, this drug/organism
combination is not indicated for use with the Selux AST System. The following limitation
statement is included in the device labeling to restrict reporting of A. baumannii due to the
unacceptable performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combinations:
• Imipenem: Acinetobacter baumannii
Imipenem-relebactam. A total of 471 Enterobacterales isolates (55C. freundii, 55 C. koseri,
172 E. coli, 31 K. aerogenes, 27 K. oxytoca, 131 K. pneumoniae) were evaluated with
imipenem-relebactam. The combined results from clinical and challenge isolate testing
demonstrated an EA of 93.4% and CA of 97.5%. There were 9 minor, 3 major and 0 very
major errors. When evaluating results by individual species, K. oxytoca had 1 major error
(1/27 = 3.7%) at a Selux MIC value of 4 µg/mL which represents 3.7% (1/27) of results from
this drug/organism combination. K. aerogenes and K. pneumoniae had an EA <90%, which
is not acceptable. Due to the unacceptable performance for K. aerogenes and K. pneumoniae,
these drug/organism combinations are not indicated for use with the Selux AST System. The
following limitation is included in the device labeling to address the K. oxytoca major error
and restrict reporting of K. aerogenes and K. pneumoniae due to unacceptable performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Imipenem-relebactam: Klebsiella oxytoca when the Selux MIC is 4 µg/mL due to
one major error, Klebsiella pneumoniae, Klebsiella aerogenes
A total of 165 P. aeruginosa isolates were evaluated with imipenem-relebactam. The
combined results from clinical and challenge isolate testing demonstrated an EA of 96.4%
and CA of 98.2%. There were 3 minor, 0 major and 0 very major errors. Overall,
performance was acceptable.
A limitation statement is included in the device labeling to address the lack of testing with
resistant C. koseri, K. aerogenes, and K. oxytoca isolates.
Analysis of trending indicated that MIC values for C. freundii tended to be one doubling
dilution lower than the reference MIC value while MIC values for K. oxytoca tended to be
one doubling dilution higher than the reference MIC value. The following statements are
included as footnotes to the AST performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution lower than the reference MIC value:
• Imipenem-relebactam: Citrobacter freundii
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution higher than the reference MIC value:
K211748 - Page 25 of 43

--- Page 26 ---
• Imipenem-relebactam: Klebsiella oxytoca
Levofloxacin. A total of 784 Enterobacterales isolates (63 C. freundii, 54 C. koseri, 75 E.
cloacae, 171 E. coli, 32 K. aerogenes, 27 K. oxytoca, 110 K. pneumoniae, 62 M. morganii,
67 P. mirabilis, 55 P. vulgaris, 68 S. marcescens) were evaluated with levofloxacin. The
combined results from clinical and challenge isolate testing demonstrated an EA of 96.1%
and CA of 94.9%. There were 33 minor, 6 major and 1 very major errors. When evaluating
results by individual species, K. aerogenes had 1 major error (1/30 = 3.3%) at a Selux MIC
value of 2 µg/mL, which represents 3.1% (1/32) of results from this drug/organism
combination. C. freundii had 2 major errors (2/55 = 3.6%) at a Selux MIC value of 2 µg/mL
which represent 4.8% (3/63) of results from this drug/organism combination, as well as 1
very major error (1/7 = 14.3%), which was considered a random error due to the limited
number of resistant isolates tested. The following limitation is included in the device labeling
to address the major errors:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Levofloxacin: Citrobacter freundii when the Selux MIC is 2 µg/mL due to two
major errors, Klebsiella aerogenes when the Selux MIC is 2 µg/mL due to one
major error
A total of 171 P. aeruginosa isolates were evaluated with levofloxacin. The combined results
from clinical and challenge isolate testing demonstrated an EA of 94.2% and CA of 90.1%.
There were 14 minor, 1 major and 2 very major errors (2/42 = 4.8%), which is not
acceptable. Due to the unacceptable performance for P. aeruginosa, this drug/organism
combination is not indicated for use with the Selux AST System. The following limitation is
included in the device labeling to restrict reporting of P. aeruginosa due to unacceptable
performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Levofloxacin: Pseudomonas aeruginosa
A limitation statement is included in the device labeling to address the lack of testing with
resistant C. koseri isolates.
Analysis of trending indicated that MIC values for C. freundii, C. koseri, E. cloacae, E. coli,
K. aerogenes, K. oxytoca, K. pneumoniae, M. morganii, P. mirabilis, and P. vulgaris tended
to be one doubling dilution higher than the reference MIC value. The following statement is
included as a footnote to the AST performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution higher than the reference MIC value:
• Levofloxacin: C. freundii, C. koseri, E. cloacae, E. coli, K. aerogenes, K. oxytoca,
K. pneumoniae, M. morganii, P. mirabilis, P. vulgaris
Meropenem. A total of 126 A. baumannii isolates were evaluated with meropenem. The
combined results from clinical and challenge isolate testing demonstrated an EA of 86.5%
K211748 - Page 26 of 43

--- Page 27 ---
and CA of 98.4%. There were 0 minor, 2 major (2/63 = 3.2%) and 0 very major errors. Due
to the unacceptable performance for A. baumannii, this drug/organism combination is not
indicated for use with the Selux AST System. The following limitation statement is included
in the device labeling to restrict reporting of A. baumannii due to the unacceptable
performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combinations:
• Meropenem: Acinetobacter baumannii
A total of 865 Enterobacterales isolates (indicated species: 78 C. freundii, 74 C. koseri, 74 E.
cloacae, 166 E. coli, 27 K. oxytoca, 126 K. pneumoniae, 62 M. morganii, 66 P. mirabilis, 55
P. vulgaris, 105 S. marcescens; non-indicated species: 32 K. aerogenes) were evaluated with
meropenem. The combined results from clinical and challenge isolate testing demonstrated
an EA of 96.3% and CA of 98.0%. There were 4 minor, 12 major and 1 very major errors.
When evaluating results by individual species, C. freundii has 3 major errors (3/74 = 4.1%) at
Selux MIC values of 16 and 32 µg/mL, which represent 6.4% (5/78) of results from this
drug/organism combination. S. marcescens had 4 major errors (4/101 = 4.0%) at Selux MIC
value of 16 and 32 µg/mL, which represent 6.7% (7/105) of results from this drug/organism
combination, as well as 1 very major error (1/4 = 25%) which was considered a random error
due to the limited number of resistant isolates tested. The following limitations are included
in the device labeling to address the major errors:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Meropenem: Citrobacter freundii complex when the Selux MIC is 16 or 32
μg/mL due to 3 major errors, Serratia marcescens when the Selux MIC is 16 or
32 μg/mL due to 4 major errors
A total of 175 P. aeruginosa isolates were evaluated with levofloxacin. The combined results
from clinical and challenge isolate testing demonstrated an EA of 93.1% and CA of 96.0%.
There were 7 minor, 0 major and 0 very major errors. Overall, performance was acceptable.
A limitation is included in the device labeling to address the lack of testing with resistant C.
koseri, K. oxytoca, M. morganii, P. vulgaris isolates.
Analysis of trending indicated that MIC values for C. freundii, C. koseri, E. cloacae, K.
aerogenes, K. oxytoca, K. pneumoniae, M. morganii, P. mirabilis, P. vulgaris, and S.
marcescens tended to be one doubling dilution higher than the reference MIC value. The
following statement is included as a footnote to the AST performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution higher than the reference MIC value:
• Meropenem: Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae,
Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella
morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens
K211748 - Page 27 of 43

--- Page 28 ---
Meropenem-vaborbactam. A total of 865 Enterobacterales isolates (indicated species: 64 C.
freundii, 54 C. koseri, 70 E. cloacae, 167 E. coli, 50 K. aerogenes, 47 K. oxytoca, 113 K.
pneumoniae, 64 M. morganii, 66 P. mirabilis, 65 S. marcescens; non-indicated species: 100
P. vulgaris) were evaluated with meropenem-vaborbactam. The combined results from
clinical and challenge isolate testing demonstrated an EA of 91.7% and CA of 96.9%. There
were 10 minor, 16 major and 1 very major errors. When evaluating results by individual
species, P. mirabilis had an EA of 62%, CA of 97.0%, 2 minor, 0 major and 0 very major
errors. P. vulgaris had an EA of 62%, CA of 81%, 15 major errors (15/100 = 15%). Due to
the unacceptable performance for P. mirabilis and P. vulgaris, these drug/organism
combinations are not indicated for use with the Selux AST System.The following limitation
is included in the device labeling to restrict reporting due to unacceptable performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Meropenem-vaborbactam: Proteus mirabilis; Proteus vulgaris
A limitation is included in the device labeling to address the lack of testing with resistant C.
koseri, K. aerogenes, K. oxytoca, M. morganii, P. mirabilis, P. vulgaris, and S. marcescens
isolates.
Analysis of trending indicated that MIC values for C. freundii, C. koseri, E. cloacae
complex, E. coli, K. aerogenes, K. oxytoca, K. pneumoniae, M. morganii, and S. marcescens
tended to be one doubling dilution higher than the reference MIC value. The following
statement is included as a footnote to the AST performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution higher than the reference MIC value:
• Meropenem-vaborbactam: Citrobacter freundii, Citrobacter koseri, Enterobacter
cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca,
Klebsiella pneumoniae, Morganella morganii, Serratia marcescens
Minocycline. A total of 199 A. baumannii isolates were evaluated with minocycline. The
combined results from clinical and challenge isolate testing demonstrated an EA of 88.9%
and CA of 91.0%. There were 13 minor, 5 major (5/150 = 3.3%) and 0 very major errors.
Due to the unacceptable performance for A. baumannii, this drug/organism combination is
not indicated for use with the Selux AST System. The following limitation statement is
included in the device labeling to restrict reporting of A. baumannii due to unacceptable
performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combinations:
• Minocycline: Acinetobacter baumannii
A total of 404 Enterobacterales isolates (198 E. coli, 53 K. aerogenes, 27 K. oxytoca, 126 K.
pneumoniae) were evaluated with minocycline. The combined results from clinical and
challenge isolate testing demonstrated an EA of 89.6% and CA of 94.3%. There were 16
minor, 3 major and 4 very major errors. When evaluating results by individual species, E.
coli had an EA of 87.4% as well as 8 minor, 2 major (2/182 = 1.1%) and 1 very major (1/7 =
K211748 - Page 28 of 43

--- Page 29 ---
14.3%) errors, which was considered a random error due to the limited number of resistant
isolates tested. K. aerogenes had 1 very major error (1/3 = 33.3%), which was considered a
random error due to the limited number of resistant isolates tested. K. pneumoniae had an EA
of 88.9% and 2 very major errors (2/33 = 6.1%) at a Selux MIC of 4. Restricting K.
pneumoniae reporting at a Selux MIC of 4 μg/mL, which represents 6.3% (8/126) of results
from this drug/organism combination addresses both very major errors and improves EA to
89.8%. Due to the unacceptable performance for E. coli, this drug/organism combination is
not indicated for use with the Selux AST System. The following limitation statement is
included in the device labeling to restrict reporting of E. coli due to unacceptable
performance and address the K. pneumoniae very major errors:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Minocycline: Escherichia coli, Klebsiella pneumoniae when the Selux MIC is 4
μg/mL due to two very major errors
A limitation is included in the device labeling to address the lack of testing with resistant K.
oxytoca isolates.
There was no evidence of trending observed with Enterobacterales with minocycline.
Piperacillin-tazobactam. A total of 113 A. baumannii isolates were evaluated with
piperacillin-tazobactam. The combined results from clinical and challenge isolate testing
demonstrated an EA of 81.4% and CA of 91.2%. There were 9 minor errors, 0 major errors
and 1 very major error (1/58 = 1.7%). Due to the unacceptable performance for A.
baumannii, this drug/organism combination is not indicated for use with the Selux AST
System. The following limitation statement is included in the device labeling to restrict
reporting of A. baumannii due to unacceptable performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combinations:
• Piperacillin-tazobactam: Acinetobacter baumannii
A total of 926 Enterobacterales isolates (indicated species: 75 C. koseri, 176 E. coli, 142 K.
pneumoniae, 75 M. morganii, 88 P. mirabilis, 55 P. vulgaris, 60 S. marcescens; non-
indicated species: 78 C. freundii, 96 E. cloacae, 53 K. aerogenes, 28 K. oxytoca) were
evaluated with piperacillin-tazobactam. The combined results from clinical and challenge
isolate testing demonstrated an EA of 90.2% and CA of 94.8%. There were 35 minor, 9
major and 4 very major errors. When evaluating results by individual species, C. freundii had
an EA of 79.5%, CA of 84.6% as well as 11 minor, 0 major, and 1 very major (1/11 = 9.1%)
errors. E. cloacae had an EA and CA of 86.5% as well as 9 minor and 4 major (4/61 = 6.6%)
errors. K. aerogenes had an EA of 86.8% as well as 2 minor and 2 major (2/42 = 4.8%)
errors. S. marcescens had an EA of 66.7% as well as 1 minor and 1 very major (1/2) error,
which was considered a random error due to the limited number of resistant isolates tested.
Due to the unacceptable performance for reporting of C. freundii, E. cloacae, K. aerogenes
and S. marcescens, these drug/organism combinations are not indicated for use with the
Selux AST System. The following limitation statement is included in the device labeling to
K211748 - Page 29 of 43

--- Page 30 ---
restrict reporting of C. freundii, E. cloacae, K. aerogenes and S. marcescens due to
unacceptable performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Piperacillin-tazobactam: Citrobacter freundii, Enterobacter cloacae, Klebsiella
aerogenes, Serratia marcescens
A total of 217 P. aeruginosa isolates were evaluated with piperacillin-tazobactam. The
combined results from clinical and challenge isolate testing demonstrated an EA of 80.7%
and CA of 83.9%. There were 27 minor errors, 2 major errors (2/167 = 1.2%), and 6 very
major errors (6/28 = 21.4%). Due to the unacceptable performance for P. aeruginosa, this
drug/organism combination is not indicated for use with the Selux AST System. The
following limitation statement is included in the device labeling to restrict reporting of P.
aeruginosa due to unacceptable performance:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combinations:
• Piperacillin-tazobactam: Pseudomonas aeruginosa
A limitation is included in the device labeling to address the lack of testing with resistant C.
koseri, P. mirabilis, and P. vulgaris isolates.
Analysis of trending indicated that MIC values for K. oxytoca and K. pneumoniae tended to
be one doubling dilution lower than the reference MIC value while MIC values for M.
morganii, P. mirabilis and P. vulgaris tended to be one doubling dilution higher than the
reference MIC value. The following statements are included as a footnote to the AST
performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution lower than the reference MIC value:
• Piperacillin-tazobactam: Klebsiella oxytoca, Klebsiella pneumoniae
Selux MIC values for the following antimicrobial/organism combinations tended to
be one doubling dilution higher than the reference MIC value:
• Piperacillin-tazobactam: Morganella morganii, Proteus mirabilis, Proteus
vulgaris
Tobramycin. A total of 166 P. aeruginosa isolates were evaluated with tobramycin. The
combined results from clinical and challenge isolate testing demonstrated an EA of 93.4% and
CA of 97.6%. There were 3 minor errors, 1 major error (1/150 = 0.7%), and 0 very major errors
(6/28 = 21.4%). Overall, performance was acceptable.
There was no evidence of trending observed with P. aeruginosa with tobramycin.
Trimethoprim-Sulfamethoxazole. A total of 526 Enterobacterales isolates (indicated species:
76 E. cloacae, 203 E. coli, 32 K. aerogenes, 29 K. oxytoca, 109 K. pneumoniae; non-indicated
species: 77 C. freundii) were evaluated with trimethoprim-sulfamethoxazole. The combined
K211748 - Page 30 of 43

--- Page 31 ---
results from clinical and challenge isolate testing demonstrated an EA of 97.0% and CA of
98.5%. There were 0 minor, 2 major and 6 very major errors. When evaluating results by
individual species, C. freundii had 1 very major error (1/17 = 5.9%), E. coli had 4 very major
errors (4/67 = 6.0%), K. pneumoniae had 2 major (2/61 = 3.3%) and 1 very major (1/28 = 3.6%)
errors. Due to the lack of an intermediate interpretive criterion, further analysis of the errors was
performed and adjustments were made by considering the MIC values of the errors compared to
the reference MIC value. One of the 2 major errors and 1 of the 1 very major errors from K.
pneumoniae had an MIC value that was in essential agreement with the reference MIC value.
Therefore, K. pneumoniae has an adjusted major error rate of 1.6% (1/61) and an adjusted very
major error rate of 0% (0/28), which is acceptable. Due to the unacceptable performance for C.
freundii and E. coli, these drug/organism combinations are not indicated for use with the Selux
AST System. The following limitation statement is included in the device labeling to restrict
reporting of C. freundii and E. coli:
Perform an alternative method of testing prior to reporting results for the following
antibiotic/organism combination(s):
• Trimethoprim-Sulfamethoxazole: Citrobacter freundii, Escherichia coli
Analysis of trending indicated that MIC values for E. cloacae, K. aerogenes, K. oxytoca, and K.
pneumoniae tended to be one doubling dilution higher than the reference MIC value. The
following statement is included as a footnote to the AST performance table:
Selux MIC values for the following antimicrobial/organism combinations tended to be
one doubling dilution higher than the reference MIC value:
Trimethoprim-Sulfamethoxazole: Enterobacter cloacae, Klebsiella aerogenes, Klebsiella
oxytoca, Klebsiella pneumoniae
Table 6. Selux AST System – Gram-Negative Panel Performance
Eval No. Eval
No. EA No. CA No. R
Tot EA Eval EA No. S min maj vmj
EA % CA % or NS
Tot EA %
aAmikacin - Acinetobacter baumannii [Breakpoints (μg/mL): 16 (S), 32 (I), 64 (R)]
Clinical 86 47 54.65 77 38 49.35 78 90.7 14 69 3 4 1
Challenge 25 14 56 16 5 31.25 18 72 11 11 3 4 0
Combined 111 61 54.95 93 43 46.24 96 86.49 25 80 6 8 1
Amikacin - Pseudomonas aeruginosa [Breakpoints (μg/mL): 16 (S), 32 (I), 64 (R)]
Clinical 159 145 91.19 158 144 91.14 156 98.11 3 154 3 0 0
Challenge 6 5 83.33 5 4 80 6 100 4 2 0 0 0
Combined 165 150 90.91 163 148 90.8 162 98.18 7 156 3 0 0
Amoxicillin-Clavulanate – Enterobacterales [Breakpoints (μg/mL): 8 (S), 16 (I), 32 (R)]
Clinical 502 463 92.23 454 415 91.41 460 91.63 40 412 37 4 1
Challenge 91 90 98.9 49 48 97.96 90 98.9 71 19 0 1 0
Combined 593 553 93.25 503 463 92.05 550 92.75 111 431 37 5 1
Ampicillin: Enterobacterales [Breakpoints (μg/mL): 8 (S), 16 (I), 32 (R)]
Clinical 247 234 94.74 138 125 90.58 244 98.79 111 135 1 1 1
Challenge 7 7 100 0 0 NA 7 100 7 0 0 0 0
Combined 254 241 94.88 138 125 90.58 251 98.82 118 135 1 1 1
Ampicillin-Sulbactam: Acinetobacter baumannii [Breakpoints (μg/mL): 8 (S), 16 (I), 32 (R)]
Clinical 121 111 91.74 111 101 90.99 112 92.56 50 65 6 2 1
Challenge 2 2 100 2 2 100 2 100 2 0 0 0 0
Combined 123 113 91.87 113 103 91.15 114 92.68 52 65 6 2 1
Ampicillin-Sulbactam: Enterobacterales [Breakpoints (μg/mL): 8 (S), 16 (I), 32 (R)]
K211748 - Page 31 of 43

[Table 1 on page 31]
		Tot	No.
EA	EA
%		Eval			No.			Eval		No.
CA	CA
%	No. R
or NS	No. S	min	maj	vmj	
						EA			Eval			EA									
						Tot			EA			%									
	aAmikacin - Acinetobacter baumannii [Breakpoints (μg/mL): 16 (S), 32 (I), 64 (R)]																				
Clinical		86	47	54.65	77			38			49.35			78	90.7	14	69	3	4	1	
Challenge		25	14	56	16			5			31.25			18	72	11	11	3	4	0	
Combined		111	61	54.95	93			43			46.24			96	86.49	25	80	6	8	1	
	Amikacin - Pseudomonas aeruginosa [Breakpoints (μg/mL): 16 (S), 32 (I), 64 (R)]																				
Clinical		159	145	91.19	158			144			91.14			156	98.11	3	154	3	0	0	
Challenge		6	5	83.33	5			4			80			6	100	4	2	0	0	0	
Combined		165	150	90.91	163			148			90.8			162	98.18	7	156	3	0	0	
	Amoxicillin-Clavulanate – Enterobacterales [Breakpoints (μg/mL): 8 (S), 16 (I), 32 (R)]																				
Clinical		502	463	92.23	454			415			91.41			460	91.63	40	412	37	4	1	
Challenge		91	90	98.9	49			48			97.96			90	98.9	71	19	0	1	0	
Combined		593	553	93.25	503			463			92.05			550	92.75	111	431	37	5	1	
	Ampicillin: Enterobacterales [Breakpoints (μg/mL): 8 (S), 16 (I), 32 (R)]																				
Clinical		247	234	94.74	138			125			90.58			244	98.79	111	135	1	1	1	
Challenge		7	7	100	0			0			NA			7	100	7	0	0	0	0	
Combined		254	241	94.88	138			125			90.58			251	98.82	118	135	1	1	1	
	Ampicillin-Sulbactam: Acinetobacter baumannii [Breakpoints (μg/mL): 8 (S), 16 (I), 32 (R)]																				
Clinical		121	111	91.74	111			101			90.99			112	92.56	50	65	6	2	1	
Challenge		2	2	100	2			2			100			2	100	2	0	0	0	0	
Combined		123	113	91.87	113			103			91.15			114	92.68	52	65	6	2	1	
	Ampicillin-Sulbactam: Enterobacterales [Breakpoints (μg/mL): 8 (S), 16 (I), 32 (R)]																				

[Table 2 on page 31]
No.
EA

[Table 3 on page 31]
EA
%

[Table 4 on page 31]
No.
CA

[Table 5 on page 31]
CA
%

[Table 6 on page 31]
No. R
or NS

--- Page 32 ---
Eval No. Eval
No. EA No. CA No. R
Tot EA Eval EA No. S min maj vmj
EA % CA % or NS
Tot EA %
Clinical 518 502 96.91 475 459 96.63 433 83.59 163 279 81 4 0
Challenge 56 54 96.43 26 24 92.31 46 82.14 39 11 9 1 0
Combined 574 556 96.86 501 483 96.41 479 83.45 202 290 90 5 0
aAztreonam: Enterobacterales [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]
Clinical 159 156 98.11 144 141 97.92 154 96.86 22 129 5 0 0
Challenge 24 23 95.83 10 9 90 24 100 24 0 0 0 0
Combined 183 179 97.81 154 150 97.4 178 97.27 46 129 5 0 0
Aztreonam: Pseudomonas aeruginosa [Breakpoints (μg/mL): 8 (S), 16 (I), 32 (R)]
Clinical 208 189 90.87 202 183 90.59 181 87.02 37 158 20 3 4
Challenge 11 11 100 4 4 100 11 100 11 0 0 0 0
Combined 219 200 91.32 206 187 90.78 192 87.67 48 158 20 3 4
Cefazolin: Enterobacterales [Breakpoints (μg/mL): 1 (S), 2 (I), 4 (R)]
Clinical 368 344 93.48 290 266 91.72 264 71.74 174 99 102 1 1
Challenge 44 44 100 0 0 NA 44 100 44 0 0 0 0
Combined 412 388 94.17 290 266 91.72 308 74.76 218 99 102 1 1
Cefepime: Enterobacterales [Breakpoints (μg/mL): 2 (S), 4-8 (I), 16 (R)]
Clinical 905 857 94.7 127 79 62.2 867 95.8 78 810 26 10 2
Challenge 51 49 96.08 17 15 88.24 51 100 49 2 0 0 0
Combined 956 906 94.77 144 94 65.28 918 96.03 127 812 26 10 2
aCefepime: Pseudomonas aeruginosa [Breakpoints (μg/mL): 8 (S), - (I), 16 (R)]
Clinical 208 182 87.5 203 177 87.19 188 90.38 30 178 0 13 7
Challenge 7 6 85.71 2 1 50 7 100 7 0 0 0 0
Combined 215 188 87.44 205 178 86.83 195 90.7 37 178 0 13 7
Cefoxitin: Enterobacterales [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]
Clinical 600 551 91.83 576 527 91.49 474 79 71 394 114 9 3
Challenge 37 37 100 15 15 100 37 100 35 2 0 0 0
Combined 637 588 92.31 591 542 91.71 511 80.22 106 396 114 9 3
aCeftazidime: Acinetobacter baumannii [Breakpoints (μg/mL): 8 (S), 16 (I), 32 (R)]
Clinical 121 105 86.78 90 74 82.22 114 94.21 52 61 7 0 0
Challenge 6 5 83.33 2 1 50 6 100 5 1 0 0 0
Combined 127 110 86.61 92 75 81.52 120 94.49 57 62 7 0 0
Ceftazidime: Enterobacterales [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]
Clinical 670 635 94.78 140 105 75 642 95.82 95 563 26 1 1
Challenge 117 117 100 11 11 100 117 100 113 4 0 0 0
Combined 787 752 95.55 151 116 76.82 759 96.44 208 567 26 1 1
aCeftazidime: Pseudomonas aeruginosa [Breakpoints (μg/mL): 8 (S), - (I), 16 (R)]
Clinical 211 185 87.68 205 179 87.32 196 92.89 34 177 0 9 6
Challenge 13 12 92.31 8 7 87.5 13 100 12 1 0 0 0
Combined 224 197 87.95 213 186 87.32 209 93.3 46 178 0 9 6
Ceftazidime-avibactam: Enterobacterales [Breakpoints (μg/mL): 8 (S), - (I), 16 (R)]
Clinical 772 751 97.28 211 190 90.05 767 99.35 2 770 0 5 0
Challenge 43 42 97.67 11 10 90.91 43 100 30 13 0 0 0
Combined 815 793 97.3 222 200 90.09 810 99.39 32 783 0 5 0
Ceftazidime-avibactam: Pseudomonas aeruginosa [Breakpoints (μg/mL): 8 (S), - (I), 16 (R)]
Clinical 157 140 89.17 153 136 88.89 153 97.45 5 152 0 4 0
Challenge 6 6 100 2 2 100 5 83.33 5 1 0 0 1
Combined 163 146 89.57 155 138 89.03 158 96.93 10 153 0 4 1
Ceftriaxone: Enterobacterales [Breakpoints (μg/mL): 1 (S), 2 (I), 4 (R)]
Clinical 666 648 97.3 68 50 73.53 655 98.35 134 530 3 4 4
Challenge 56 56 100 1 1 100 56 100 54 1 0 0 0
Combined 722 704 97.51 69 51 73.91 711 98.48 188 531 3 4 4
Ciprofloxacin: Enterobacterales [Breakpoints (μg/mL): 0.25 (S), 0.5 (I), 1 (R)]
Clinical 770 743 96.49 150 123 82 739 95.97 130 622 26 3 2
K211748 - Page 32 of 43

[Table 1 on page 32]
		Tot	No.
EA	EA
%		Eval			No.			Eval		No.
CA	CA
%	No. R
or NS	No. S	min	maj	vmj	
						EA			Eval			EA									
						Tot			EA			%									
Clinical		518	502	96.91	475			459			96.63			433	83.59	163	279	81	4	0	
Challenge		56	54	96.43	26			24			92.31			46	82.14	39	11	9	1	0	
Combined		574	556	96.86	501			483			96.41			479	83.45	202	290	90	5	0	
	aAztreonam: Enterobacterales [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]																				
Clinical		159	156	98.11	144			141			97.92			154	96.86	22	129	5	0	0	
Challenge		24	23	95.83	10			9			90			24	100	24	0	0	0	0	
Combined		183	179	97.81	154			150			97.4			178	97.27	46	129	5	0	0	
	Aztreonam: Pseudomonas aeruginosa [Breakpoints (μg/mL): 8 (S), 16 (I), 32 (R)]																				
Clinical		208	189	90.87	202			183			90.59			181	87.02	37	158	20	3	4	
Challenge		11	11	100	4			4			100			11	100	11	0	0	0	0	
Combined		219	200	91.32	206			187			90.78			192	87.67	48	158	20	3	4	
	Cefazolin: Enterobacterales [Breakpoints (μg/mL): 1 (S), 2 (I), 4 (R)]																				
Clinical		368	344	93.48	290			266			91.72			264	71.74	174	99	102	1	1	
Challenge		44	44	100	0			0			NA			44	100	44	0	0	0	0	
Combined		412	388	94.17	290			266			91.72			308	74.76	218	99	102	1	1	
	Cefepime: Enterobacterales [Breakpoints (μg/mL): 2 (S), 4-8 (I), 16 (R)]																				
Clinical		905	857	94.7	127			79			62.2			867	95.8	78	810	26	10	2	
Challenge		51	49	96.08	17			15			88.24			51	100	49	2	0	0	0	
Combined		956	906	94.77	144			94			65.28			918	96.03	127	812	26	10	2	
	aCefepime: Pseudomonas aeruginosa [Breakpoints (μg/mL): 8 (S), - (I), 16 (R)]																				
Clinical		208	182	87.5	203			177			87.19			188	90.38	30	178	0	13	7	
Challenge		7	6	85.71	2			1			50			7	100	7	0	0	0	0	
Combined		215	188	87.44	205			178			86.83			195	90.7	37	178	0	13	7	
	Cefoxitin: Enterobacterales [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]																				
Clinical		600	551	91.83	576			527			91.49			474	79	71	394	114	9	3	
Challenge		37	37	100	15			15			100			37	100	35	2	0	0	0	
Combined		637	588	92.31	591			542			91.71			511	80.22	106	396	114	9	3	
	aCeftazidime: Acinetobacter baumannii [Breakpoints (μg/mL): 8 (S), 16 (I), 32 (R)]																				
Clinical		121	105	86.78	90			74			82.22			114	94.21	52	61	7	0	0	
Challenge		6	5	83.33	2			1			50			6	100	5	1	0	0	0	
Combined		127	110	86.61	92			75			81.52			120	94.49	57	62	7	0	0	
	Ceftazidime: Enterobacterales [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]																				
Clinical		670	635	94.78	140			105			75			642	95.82	95	563	26	1	1	
Challenge		117	117	100	11			11			100			117	100	113	4	0	0	0	
Combined		787	752	95.55	151			116			76.82			759	96.44	208	567	26	1	1	
	aCeftazidime: Pseudomonas aeruginosa [Breakpoints (μg/mL): 8 (S), - (I), 16 (R)]																				
Clinical		211	185	87.68	205			179			87.32			196	92.89	34	177	0	9	6	
Challenge		13	12	92.31	8			7			87.5			13	100	12	1	0	0	0	
Combined		224	197	87.95	213			186			87.32			209	93.3	46	178	0	9	6	
	Ceftazidime-avibactam: Enterobacterales [Breakpoints (μg/mL): 8 (S), - (I), 16 (R)]																				
Clinical		772	751	97.28	211			190			90.05			767	99.35	2	770	0	5	0	
Challenge		43	42	97.67	11			10			90.91			43	100	30	13	0	0	0	
Combined		815	793	97.3	222			200			90.09			810	99.39	32	783	0	5	0	
	Ceftazidime-avibactam: Pseudomonas aeruginosa [Breakpoints (μg/mL): 8 (S), - (I), 16 (R)]																				
Clinical		157	140	89.17	153			136			88.89			153	97.45	5	152	0	4	0	
Challenge		6	6	100	2			2			100			5	83.33	5	1	0	0	1	
Combined		163	146	89.57	155			138			89.03			158	96.93	10	153	0	4	1	
	Ceftriaxone: Enterobacterales [Breakpoints (μg/mL): 1 (S), 2 (I), 4 (R)]																				
Clinical		666	648	97.3	68			50			73.53			655	98.35	134	530	3	4	4	
Challenge		56	56	100	1			1			100			56	100	54	1	0	0	0	
Combined		722	704	97.51	69			51			73.91			711	98.48	188	531	3	4	4	
	Ciprofloxacin: Enterobacterales [Breakpoints (μg/mL): 0.25 (S), 0.5 (I), 1 (R)]																				
Clinical		770	743	96.49	150			123			82			739	95.97	130	622	26	3	2	

[Table 2 on page 32]
No.
EA

[Table 3 on page 32]
EA
%

[Table 4 on page 32]
No.
CA

[Table 5 on page 32]
CA
%

[Table 6 on page 32]
No. R
or NS

--- Page 33 ---
Eval No. Eval
No. EA No. CA No. R
Tot EA Eval EA No. S min maj vmj
EA % CA % or NS
Tot EA %
Challenge 48 48 100 6 6 100 48 100 47 1 0 0 0
Combined 818 791 96.7 156 129 82.69 787 96.21 177 623 26 3 2
Ciprofloxacin: Pseudomonas aeruginosa [Breakpoints (μg/mL): 0.5 (S), 1 (I), 2 (R)]
Clinical 159 152 95.6 147 140 95.24 150 94.34 23 132 5 4 0
Challenge 10 10 100 1 1 100 10 100 10 0 0 0 0
Combined 169 162 95.86 148 141 95.27 160 94.67 33 132 5 4 0
Eravacycline: Enterobacterales [Breakpoints (μg/mL): 0.5 (S), - (I), - (R)]
Clinical 441 432 97.96 436 427 97.94 434 98.41 23 418 0 4 3
Challenge 46 46 100 39 39 100 46 100 31 15 0 0 0
Combined 487 478 98.15 475 466 98.11 480 98.56 54 433 0 4 3
Ertapenem: Enterobacterales [Breakpoints (μg/mL): 0.5 (S), 1 (I), 2 (R)]
Clinical 880 832 94.55 123 75 60.98 857 97.39 31 842 9 14 0
Challenge 97 93 95.88 14 10 71.43 95 97.94 90 7 2 0 0
Combined 977 925 94.68 137 85 62.04 952 97.44 121 849 11 14 0
Gentamicin: Enterobacterales [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]
Clinical 745 713 95.7 704 672 95.45 735 98.66 60 679 7 1 2
Challenge 72 71 98.61 20 19 95 72 100 61 11 0 0 0
Combined 817 784 95.96 724 691 95.44 807 98.78 121 690 7 1 2
Gentamicin: Pseudomonas aeruginosa [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]
Clinical 208 183 87.98 200 175 87.5 202 97.12 7 195 6 0 0
Challenge 10 10 100 2 2 100 10 100 8 2 0 0 0
Combined 218 193 88.53 202 177 87.62 212 97.25 15 197 6 0 0
aImipenem: Acinetobacter baumannii [Breakpoints (μg/mL): 2 (S), 4 (I), 8 (R)]
Clinical 121 107 88.43 77 63 81.82 119 98.35 57 64 0 0 2
Challenge 5 5 100 1 1 100 5 100 5 0 0 0 0
Combined 126 112 88.89 78 64 82.05 124 98.41 62 64 0 0 2
Imipenem-Relebactam: Enterobacterales [Breakpoints (μg/mL): 1 (S), 2 (I), 4 (R)]
Clinical 433 406 93.76 427 400 93.68 422 97.46 4 428 8 3 0
Challenge 38 34 89.47 37 33 89.19 37 97.37 29 8 1 0 0
Combined 471 440 93.42 464 433 93.32 459 97.45 33 436 9 3 0
Imipenem-Relebactam: Pseudomonas aeruginosa [Breakpoints (μg/mL): 2 (S), 4 (I), 8 (R)]
Clinical 158 152 96.2 158 152 96.2 155 98.1 3 153 3 0 0
Challenge 7 7 100 4 4 100 7 100 3 4 0 0 0
Combined 165 159 96.36 162 156 96.3 162 98.18 6 157 3 0 0
Levofloxacin: Enterobacterales [Breakpoints (μg/mL): 0.5 (S), 1 (I), 2 (R)]
Clinical 732 701 95.77 235 204 86.81 692 94.54 112 600 33 6 1
Challenge 52 52 100 7 7 100 52 100 49 3 0 0 0
Combined 784 753 96.05 242 211 87.19 744 94.9 161 603 33 6 1
aLevofloxacin: Pseudomonas aeruginosa [Breakpoints (μg/mL): 1 (S), 2 (I), 4 (R)]
Clinical 159 149 93.71 148 138 93.24 142 89.31 30 117 14 1 2
Challenge 12 12 100 3 3 100 12 100 12 0 0 0 0
Combined 171 161 94.15 151 141 93.38 154 90.06 42 117 14 1 2
aMeropenem: Acinetobacter baumannii [Breakpoints (μg/mL): 2 (S), 4 (I), 8 (R)]
Clinical 121 104 85.95 42 25 59.52 119 98.35 58 63 0 2 0
Challenge 5 5 100 0 0 NA 5 100 5 0 0 0 0
Combined 126 109 86.51 42 25 59.52 124 98.41 63 63 0 2 0
Meropenem: Enterobacterales [Breakpoints (μg/mL): 1 (S), 2 (I), 4 (R)]
Clinical 805 776 96.4 54 25 46.3 789 98.01 25 777 4 12 0
Challenge 60 57 95 25 22 88 59 98.33 59 1 0 0 1
Combined 865 833 96.3 79 47 59.49 848 98.03 84 778 4 12 1
Meropenem: Pseudomonas aeruginosa [Breakpoints (μg/mL): 2 (S), 4 (I), 8 (R)]
Clinical 159 148 93.08 131 120 91.6 152 95.6 23 131 7 0 0
Challenge 16 15 93.75 11 10 90.91 16 100 15 1 0 0 0
K211748 - Page 33 of 43

[Table 1 on page 33]
		Tot	No.
EA	EA
%		Eval			No.			Eval		No.
CA	CA
%	No. R
or NS	No. S	min	maj	vmj	
						EA			Eval			EA									
						Tot			EA			%									
Challenge		48	48	100	6			6			100			48	100	47	1	0	0	0	
Combined		818	791	96.7	156			129			82.69			787	96.21	177	623	26	3	2	
	Ciprofloxacin: Pseudomonas aeruginosa [Breakpoints (μg/mL): 0.5 (S), 1 (I), 2 (R)]																				
Clinical		159	152	95.6	147			140			95.24			150	94.34	23	132	5	4	0	
Challenge		10	10	100	1			1			100			10	100	10	0	0	0	0	
Combined		169	162	95.86	148			141			95.27			160	94.67	33	132	5	4	0	
	Eravacycline: Enterobacterales [Breakpoints (μg/mL): 0.5 (S), - (I), - (R)]																				
Clinical		441	432	97.96	436			427			97.94			434	98.41	23	418	0	4	3	
Challenge		46	46	100	39			39			100			46	100	31	15	0	0	0	
Combined		487	478	98.15	475			466			98.11			480	98.56	54	433	0	4	3	
	Ertapenem: Enterobacterales [Breakpoints (μg/mL): 0.5 (S), 1 (I), 2 (R)]																				
Clinical		880	832	94.55	123			75			60.98			857	97.39	31	842	9	14	0	
Challenge		97	93	95.88	14			10			71.43			95	97.94	90	7	2	0	0	
Combined		977	925	94.68	137			85			62.04			952	97.44	121	849	11	14	0	
	Gentamicin: Enterobacterales [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]																				
Clinical		745	713	95.7	704			672			95.45			735	98.66	60	679	7	1	2	
Challenge		72	71	98.61	20			19			95			72	100	61	11	0	0	0	
Combined		817	784	95.96	724			691			95.44			807	98.78	121	690	7	1	2	
	Gentamicin: Pseudomonas aeruginosa [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]																				
Clinical		208	183	87.98	200			175			87.5			202	97.12	7	195	6	0	0	
Challenge		10	10	100	2			2			100			10	100	8	2	0	0	0	
Combined		218	193	88.53	202			177			87.62			212	97.25	15	197	6	0	0	
	aImipenem: Acinetobacter baumannii [Breakpoints (μg/mL): 2 (S), 4 (I), 8 (R)]																				
Clinical		121	107	88.43	77			63			81.82			119	98.35	57	64	0	0	2	
Challenge		5	5	100	1			1			100			5	100	5	0	0	0	0	
Combined		126	112	88.89	78			64			82.05			124	98.41	62	64	0	0	2	
	Imipenem-Relebactam: Enterobacterales [Breakpoints (μg/mL): 1 (S), 2 (I), 4 (R)]																				
Clinical		433	406	93.76	427			400			93.68			422	97.46	4	428	8	3	0	
Challenge		38	34	89.47	37			33			89.19			37	97.37	29	8	1	0	0	
Combined		471	440	93.42	464			433			93.32			459	97.45	33	436	9	3	0	
	Imipenem-Relebactam: Pseudomonas aeruginosa [Breakpoints (μg/mL): 2 (S), 4 (I), 8 (R)]																				
Clinical		158	152	96.2	158			152			96.2			155	98.1	3	153	3	0	0	
Challenge		7	7	100	4			4			100			7	100	3	4	0	0	0	
Combined		165	159	96.36	162			156			96.3			162	98.18	6	157	3	0	0	
	Levofloxacin: Enterobacterales [Breakpoints (μg/mL): 0.5 (S), 1 (I), 2 (R)]																				
Clinical		732	701	95.77	235			204			86.81			692	94.54	112	600	33	6	1	
Challenge		52	52	100	7			7			100			52	100	49	3	0	0	0	
Combined		784	753	96.05	242			211			87.19			744	94.9	161	603	33	6	1	
	aLevofloxacin: Pseudomonas aeruginosa [Breakpoints (μg/mL): 1 (S), 2 (I), 4 (R)]																				
Clinical		159	149	93.71	148			138			93.24			142	89.31	30	117	14	1	2	
Challenge		12	12	100	3			3			100			12	100	12	0	0	0	0	
Combined		171	161	94.15	151			141			93.38			154	90.06	42	117	14	1	2	
	aMeropenem: Acinetobacter baumannii [Breakpoints (μg/mL): 2 (S), 4 (I), 8 (R)]																				
Clinical		121	104	85.95	42			25			59.52			119	98.35	58	63	0	2	0	
Challenge		5	5	100	0			0			NA			5	100	5	0	0	0	0	
Combined		126	109	86.51	42			25			59.52			124	98.41	63	63	0	2	0	
	Meropenem: Enterobacterales [Breakpoints (μg/mL): 1 (S), 2 (I), 4 (R)]																				
Clinical		805	776	96.4	54			25			46.3			789	98.01	25	777	4	12	0	
Challenge		60	57	95	25			22			88			59	98.33	59	1	0	0	1	
Combined		865	833	96.3	79			47			59.49			848	98.03	84	778	4	12	1	
	Meropenem: Pseudomonas aeruginosa [Breakpoints (μg/mL): 2 (S), 4 (I), 8 (R)]																				
Clinical		159	148	93.08	131			120			91.6			152	95.6	23	131	7	0	0	
Challenge		16	15	93.75	11			10			90.91			16	100	15	1	0	0	0	

[Table 2 on page 33]
No.
EA

[Table 3 on page 33]
EA
%

[Table 4 on page 33]
No.
CA

[Table 5 on page 33]
CA
%

[Table 6 on page 33]
No. R
or NS

--- Page 34 ---
Eval No. Eval
No. EA No. CA No. R
Tot EA Eval EA No. S min maj vmj
EA % CA % or NS
Tot EA %
Combined 175 163 93.14 142 130 91.55 168 96 38 132 7 0 0
Meropenem-vaborbactam: Enterobacterales [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]
Clinical 817 748 91.55 152 83 54.61 791 96.82 4 810 9 16 1
Challenge 43 41 95.35 12 10 83.33 42 97.67 37 6 1 0 0
Combined 860 789 91.74 164 93 56.71 833 96.86 41 816 10 16 1
aMinocycline: Acinetobacter baumannii [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]
Clinical 196 174 88.78 96 74 77.08 178 90.82 38 148 13 5 0
Challenge 3 3 100 3 3 100 3 100 1 2 0 0 0
Combined 199 177 88.94 99 77 77.78 181 90.95 39 150 13 5 0
Minocycline: Enterobacterales [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]
Clinical 381 341 89.5 339 299 88.2 358 93.96 30 334 16 3 4
Challenge 23 21 91.3 15 13 86.67 23 100 13 9 0 0 0
Combined 404 362 89.6 354 312 88.14 381 94.31 43 343 16 3 4
aPiperacillin-Tazobactam: Acinetobacter baumannii [Breakpoints (μg/mL): 16(S), 32-64 (I), 128 (R)]
Clinical 108 87 80.56 31 10 32.26 98 90.74 53 51 9 0 1
Challenge 5 5 100 1 1 100 5 100 5 0 0 0 0
Combined 113 92 81.42 32 11 34.38 103 91.15 58 51 9 0 1
Piperacillin-Tazobactam: Enterobacterales [Breakpoints (μg/mL): 16(S), 32-64 (I), 128 (R)]
Clinical 815 728 89.33 641 554 86.43 768 94.23 56 730 35 8 4
Challenge 111 107 96.4 36 32 88.89 110 99.1 92 19 0 1 0
Combined 926 835 90.17 677 586 86.56 878 94.82 148 749 35 9 4
aPiperacillin-Tazobactam: Pseudomonas aeruginosa [Breakpoints (μg/mL): 16(S), 32-64 (I), 128 (R)]
Clinical 211 170 80.57 208 167 80.29 177 83.89 22 167 26 2 6
Challenge 6 5 83.33 5 4 80 5 83.33 6 0 1 0 0
Combined 217 175 80.65 213 171 80.28 182 83.87 28 167 27 2 6
Tobramycin: Pseudomonas aeruginosa [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]
Clinical 158 147 93.04 152 141 92.76 154 97.47 6 150 3 1 0
Challenge 8 8 100 2 2 100 8 100 8 0 0 0 0
Combined 166 155 93.37 154 143 92.86 162 97.59 14 150 3 1 0
Trimethoprim Sulfamethoxazole: Enterobacterales [Breakpoints (μg/mL): 2 (S), - (I), 4 (R)]
Clinical 480 464 96.67 52 36 69.23 472 98.33 116 364 0 2 6
Challenge 46 46 100 2 2 100 46 100 43 3 0 0 0
Combined 526 510 96.96 54 38 70.37 518 98.48 159 367 0 2 6
a Due to unacceptable performance, do not report Selux MIC results for these drug/organism combinations.
EA – Essential Agreement R – Resistant isolates min – minor errors
CA – Category Agreement NS – Non-susceptible isolates maj – major errors
EVAL – Evaluable isolates S – Susceptible isolates vmj – very major errors
Table 7. Selux AST System – Gram-Negative Panel Trending
Total On ≥ 1 Dilution ≥ 1 Dilution Percent Significant
Exact
Drug Organism Name Scale for Lower # Higher # Difference Trending
# (%)
Trending (%) (%) (95% CI) Noteda
Pseudomonas 76 10 -40%
Amikacin 164 78 Yes
aeruginosa (46.34) (6.1) (-48%, -31%)
Amoxicillin- 64 18 -26%
Escherichia coli 179 97 No
Clavulanate (35.75) (10.06) (-34%, -17%)
Amoxicillin- 21 9 -25%
Klebsiella oxytoca 48 18 No
Clavulanate (43.75) (18.75) (-41%, -6%)
Amoxicillin- 89 7 -58%
Klebsiella pneumoniae 142 46 Yes
Clavulanate (62.68) (4.93) (-66%, -48%)
Amoxicillin- 11 35 27%
Proteus mirabilis 88 42 No
Clavulanate (12.5) (39.77) (14%, 39%)
Ampicillin Escherichia coli 84 64 18 2 -74% Yes
K211748 - Page 34 of 43

[Table 1 on page 34]
		Tot	No.
EA	EA
%		Eval			No.			Eval		No.
CA	CA
%	No. R
or NS	No. S	min	maj	vmj	
						EA			Eval			EA									
						Tot			EA			%									
Combined		175	163	93.14	142			130			91.55			168	96	38	132	7	0	0	
	Meropenem-vaborbactam: Enterobacterales [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]																				
Clinical		817	748	91.55	152			83			54.61			791	96.82	4	810	9	16	1	
Challenge		43	41	95.35	12			10			83.33			42	97.67	37	6	1	0	0	
Combined		860	789	91.74	164			93			56.71			833	96.86	41	816	10	16	1	
	aMinocycline: Acinetobacter baumannii [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]																				
Clinical		196	174	88.78	96			74			77.08			178	90.82	38	148	13	5	0	
Challenge		3	3	100	3			3			100			3	100	1	2	0	0	0	
Combined		199	177	88.94	99			77			77.78			181	90.95	39	150	13	5	0	
	Minocycline: Enterobacterales [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]																				
Clinical		381	341	89.5	339			299			88.2			358	93.96	30	334	16	3	4	
Challenge		23	21	91.3	15			13			86.67			23	100	13	9	0	0	0	
Combined		404	362	89.6	354			312			88.14			381	94.31	43	343	16	3	4	
	aPiperacillin-Tazobactam: Acinetobacter baumannii [Breakpoints (μg/mL): 16(S), 32-64 (I), 128 (R)]																				
Clinical		108	87	80.56	31			10			32.26			98	90.74	53	51	9	0	1	
Challenge		5	5	100	1			1			100			5	100	5	0	0	0	0	
Combined		113	92	81.42	32			11			34.38			103	91.15	58	51	9	0	1	
	Piperacillin-Tazobactam: Enterobacterales [Breakpoints (μg/mL): 16(S), 32-64 (I), 128 (R)]																				
Clinical		815	728	89.33	641			554			86.43			768	94.23	56	730	35	8	4	
Challenge		111	107	96.4	36			32			88.89			110	99.1	92	19	0	1	0	
Combined		926	835	90.17	677			586			86.56			878	94.82	148	749	35	9	4	
	aPiperacillin-Tazobactam: Pseudomonas aeruginosa [Breakpoints (μg/mL): 16(S), 32-64 (I), 128 (R)]																				
Clinical		211	170	80.57	208			167			80.29			177	83.89	22	167	26	2	6	
Challenge		6	5	83.33	5			4			80			5	83.33	6	0	1	0	0	
Combined		217	175	80.65	213			171			80.28			182	83.87	28	167	27	2	6	
	Tobramycin: Pseudomonas aeruginosa [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]																				
Clinical		158	147	93.04	152			141			92.76			154	97.47	6	150	3	1	0	
Challenge		8	8	100	2			2			100			8	100	8	0	0	0	0	
Combined		166	155	93.37	154			143			92.86			162	97.59	14	150	3	1	0	
	Trimethoprim Sulfamethoxazole: Enterobacterales [Breakpoints (μg/mL): 2 (S), - (I), 4 (R)]																				
Clinical		480	464	96.67	52			36			69.23			472	98.33	116	364	0	2	6	
Challenge		46	46	100	2			2			100			46	100	43	3	0	0	0	
Combined		526	510	96.96	54			38			70.37			518	98.48	159	367	0	2	6	

[Table 2 on page 34]
No.
EA

[Table 3 on page 34]
EA
%

[Table 4 on page 34]
No.
CA

[Table 5 on page 34]
No. R
or NS

[Table 6 on page 34]
Drug	Organism Name		Total On			≥ 1 Dilution		Exact
# (%)	≥ 1 Dilution			Percent			Significant	
			Scale for			Lower #			Higher #			Difference			Trending	
			Trending			(%)			(%)			(95% CI)			Noteda	
Amikacin	Pseudomonas
aeruginosa	164			76
(46.34)			78	10
(6.1)		-40%
(-48%, -31%)			Yes		
Amoxicillin-
Clavulanate	Escherichia coli	179			64
(35.75)			97	18
(10.06)		-26%
(-34%, -17%)			No		
Amoxicillin-
Clavulanate	Klebsiella oxytoca	48			21
(43.75)			18	9
(18.75)		-25%
(-41%, -6%)			No		
Amoxicillin-
Clavulanate	Klebsiella pneumoniae	142			89
(62.68)			46	7
(4.93)		-58%
(-66%, -48%)			Yes		
Amoxicillin-
Clavulanate	Proteus mirabilis	88			11
(12.5)			42	35
(39.77)		27%
(14%, 39%)			No		
Ampicillin	Escherichia coli	84			64			18	2		-74%			Yes		

[Table 7 on page 34]
Exact
# (%)

--- Page 35 ---
Total On ≥ 1 Dilution ≥ 1 Dilution Percent Significant
Exact
Drug Organism Name Scale for Lower # Higher # Difference Trending
# (%)
Trending (%) (%) (95% CI) Noteda
(76.19) (2.38) (-82%, -62%)
25 14 -14%
Ampicillin Proteus mirabilis 81 42 No
(30.86) (17.28) (-26%, 0%)
Ampicillin- Acinetobacter 32 31 -1%
123 60 No
sulbactam baumannii (complex) (26.02) (25.2) (-12%, 10%)
Ampicillin- 53 27 -13%
Escherichia coli 198 118 No
sulbactam (26.77) (13.64) (-21%, -5%)
Ampicillin- 17 4 -45%
Klebsiella oxytoca 29 8 Yes
sulbactam (58.62) (13.79) (-63%, -20%)
Ampicillin- 50 31 -16%
Klebsiella pneumoniae 116 35 No
sulbactam (43.1) (26.72) (-28%, -4%)
Ampicillin- 9 19 13%
Morganella morganii 75 47 No
sulbactam (12) (25.33) (1%, 26%)
Ampicillin- 11 19 9%
Proteus mirabilis 88 58 No
sulbactam (12.5) (21.59) (-2%, 20%)
Ampicillin- 2 33 50%
Proteus vulgaris 62 27 Yes
sulbactam (3.23) (53.23) (35%, 62%)
73 25 -27%
Aztreonam Escherichia coli 179 81 No
(40.78) (13.97) (-35%, -18%)
81 21 -35%
Cefazolin Escherichia coli 171 69 Yes
(47.37) (12.28) (-44%, -26%)
67 17 -44%
Cefazolin Klebsiella pneumoniae 113 29 Yes
(59.29) (15.04) (-54%, -32%)
Citrobacter freundii 11 59 62%
Cefepime 77 7 Yes
(complex) (14.29) (76.62) (48%, 72%)
0 72 100%
Cefepime Citrobacter koseri 72 0 Yes
(0) (100) (93%, 100%)
Enterobacter cloacae 13 55 55%
Cefepime 77 9 Yes
(complex) (16.88) (71.43) (40%, 66%)
21 129 68%
Cefepime Escherichia coli 158 8 Yes
(13.29) (81.65) (59%, 75%)
2 39 90%
Cefepime Klebsiella aerogenes 41 0 Yes
(4.88) (95.12) (74%, 95%)
5 14 45%
Cefepime Klebsiella oxytoca 20 1 Yes
(25) (70) (14%, 66%)
38 60 20%
Cefepime Klebsiella pneumoniae 111 13 No
(34.23) (54.05) (7%, 32%)
1 16 88%
Cefepime Morganella morganii 17 0 Yes
(5.88) (94.12) (58%, 95%)
3 81 91%
Cefepime Proteus mirabilis 86 2 Yes
(3.49) (94.19) (81%, 95%)
4 82 87%
Cefepime Proteus vulgaris 90 4 Yes
(4.44) (91.11) (77%, 92%)
3 93 92%
Cefepime Serratia marcescens 98 2 Yes
(3.06) (94.9) (83%, 95%)
41 38 -2%
Cefoxitin Escherichia coli 166 87 No
(24.7) (22.89) (-11%, 7%)
6 7 3%
Cefoxitin Klebsiella oxytoca 29 16 No
(20.69) (24.14) (-18%, 24%)
27 20 -6%
Cefoxitin Klebsiella pneumoniae 109 62 No
(24.77) (18.35) (-17%, 5%)
10 10 0%
Cefoxitin Morganella morganii 59 39 No
(16.95) (16.95) (-14%, 14%)
K211748 - Page 35 of 43

[Table 1 on page 35]
Drug	Organism Name		Total On			≥ 1 Dilution		Exact
# (%)		≥ 1 Dilution			Percent			Significant	
			Scale for			Lower #				Higher #			Difference			Trending	
			Trending			(%)				(%)			(95% CI)			Noteda	
					(76.19)				(2.38)			(-82%, -62%)					
Ampicillin	Proteus mirabilis	81			25
(30.86)			42	14
(17.28)			-14%
(-26%, 0%)			No		
Ampicillin-
sulbactam	Acinetobacter
baumannii (complex)	123			32
(26.02)			60	31
(25.2)			-1%
(-12%, 10%)			No		
Ampicillin-
sulbactam	Escherichia coli	198			53
(26.77)			118	27
(13.64)			-13%
(-21%, -5%)			No		
Ampicillin-
sulbactam	Klebsiella oxytoca	29			17
(58.62)			8	4
(13.79)			-45%
(-63%, -20%)			Yes		
Ampicillin-
sulbactam	Klebsiella pneumoniae	116			50
(43.1)			35	31
(26.72)			-16%
(-28%, -4%)			No		
Ampicillin-
sulbactam	Morganella morganii	75			9
(12)			47	19
(25.33)			13%
(1%, 26%)			No		
Ampicillin-
sulbactam	Proteus mirabilis	88			11
(12.5)			58	19
(21.59)			9%
(-2%, 20%)			No		
Ampicillin-
sulbactam	Proteus vulgaris	62			2
(3.23)			27	33
(53.23)			50%
(35%, 62%)			Yes		
Aztreonam	Escherichia coli	179			73
(40.78)			81	25
(13.97)			-27%
(-35%, -18%)			No		
Cefazolin	Escherichia coli	171			81
(47.37)			69	21
(12.28)			-35%
(-44%, -26%)			Yes		
Cefazolin	Klebsiella pneumoniae	113			67
(59.29)			29	17
(15.04)			-44%
(-54%, -32%)			Yes		
Cefepime	Citrobacter freundii
(complex)	77			11
(14.29)			7	59
(76.62)			62%
(48%, 72%)			Yes		
Cefepime	Citrobacter koseri	72			0
(0)			0	72
(100)			100%
(93%, 100%)			Yes		
Cefepime	Enterobacter cloacae
(complex)	77			13
(16.88)			9	55
(71.43)			55%
(40%, 66%)			Yes		
Cefepime	Escherichia coli	158			21
(13.29)			8	129
(81.65)			68%
(59%, 75%)			Yes		
Cefepime	Klebsiella aerogenes	41			2
(4.88)			0	39
(95.12)			90%
(74%, 95%)			Yes		
Cefepime	Klebsiella oxytoca	20			5
(25)			1	14
(70)			45%
(14%, 66%)			Yes		
Cefepime	Klebsiella pneumoniae	111			38
(34.23)			13	60
(54.05)			20%
(7%, 32%)			No		
Cefepime	Morganella morganii	17			1
(5.88)			0	16
(94.12)			88%
(58%, 95%)			Yes		
Cefepime	Proteus mirabilis	86			3
(3.49)			2	81
(94.19)			91%
(81%, 95%)			Yes		
Cefepime	Proteus vulgaris	90			4
(4.44)			4	82
(91.11)			87%
(77%, 92%)			Yes		
Cefepime	Serratia marcescens	98			3
(3.06)			2	93
(94.9)			92%
(83%, 95%)			Yes		
Cefoxitin	Escherichia coli	166			41
(24.7)			87	38
(22.89)			-2%
(-11%, 7%)			No		
Cefoxitin	Klebsiella oxytoca	29			6
(20.69)			16	7
(24.14)			3%
(-18%, 24%)			No		
Cefoxitin	Klebsiella pneumoniae	109			27
(24.77)			62	20
(18.35)			-6%
(-17%, 5%)			No		
Cefoxitin	Morganella morganii	59			10
(16.95)			39	10
(16.95)			0%
(-14%, 14%)			No		

[Table 2 on page 35]
Exact
# (%)

--- Page 36 ---
Total On ≥ 1 Dilution ≥ 1 Dilution Percent Significant
Exact
Drug Organism Name Scale for Lower # Higher # Difference Trending
# (%)
Trending (%) (%) (95% CI) Noteda
Citrobacter freundii 12 29 32%
Ceftazidime 53 12 Yes
(complex) (22.64) (54.72) (14%, 48%)
1 42 91%
Ceftazidime Citrobacter koseri 45 2 Yes
(2.22) (93.33) (77%, 96%)
Enterobacter cloacae 9 33 46%
Ceftazidime 52 10 Yes
(complex) (17.31) (63.46) (28%, 60%)
31 34 4%
Ceftazidime Escherichia coli 74 9 No
(41.89) (45.95) (-12%, 20%)
2 20 62%
Ceftazidime Klebsiella aerogenes 29 7 Yes
(6.9) (68.97) (38%, 77%)
2 18 70%
Ceftazidime Klebsiella oxytoca 23 3 Yes
(8.7) (78.26) (42%, 83%)
12 52 55%
Ceftazidime Klebsiella pneumoniae 73 9 Yes
(16.44) (71.23) (40%, 66%)
1 58 90%
Ceftazidime Proteus mirabilis 63 4 Yes
(1.59) (92.06) (79%, 95%)
2 47 90%
Ceftazidime Proteus vulgaris 50 1 Yes
(4) (94) (76%, 95%)
3 44 73%
Ceftazidime Serratia marcescens 56 9 Yes
(5.36) (78.57) (58%, 83%)
Ceftazidime- Citrobacter freundii 11 35 39%
61 15 Yes
avibactam (complex) (18.03) (57.38) (22%, 53%)
Ceftazidime- 0 48 89%
Citrobacter koseri 54 6 Yes
avibactam (0) (88.89) (76%, 95%)
Ceftazidime- Enterobacter cloacae 19 29 13%
75 27 No
avibactam (complex) (25.33) (38.67) (-2%, 27%)
Ceftazidime- 15 101 63%
Escherichia coli 136 20 Yes
avibactam (11.03) (74.26) (53%, 71%)
Ceftazidime- 2 39 71%
Klebsiella aerogenes 52 11 Yes
avibactam (3.85) (75) (55%, 81%)
Ceftazidime- 3 21 64%
Klebsiella oxytoca 28 4 Yes
avibactam (10.71) (75) (40%, 78%)
Ceftazidime- 23 31 11%
Klebsiella pneumoniae 73 19 No
avibactam (31.51) (42.47) (-5%, 26%)
Ceftazidime- 1 58 92%
Morganella morganii 62 3 Yes
avibactam (1.61) (93.55) (81%, 96%)
Ceftazidime- 0 63 97%
Proteus mirabilis 65 2 Yes
avibactam (0) (96.92) (88%, 99%)
Ceftazidime- 0 53 96%
Proteus vulgaris 55 2 Yes
avibactam (0) (96.36) (85%, 99%)
Ceftazidime- Pseudomonas 70 25 -28%
158 63 No
avibactam aeruginosa (44.3) (15.82) (-38%, -19%)
Ceftazidime- 10 23 20%
Serratia marcescens 66 33 No
avibactam (15.15) (34.85) (5%, 33%)
Citrobacter freundii 8 34 53%
Ceftriaxone 49 7 Yes
(complex) (16.33) (69.39) (34%, 67%)
1 26 93%
Ceftriaxone Citrobacter koseri 27 0 Yes
(3.7) (96.3) (72%, 97%)
7 36 66%
Ceftriaxone Escherichia coli 44 1 Yes
(15.91) (81.82) (47%, 78%)
6 25 56%
Ceftriaxone Klebsiella aerogenes 34 3 Yes
(17.65) (73.53) (33%, 71%)
5 23 62%
Ceftriaxone Klebsiella oxytoca 29 1 Yes
(17.24) (79.31) (37%, 77%)
K211748 - Page 36 of 43

[Table 1 on page 36]
Drug	Organism Name		Total On			≥ 1 Dilution		Exact
# (%)		≥ 1 Dilution			Percent			Significant	
			Scale for			Lower #				Higher #			Difference			Trending	
			Trending			(%)				(%)			(95% CI)			Noteda	
Ceftazidime	Citrobacter freundii
(complex)	53			12
(22.64)			12	29
(54.72)			32%
(14%, 48%)			Yes		
Ceftazidime	Citrobacter koseri	45			1
(2.22)			2	42
(93.33)			91%
(77%, 96%)			Yes		
Ceftazidime	Enterobacter cloacae
(complex)	52			9
(17.31)			10	33
(63.46)			46%
(28%, 60%)			Yes		
Ceftazidime	Escherichia coli	74			31
(41.89)			9	34
(45.95)			4%
(-12%, 20%)			No		
Ceftazidime	Klebsiella aerogenes	29			2
(6.9)			7	20
(68.97)			62%
(38%, 77%)			Yes		
Ceftazidime	Klebsiella oxytoca	23			2
(8.7)			3	18
(78.26)			70%
(42%, 83%)			Yes		
Ceftazidime	Klebsiella pneumoniae	73			12
(16.44)			9	52
(71.23)			55%
(40%, 66%)			Yes		
Ceftazidime	Proteus mirabilis	63			1
(1.59)			4	58
(92.06)			90%
(79%, 95%)			Yes		
Ceftazidime	Proteus vulgaris	50			2
(4)			1	47
(94)			90%
(76%, 95%)			Yes		
Ceftazidime	Serratia marcescens	56			3
(5.36)			9	44
(78.57)			73%
(58%, 83%)			Yes		
Ceftazidime-
avibactam	Citrobacter freundii
(complex)	61			11
(18.03)			15	35
(57.38)			39%
(22%, 53%)			Yes		
Ceftazidime-
avibactam	Citrobacter koseri	54			0
(0)			6	48
(88.89)			89%
(76%, 95%)			Yes		
Ceftazidime-
avibactam	Enterobacter cloacae
(complex)	75			19
(25.33)			27	29
(38.67)			13%
(-2%, 27%)			No		
Ceftazidime-
avibactam	Escherichia coli	136			15
(11.03)			20	101
(74.26)			63%
(53%, 71%)			Yes		
Ceftazidime-
avibactam	Klebsiella aerogenes	52			2
(3.85)			11	39
(75)			71%
(55%, 81%)			Yes		
Ceftazidime-
avibactam	Klebsiella oxytoca	28			3
(10.71)			4	21
(75)			64%
(40%, 78%)			Yes		
Ceftazidime-
avibactam	Klebsiella pneumoniae	73			23
(31.51)			19	31
(42.47)			11%
(-5%, 26%)			No		
Ceftazidime-
avibactam	Morganella morganii	62			1
(1.61)			3	58
(93.55)			92%
(81%, 96%)			Yes		
Ceftazidime-
avibactam	Proteus mirabilis	65			0
(0)			2	63
(96.92)			97%
(88%, 99%)			Yes		
Ceftazidime-
avibactam	Proteus vulgaris	55			0
(0)			2	53
(96.36)			96%
(85%, 99%)			Yes		
Ceftazidime-
avibactam	Pseudomonas
aeruginosa	158			70
(44.3)			63	25
(15.82)			-28%
(-38%, -19%)			No		
Ceftazidime-
avibactam	Serratia marcescens	66			10
(15.15)			33	23
(34.85)			20%
(5%, 33%)			No		
Ceftriaxone	Citrobacter freundii
(complex)	49			8
(16.33)			7	34
(69.39)			53%
(34%, 67%)			Yes		
Ceftriaxone	Citrobacter koseri	27			1
(3.7)			0	26
(96.3)			93%
(72%, 97%)			Yes		
Ceftriaxone	Escherichia coli	44			7
(15.91)			1	36
(81.82)			66%
(47%, 78%)			Yes		
Ceftriaxone	Klebsiella aerogenes	34			6
(17.65)			3	25
(73.53)			56%
(33%, 71%)			Yes		
Ceftriaxone	Klebsiella oxytoca	29			5
(17.24)			1	23
(79.31)			62%
(37%, 77%)			Yes		

[Table 2 on page 36]
Exact
# (%)

--- Page 37 ---
Total On ≥ 1 Dilution ≥ 1 Dilution Percent Significant
Exact
Drug Organism Name Scale for Lower # Higher # Difference Trending
# (%)
Trending (%) (%) (95% CI) Noteda
52 53 1%
Ceftriaxone Klebsiella pneumoniae 107 2 No
(48.6) (49.53) (-12%, 14%)
5 32 73%
Ceftriaxone Proteus mirabilis 37 0 Yes
(13.51) (86.49) (53%, 84%)
Citrobacter freundii 14 36 39%
Ciprofloxacin 57 7 Yes
(complex) (24.56) (63.16) (21%, 53%)
1 34 92%
Ciprofloxacin Citrobacter koseri 36 1 Yes
(2.78) (94.44) (75%, 96%)
Enterobacter cloacae 14 49 51%
Ciprofloxacin 68 5 Yes
(complex) (20.59) (72.06) (35%, 64%)
51 102 30%
Ciprofloxacin Escherichia coli 170 17 Yes
(30) (60) (20%, 40%)
0 28 93%
Ciprofloxacin Klebsiella aerogenes 30 2 Yes
(0) (93.33) (75%, 98%)
1 21 71%
Ciprofloxacin Klebsiella oxytoca 28 6 Yes
(3.57) (75) (48%, 84%)
7 11 17%
Ciprofloxacin Klebsiella pneumoniae 23 5 No
(30.43) (47.83) (-10%, 42%)
3 49 79%
Ciprofloxacin Morganella morganii 58 6 Yes
(5.17) (84.48) (65%, 87%)
9 10 4%
Ciprofloxacin Proteus mirabilis 24 5 No
(37.5) (41.67) (-22%, 30%)
3 11 47%
Ciprofloxacin Proteus vulgaris 17 3 Yes
(17.65) (64.71) (14%, 68%)
Pseudomonas 62 15 -31%
Ciprofloxacin 151 74 Yes
aeruginosa (41.06) (9.93) (-40%, -22%)
Citrobacter freundii 2 28 42%
Eravacycline 62 32 Yes
(complex) (3.23) (45.16) (28%, 54%)
Enterobacter cloacae 13 16 4%
Eravacycline 76 47 No
(complex) (17.11) (21.05) (-9%, 16%)
40 28 -7%
Eravacycline Escherichia coli 167 99 No
(23.95) (16.77) (-16%, 1%)
4 13 19%
Eravacycline Klebsiella oxytoca 47 30 No
(8.51) (27.66) (3%, 34%)
Citrobacter freundii 3 16 54%
Ertapenem 24 5 Yes
(complex) (12.5) (66.67) (27%, 72%)
0 72 100%
Ertapenem Citrobacter koseri 72 0 Yes
(0) (100) (93%, 100%)
11 188 84%
Ertapenem Escherichia coli 210 11 Yes
(5.24) (89.52) (78%, 88%)
1 1 0%
Ertapenem Klebsiella oxytoca 3 1 No
(33.33) (33.33) (-53%, 53%)
10 7 -13%
Ertapenem Klebsiella pneumoniae 23 6 No
(43.48) (30.43) (-38%, 14%)
7 1 -60%
Ertapenem Morganella morganii 10 2 Yes
(70) (10) (-81%, -17%)
2 83 95%
Ertapenem Proteus mirabilis 85 0 Yes
(2.35) (97.65) (87%, 98%)
0 97 99%
Ertapenem Proteus vulgaris 98 1 Yes
(0) (98.98) (93%, 100%)
6 48 65%
Ertapenem Serratia marcescens 65 11 Yes
(9.23) (73.85) (49%, 75%)
Citrobacter freundii 41 1 -62%
Gentamicin 64 22 Yes
(complex) (64.06) (1.56) (-73%, -49%)
K211748 - Page 37 of 43

[Table 1 on page 37]
Drug	Organism Name		Total On			≥ 1 Dilution		Exact
# (%)		≥ 1 Dilution			Percent			Significant	
			Scale for			Lower #				Higher #			Difference			Trending	
			Trending			(%)				(%)			(95% CI)			Noteda	
Ceftriaxone	Klebsiella pneumoniae	107			52
(48.6)			2	53
(49.53)			1%
(-12%, 14%)			No		
Ceftriaxone	Proteus mirabilis	37			5
(13.51)			0	32
(86.49)			73%
(53%, 84%)			Yes		
Ciprofloxacin	Citrobacter freundii
(complex)	57			14
(24.56)			7	36
(63.16)			39%
(21%, 53%)			Yes		
Ciprofloxacin	Citrobacter koseri	36			1
(2.78)			1	34
(94.44)			92%
(75%, 96%)			Yes		
Ciprofloxacin	Enterobacter cloacae
(complex)	68			14
(20.59)			5	49
(72.06)			51%
(35%, 64%)			Yes		
Ciprofloxacin	Escherichia coli	170			51
(30)			17	102
(60)			30%
(20%, 40%)			Yes		
Ciprofloxacin	Klebsiella aerogenes	30			0
(0)			2	28
(93.33)			93%
(75%, 98%)			Yes		
Ciprofloxacin	Klebsiella oxytoca	28			1
(3.57)			6	21
(75)			71%
(48%, 84%)			Yes		
Ciprofloxacin	Klebsiella pneumoniae	23			7
(30.43)			5	11
(47.83)			17%
(-10%, 42%)			No		
Ciprofloxacin	Morganella morganii	58			3
(5.17)			6	49
(84.48)			79%
(65%, 87%)			Yes		
Ciprofloxacin	Proteus mirabilis	24			9
(37.5)			5	10
(41.67)			4%
(-22%, 30%)			No		
Ciprofloxacin	Proteus vulgaris	17			3
(17.65)			3	11
(64.71)			47%
(14%, 68%)			Yes		
Ciprofloxacin	Pseudomonas
aeruginosa	151			62
(41.06)			74	15
(9.93)			-31%
(-40%, -22%)			Yes		
Eravacycline	Citrobacter freundii
(complex)	62			2
(3.23)			32	28
(45.16)			42%
(28%, 54%)			Yes		
Eravacycline	Enterobacter cloacae
(complex)	76			13
(17.11)			47	16
(21.05)			4%
(-9%, 16%)			No		
Eravacycline	Escherichia coli	167			40
(23.95)			99	28
(16.77)			-7%
(-16%, 1%)			No		
Eravacycline	Klebsiella oxytoca	47			4
(8.51)			30	13
(27.66)			19%
(3%, 34%)			No		
Ertapenem	Citrobacter freundii
(complex)	24			3
(12.5)			5	16
(66.67)			54%
(27%, 72%)			Yes		
Ertapenem	Citrobacter koseri	72			0
(0)			0	72
(100)			100%
(93%, 100%)			Yes		
Ertapenem	Escherichia coli	210			11
(5.24)			11	188
(89.52)			84%
(78%, 88%)			Yes		
Ertapenem	Klebsiella oxytoca	3			1
(33.33)			1	1
(33.33)			0%
(-53%, 53%)			No		
Ertapenem	Klebsiella pneumoniae	23			10
(43.48)			6	7
(30.43)			-13%
(-38%, 14%)			No		
Ertapenem	Morganella morganii	10			7
(70)			2	1
(10)			-60%
(-81%, -17%)			Yes		
Ertapenem	Proteus mirabilis	85			2
(2.35)			0	83
(97.65)			95%
(87%, 98%)			Yes		
Ertapenem	Proteus vulgaris	98			0
(0)			1	97
(98.98)			99%
(93%, 100%)			Yes		
Ertapenem	Serratia marcescens	65			6
(9.23)			11	48
(73.85)			65%
(49%, 75%)			Yes		
Gentamicin	Citrobacter freundii
(complex)	64			41
(64.06)			22	1
(1.56)			-62%
(-73%, -49%)			Yes		

[Table 2 on page 37]
Exact
# (%)

--- Page 38 ---
Total On ≥ 1 Dilution ≥ 1 Dilution Percent Significant
Exact
Drug Organism Name Scale for Lower # Higher # Difference Trending
# (%)
Trending (%) (%) (95% CI) Noteda
23 8 -28%
Gentamicin Citrobacter koseri 54 23 No
(42.59) (14.81) (-43%, -11%)
Enterobacter cloacae 36 7 -39%
Gentamicin 74 31 Yes
(complex) (48.65) (9.46) (-51%, -25%)
84 11 -42%
Gentamicin Escherichia coli 173 78 Yes
(48.55) (6.36) (-50%, -34%)
8 5 -10%
Gentamicin Klebsiella aerogenes 31 18 No
(25.81) (16.13) (-29%, 11%)
14 0 -48%
Gentamicin Klebsiella oxytoca 29 15 Yes
(48.28) (0) (-66%, -28%)
58 6 -41%
Gentamicin Klebsiella pneumoniae 126 62 Yes
(46.03) (4.76) (-50%, -31%)
12 23 17%
Gentamicin Proteus mirabilis 64 29 No
(18.75) (35.94) (2%, 32%)
13 15 4%
Gentamicin Proteus vulgaris 55 27 No
(23.64) (27.27) (-13%, 20%)
Pseudomonas 68 64 -2%
Gentamicin 211 79 No
aeruginosa (32.23) (30.33) (-11%, 7%)
3 42 57%
Gentamicin Serratia marcescens 68 23 Yes
(4.41) (61.76) (43%, 68%)
Imipenem- Citrobacter freundii 28 7 -39%
54 19 Yes
Relebactam (complex) (51.85) (12.96) (-53%, -22%)
Imipenem- 18 13 -9%
Citrobacter koseri 55 24 No
Relebactam (32.73) (23.64) (-25%, 8%)
Imipenem- 40 31 -5%
Escherichia coli 172 101 No
Relebactam (23.26) (18.02) (-14%, 3%)
Imipenem- 0 8 30%
Klebsiella oxytoca 27 19 Yes
Relebactam (0) (29.63) (11%, 48%)
Imipenem- Pseudomonas 22 21 -1%
162 119 No
Relebactam aeruginosa (13.58) (12.96) (-8%, 7%)
Citrobacter freundii 6 42 60%
Levofloxacin 60 12 Yes
(complex) (10) (70) (44%, 71%)
0 54 100%
Levofloxacin Citrobacter koseri 54 0 Yes
(0) (100) (91%, 100%)
Enterobacter cloacae 0 63 93%
Levofloxacin 68 5 Yes
(complex) (0) (92.65) (82%, 97%)
13 125 66%
Levofloxacin Escherichia coli 169 31 Yes
(7.69) (73.96) (58%, 73%)
1 30 91%
Levofloxacin Klebsiella aerogenes 32 1 Yes
(3.12) (93.75) (72%, 96%)
1 22 78%
Levofloxacin Klebsiella oxytoca 27 4 Yes
(3.7) (81.48) (54%, 89%)
9 62 63%
Levofloxacin Klebsiella pneumoniae 84 13 Yes
(10.71) (73.81) (50%, 73%)
4 54 82%
Levofloxacin Morganella morganii 61 3 Yes
(6.56) (88.52) (68%, 89%)
3 53 77%
Levofloxacin Proteus mirabilis 65 9 Yes
(4.62) (81.54) (63%, 85%)
1 48 85%
Levofloxacin Proteus vulgaris 55 6 Yes
(1.82) (87.27) (72%, 92%)
15 19 6%
Levofloxacin Serratia marcescens 68 34 No
(22.06) (27.94) (-9%, 20%)
Citrobacter freundii 2 75 94%
Meropenem 78 1 Yes
(complex) (2.56) (96.15) (84%, 97%)
K211748 - Page 38 of 43

[Table 1 on page 38]
Drug	Organism Name		Total On			≥ 1 Dilution		Exact
# (%)		≥ 1 Dilution			Percent			Significant	
			Scale for			Lower #				Higher #			Difference			Trending	
			Trending			(%)				(%)			(95% CI)			Noteda	
Gentamicin	Citrobacter koseri	54			23
(42.59)			23	8
(14.81)			-28%
(-43%, -11%)			No		
Gentamicin	Enterobacter cloacae
(complex)	74			36
(48.65)			31	7
(9.46)			-39%
(-51%, -25%)			Yes		
Gentamicin	Escherichia coli	173			84
(48.55)			78	11
(6.36)			-42%
(-50%, -34%)			Yes		
Gentamicin	Klebsiella aerogenes	31			8
(25.81)			18	5
(16.13)			-10%
(-29%, 11%)			No		
Gentamicin	Klebsiella oxytoca	29			14
(48.28)			15	0
(0)			-48%
(-66%, -28%)			Yes		
Gentamicin	Klebsiella pneumoniae	126			58
(46.03)			62	6
(4.76)			-41%
(-50%, -31%)			Yes		
Gentamicin	Proteus mirabilis	64			12
(18.75)			29	23
(35.94)			17%
(2%, 32%)			No		
Gentamicin	Proteus vulgaris	55			13
(23.64)			27	15
(27.27)			4%
(-13%, 20%)			No		
Gentamicin	Pseudomonas
aeruginosa	211			68
(32.23)			79	64
(30.33)			-2%
(-11%, 7%)			No		
Gentamicin	Serratia marcescens	68			3
(4.41)			23	42
(61.76)			57%
(43%, 68%)			Yes		
Imipenem-
Relebactam	Citrobacter freundii
(complex)	54			28
(51.85)			19	7
(12.96)			-39%
(-53%, -22%)			Yes		
Imipenem-
Relebactam	Citrobacter koseri	55			18
(32.73)			24	13
(23.64)			-9%
(-25%, 8%)			No		
Imipenem-
Relebactam	Escherichia coli	172			40
(23.26)			101	31
(18.02)			-5%
(-14%, 3%)			No		
Imipenem-
Relebactam	Klebsiella oxytoca	27			0
(0)			19	8
(29.63)			30%
(11%, 48%)			Yes		
Imipenem-
Relebactam	Pseudomonas
aeruginosa	162			22
(13.58)			119	21
(12.96)			-1%
(-8%, 7%)			No		
Levofloxacin	Citrobacter freundii
(complex)	60			6
(10)			12	42
(70)			60%
(44%, 71%)			Yes		
Levofloxacin	Citrobacter koseri	54			0
(0)			0	54
(100)			100%
(91%, 100%)			Yes		
Levofloxacin	Enterobacter cloacae
(complex)	68			0
(0)			5	63
(92.65)			93%
(82%, 97%)			Yes		
Levofloxacin	Escherichia coli	169			13
(7.69)			31	125
(73.96)			66%
(58%, 73%)			Yes		
Levofloxacin	Klebsiella aerogenes	32			1
(3.12)			1	30
(93.75)			91%
(72%, 96%)			Yes		
Levofloxacin	Klebsiella oxytoca	27			1
(3.7)			4	22
(81.48)			78%
(54%, 89%)			Yes		
Levofloxacin	Klebsiella pneumoniae	84			9
(10.71)			13	62
(73.81)			63%
(50%, 73%)			Yes		
Levofloxacin	Morganella morganii	61			4
(6.56)			3	54
(88.52)			82%
(68%, 89%)			Yes		
Levofloxacin	Proteus mirabilis	65			3
(4.62)			9	53
(81.54)			77%
(63%, 85%)			Yes		
Levofloxacin	Proteus vulgaris	55			1
(1.82)			6	48
(87.27)			85%
(72%, 92%)			Yes		
Levofloxacin	Serratia marcescens	68			15
(22.06)			34	19
(27.94)			6%
(-9%, 20%)			No		
Meropenem	Citrobacter freundii
(complex)	78			2
(2.56)			1	75
(96.15)			94%
(84%, 97%)			Yes		

[Table 2 on page 38]
Exact
# (%)

--- Page 39 ---
Total On ≥ 1 Dilution ≥ 1 Dilution Percent Significant
Exact
Drug Organism Name Scale for Lower # Higher # Difference Trending
# (%)
Trending (%) (%) (95% CI) Noteda
0 71 99%
Meropenem Citrobacter koseri 72 1 Yes
(0) (98.61) (91%, 100%)
Enterobacter cloacae 5 63 78%
Meropenem 74 6 Yes
(complex) (6.76) (85.14) (66%, 86%)
2 3 20%
Meropenem Escherichia coli 5 0 No
(40) (60) (-32%, 60%)
0 27 100%
Meropenem Klebsiella oxytoca 27 0 Yes
(0) (100) (82%, 100%)
14 77 59%
Meropenem Klebsiella pneumoniae 106 15 Yes
(13.21) (72.64) (47%, 69%)
1 60 95%
Meropenem Morganella morganii 62 1 Yes
(1.61) (96.77) (85%, 98%)
1 62 92%
Meropenem Proteus mirabilis 66 3 Yes
(1.52) (93.94) (82%, 96%)
0 51 100%
Meropenem Proteus vulgaris 51 0 Yes
(0) (100) (90%, 100%)
Pseudomonas 52 38 -8%
Meropenem 167 77 No
aeruginosa (31.14) (22.75) (-18%, 1%)
3 97 92%
Meropenem Serratia marcescens 102 2 Yes
(2.94) (95.1) (84%, 96%)
Meropenem- Citrobacter freundii 0 56 98%
57 1 Yes
vaborbactam (complex) (0) (98.25) (88%, 100%)
Meropenem- 0 48 100%
Citrobacter koseri 48 0 Yes
vaborbactam (0) (100) (90%, 100%)
Meropenem- Enterobacter cloacae 0 51 98%
52 1 Yes
vaborbactam (complex) (0) (98.08) (87%, 100%)
Meropenem- 4 25 72%
Escherichia coli 29 0 Yes
vaborbactam (13.79) (86.21) (49%, 84%)
Meropenem- 0 49 98%
Klebsiella aerogenes 50 1 Yes
vaborbactam (0) (98) (87%, 100%)
Meropenem- 0 47 100%
Klebsiella oxytoca 47 0 Yes
vaborbactam (0) (100) (89%, 100%)
Meropenem- 4 90 86%
Klebsiella pneumoniae 100 6 Yes
vaborbactam (4) (90) (77%, 91%)
Meropenem- 0 29 45%
Morganella morganii 64 35 Yes
vaborbactam (0) (45.31) (32%, 57%)
Meropenem- 0 59 98%
Serratia marcescens 60 1 Yes
vaborbactam (0) (98.33) (89%, 100%)
43 72 15%
Minocycline Escherichia coli 198 83 No
(21.72) (36.36) (6%, 23%)
17 5 -23%
Minocycline Klebsiella aerogenes 52 30 No
(32.69) (9.62) (-38%, -7%)
3 9 22%
Minocycline Klebsiella oxytoca 27 15 No
(11.11) (33.33) (0%, 42%)
38 22 -13%
Minocycline Klebsiella pneumoniae 126 66 No
(30.16) (17.46) (-23%, -2%)
Piperacillin- 15 11 -5%
Citrobacter koseri 75 49 No
tazobactam (20) (14.67) (-17%, 7%)
Piperacillin- 47 37 -6%
Escherichia coli 175 91 No
tazobactam (26.86) (21.14) (-15%, 3%)
Piperacillin- 11 1 -37%
Klebsiella oxytoca 27 15 Yes
tazobactam (40.74) (3.7) (-56%, -15%)
Piperacillin- 80 15 -49%
Klebsiella pneumoniae 132 37 Yes
tazobactam (60.61) (11.36) (-58%, -38%)
K211748 - Page 39 of 43

[Table 1 on page 39]
Drug	Organism Name		Total On			≥ 1 Dilution		Exact
# (%)		≥ 1 Dilution			Percent			Significant	
			Scale for			Lower #				Higher #			Difference			Trending	
			Trending			(%)				(%)			(95% CI)			Noteda	
Meropenem	Citrobacter koseri	72			0
(0)			1	71
(98.61)			99%
(91%, 100%)			Yes		
Meropenem	Enterobacter cloacae
(complex)	74			5
(6.76)			6	63
(85.14)			78%
(66%, 86%)			Yes		
Meropenem	Escherichia coli	5			2
(40)			0	3
(60)			20%
(-32%, 60%)			No		
Meropenem	Klebsiella oxytoca	27			0
(0)			0	27
(100)			100%
(82%, 100%)			Yes		
Meropenem	Klebsiella pneumoniae	106			14
(13.21)			15	77
(72.64)			59%
(47%, 69%)			Yes		
Meropenem	Morganella morganii	62			1
(1.61)			1	60
(96.77)			95%
(85%, 98%)			Yes		
Meropenem	Proteus mirabilis	66			1
(1.52)			3	62
(93.94)			92%
(82%, 96%)			Yes		
Meropenem	Proteus vulgaris	51			0
(0)			0	51
(100)			100%
(90%, 100%)			Yes		
Meropenem	Pseudomonas
aeruginosa	167			52
(31.14)			77	38
(22.75)			-8%
(-18%, 1%)			No		
Meropenem	Serratia marcescens	102			3
(2.94)			2	97
(95.1)			92%
(84%, 96%)			Yes		
Meropenem-
vaborbactam	Citrobacter freundii
(complex)	57			0
(0)			1	56
(98.25)			98%
(88%, 100%)			Yes		
Meropenem-
vaborbactam	Citrobacter koseri	48			0
(0)			0	48
(100)			100%
(90%, 100%)			Yes		
Meropenem-
vaborbactam	Enterobacter cloacae
(complex)	52			0
(0)			1	51
(98.08)			98%
(87%, 100%)			Yes		
Meropenem-
vaborbactam	Escherichia coli	29			4
(13.79)			0	25
(86.21)			72%
(49%, 84%)			Yes		
Meropenem-
vaborbactam	Klebsiella aerogenes	50			0
(0)			1	49
(98)			98%
(87%, 100%)			Yes		
Meropenem-
vaborbactam	Klebsiella oxytoca	47			0
(0)			0	47
(100)			100%
(89%, 100%)			Yes		
Meropenem-
vaborbactam	Klebsiella pneumoniae	100			4
(4)			6	90
(90)			86%
(77%, 91%)			Yes		
Meropenem-
vaborbactam	Morganella morganii	64			0
(0)			35	29
(45.31)			45%
(32%, 57%)			Yes		
Meropenem-
vaborbactam	Serratia marcescens	60			0
(0)			1	59
(98.33)			98%
(89%, 100%)			Yes		
Minocycline	Escherichia coli	198			43
(21.72)			83	72
(36.36)			15%
(6%, 23%)			No		
Minocycline	Klebsiella aerogenes	52			17
(32.69)			30	5
(9.62)			-23%
(-38%, -7%)			No		
Minocycline	Klebsiella oxytoca	27			3
(11.11)			15	9
(33.33)			22%
(0%, 42%)			No		
Minocycline	Klebsiella pneumoniae	126			38
(30.16)			66	22
(17.46)			-13%
(-23%, -2%)			No		
Piperacillin-
tazobactam	Citrobacter koseri	75			15
(20)			49	11
(14.67)			-5%
(-17%, 7%)			No		
Piperacillin-
tazobactam	Escherichia coli	175			47
(26.86)			91	37
(21.14)			-6%
(-15%, 3%)			No		
Piperacillin-
tazobactam	Klebsiella oxytoca	27			11
(40.74)			15	1
(3.7)			-37%
(-56%, -15%)			Yes		
Piperacillin-
tazobactam	Klebsiella pneumoniae	132			80
(60.61)			37	15
(11.36)			-49%
(-58%, -38%)			Yes		

[Table 2 on page 39]
Exact
# (%)

--- Page 40 ---
Total On ≥ 1 Dilution ≥ 1 Dilution Percent Significant
Exact
Drug Organism Name Scale for Lower # Higher # Difference Trending
# (%)
Trending (%) (%) (95% CI) Noteda
Piperacillin- 12 36 38%
Morganella morganii 64 16 Yes
tazobactam (18.75) (56.25) (21%, 51%)
Piperacillin- 15 43 40%
Proteus mirabilis 70 12 Yes
tazobactam (21.43) (61.43) (24%, 53%)
Piperacillin- 0 34 68%
Proteus vulgaris 50 16 Yes
tazobactam (0) (68) (52%, 79%)
Pseudomonas 25 46 13%
Tobramycin 162 91 No
aeruginosa (15.43) (28.4) (4%, 22%)
Trimethoprim Enterobacter cloacae 17 44 38%
72 11 Yes
Sulfamethoxazole (complex) (23.61) (61.11) (22%, 51%)
Trimethoprim 2 29 84%
Klebsiella aerogenes 32 1 Yes
Sulfamethoxazole (6.25) (90.62) (64%, 92%)
Trimethoprim 0 22 100%
Klebsiella oxytoca 22 0 Yes
Sulfamethoxazole (0) (100) (79%, 100%)
Trimethoprim 6 55 74%
Klebsiella pneumoniae 66 5 Yes
Sulfamethoxazole (9.09) (83.33) (60%, 83%)
aSignificant trending as determined by a statistically significant confidence interval.
Characterized Resistance Mechanisms. The molecular characteristics of the challenge
isolates evaluated in the clinical study, provided by the FDA-CDC AR Isolate Bank, are
provided in Table 8.
K211748 - Page 40 of 43

[Table 1 on page 40]
Drug	Organism Name		Total On			≥ 1 Dilution		Exact
# (%)		≥ 1 Dilution			Percent			Significant	
			Scale for			Lower #				Higher #			Difference			Trending	
			Trending			(%)				(%)			(95% CI)			Noteda	
Piperacillin-
tazobactam	Morganella morganii	64			12
(18.75)			16	36
(56.25)			38%
(21%, 51%)			Yes		
Piperacillin-
tazobactam	Proteus mirabilis	70			15
(21.43)			12	43
(61.43)			40%
(24%, 53%)			Yes		
Piperacillin-
tazobactam	Proteus vulgaris	50			0
(0)			16	34
(68)			68%
(52%, 79%)			Yes		
Tobramycin	Pseudomonas
aeruginosa	162			25
(15.43)			91	46
(28.4)			13%
(4%, 22%)			No		
Trimethoprim
Sulfamethoxazole	Enterobacter cloacae
(complex)	72			17
(23.61)			11	44
(61.11)			38%
(22%, 51%)			Yes		
Trimethoprim
Sulfamethoxazole	Klebsiella aerogenes	32			2
(6.25)			1	29
(90.62)			84%
(64%, 92%)			Yes		
Trimethoprim
Sulfamethoxazole	Klebsiella oxytoca	22			0
(0)			0	22
(100)			100%
(79%, 100%)			Yes		
Trimethoprim
Sulfamethoxazole	Klebsiella pneumoniae	66			6
(9.09)			5	55
(83.33)			74%
(60%, 83%)			Yes		

[Table 2 on page 40]
Exact
# (%)

--- Page 41 ---
Table 8. Molecular characteristics of resistance markers in challenge isolates.
Antimicrobial Drug-Class Specific Truncated Porins
Amikacin aac(3)-IIa, aac(3)-Id, aac(6')-Il, aadA6, ant(2")-la, aph(3')-Ic, aph(3')-VIa, armA, strA, strB,aac(3)-Ia
CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, CTX-M-2, KPC-2, KPC-3, NDM-1, NDM-5, NDM-7, OXA-1,
Amoxicillin-
OXA-10, OXA-181, OXA-2, OXA-232, OXA-9, SHV-1, SHV-100, SHV-11, SHV-12, SHV-26, SHV-28, SHV- OmpC2, OmpK35, OmpK36, OmpF
Clavulanate
30, SHV-83, TEM-1A, TEM-1B, VIM-1, VIM-27
Ampicillin CMY-42, CTX-M-15, KPC-3, NDM-5, OXA-1, OXA-9, SHV-12, TEM-1A, TEM-1B
Ampicillin- CMY-4, CMY-6, CMY-42, CTX-M-2, CTX-M-15, KPC-3, NDM-1, NDM-5, NDM-7, OXA-1, OXA-10, OXA-
OmpF, OmpK35, OmpK36
Sulbactam 2, OXA-23, OXA-232, OXA-69, OXA-9, SHV-11, SHV-12, SHV-83, TEM-1A, TEM-1B, TEM-1D, VIM-27
carB-2, CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, KPC-2, KPC-3, NDM-1, NDM-5, OXA-1, OXA-2,
Aztreonam OmpF
OXA-10, OXA-50, OXA-9, SHV-12, TEM-1A, TEM-1B, VEB-1, VEB-5
CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, CTX-M-2, KPC-2, NDM-1, OXA-1, OXA-10, OXA-181, OXA-
Cefazolin OmpF, OmpK35, OmpK36
232, OXA-9, SHV-1, SHV-11, SHV-12, SHV-154, SHV-26, SHV-83, TEM-1A, TEM-1B, VEB-5
ACT-7, ACT-16, carB-2, CMY-42, CMY-6, CTX-M-15, CTX-M-2, IMP-1, KPC-2, KPC-6, NDM-1, OXA-1,
Cefepime OXA-10, OXA-181, OXA-2, OXA-232, OXA-50, OXA-9, PAO, SHV-1, SHV-100, SHV-11, SHV-12, SHV-26, OmpC2, OmpK35, OmpK36, OmpF
SHV-28, SHV-83, TEM-1A, TEM-1B, VEB-1, VEB-5, VIM-1
CMY-4, CMY-42, CMY-6, CTX-M-15, CTX-M-2, KPC-2, NDM-1, NDM-7, OXA-1, OXA-10, OXA-181, OXA-
Cefoxitin OmpC2, OmpK35, OmpK36, OmpF
2, OXA-232, OXA-9, SHV-1, SHV-100, SHV-11, SHV-12, SHV-28, SHV-83, TEM-1A, TEM-1B
ACT-7, ACT-16, ADC-25, CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, CTX-M-2, IMP-1, IMP-8, KPC-2,
KPC-3, KPC-6, NDM-1, NDM-5, NDM-7, OXA-1, OXA-10, OXA-181, OXA-2, OXA-23, OXA-232, OXA-24,
Ceftazidime OXA-50, OXA-65, OXA-66, OXA-69, OXA-71, OXA-9, OXA-94, PAO, SHV-1, SHV-100, SHV-11, SHV-12, OmpC2, OmpF, OmpK35, OmpK36
SHV-26, SHV-28, SHV-30, SHV-5, SHV-83, SME-3, TEM-1A, TEM-1B, TEM-1D, VEB-1, VEB-5, VIM-1,
VIM-2, VIM-27
ACT-7, CMY-4, CMY-42, CMY-6, CTX-M-15, IMP-1, IMP-8, NDM-1, NDM-5, NDM-7, OXA-1, OXA-10,
Ceftazidime-
OXA-101, OXA-181, OXA-2, OXA-232, OXA-50, OXA-9, PAO, SHV-100, SHV-11, SHV-12, SHV-26, SHV- OmpC2, OmpF, OmpK35
Avibactam
28, SHV-30, SME-3, TEM-1A, TEM-1B, VEB-1, VIM-1, VIM-2, VIM-2
ACT-7, CMY-2, CMY-4, CMY-42, CTX-M-15, CTX-M-2, KPC-2, NDM-1, NDM-7, OXA-1, OXA-10, OXA-
Ceftriaxone 181, OXA-232, OXA-9, SHV-100, SHV-11, SHV-12, SHV-26, SHV-28, SHV-83, SME-3, TEM-1A, TEM-1B, OmpC2, OmpK35, OmpK36, OmpF
VEB-5, VIM-27
Ciprofloxacin QnrB1, QnrB7, QnrS1, oqxA, oqxB,QnrB34 OmpC2, OmpK35, OmpK36, OmpF
Eravacycline tet(A), tet(D), tet(G), tet(R) OmpC2, OmpK35
ACT-16, ACT-7, CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, CTX-M-2, IMP-8, KPC-2, KPC-6, NDM-1,
Ertapenem NDM-5, NDM-7, OXA-1, OXA-10, OXA-181, OXA-2, OXA-232, OXA-9, SHV-1, SHV-100, SHV-11, SHV- OmpC2, OmpK35, OmpK36, OmpF
12, SHV-154, SHV-26, SHV-28, SHV-83, SME-3, TEM-1A, TEM-1B, VEB-5, VIM-27
aac(3)-IIa, aac(3)-IId, aac(3)-Id, aac(6')-IIa, aac(6')-IIc, aac(6')-Ian, aac(6')-Ib-cr, aac(6')-Il, aadA1,
Gentamicin aadA2, aadA5, aadA6, aadB, ant(2")-la, aph(3')-Ia, aph(3')-Ib, aph(3')-VI, aph(3')-XV, aph(6)-Id, armA, OmpC2, OmpK35, OmpK36, OmpF
rmtB, rmtC, rmtG, strA, strB,aac(6')-Ib
Imipenem ADC-25, OXA-23, OXA-24, OXA-65, OXA-66, OXA-69, OXA-71, SHV-5, TEM-1D
BCR1, CMY-4, CMY-42, CMY-6, CTX-M-15, IMP-1, KPC-2, KPC-3, NDM-1, NDM-5, NDM-7, OXA-1,
Imipenem-
OXA-10, OXA-181, OXA-2, OXA-232, OXA-50, OXA-9, PAO, SHV-1, SHV-100, SHV-11, SHV-12, SHV-26, OmpC2, OmpK35, OmpK36, OmpF
Relebactam
SHV-28, SHV-30, TEM-1A, TEM-1B, VIM-1, VIM-2, VIM-27
Levofloxacin QnrB1, QnrB34, QnrB7, QnrS1, oqxA, oqxB,norA OmpC2, OmpF, OmpK35, OmpK36
ACT-7, ADC-25, BCR1, carB-2, CMY-4, CMY-42, CMY-6, CTX-M-15, IMP-1, KPC-2, NDM-1, NDM-5,
NDM-7, OXA-1, OXA-10, OXA-101, OXA-181, OXA-2, OXA-23, OXA-232, OXA-24, OXA-50, OXA-65,
Meropenem OmpC2, OmpF, OmpK35
OXA-66, OXA-69, OXA-71, OXA-9, OXA-94, PAO, SHV-1, SHV-100, SHV-11, SHV-12, SHV-28, SHV-5,
SME-3, TEM-1A, TEM-1B, TEM-1D, VEB-1, VIM-2, VIM-27
Meropenem- CMY-4, CMY-42, CMY-6, CTX-M-15, KPC-2, NDM-1, NDM-5, NDM-7, OXA-1, OXA-10, OXA-181, OXA-
OmpC2, OmpK35, OmpK36, OmpF
Vaborbactam 2, OXA-232, OXA-9, SHV-1, SHV-100, SHV-11, SHV-12, SHV-28, TEM-1A, TEM-1B, VIM-27
Minocycline tet(A), tet(A), tet(D), tet(K), tet(R),tet(38) OmpK35
ACT-7, ACT-16, ADC-25, carB-2, CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, KPC-2, KPC-3, KPC-6,
Piperacillin- NDM-1, NDM-5, NDM-7, OXA-1, OXA-10, OXA-181, OXA-2, OXA-23, OXA-232, OXA-24, OXA-50, OXA-
OmpC2, OmpF, OmpK35
Tazobactam 65, OXA-69, OXA-71, OXA-9, OXA-94, SHV-1, SHV-100, SHV-11, SHV-12, SHV-26, SHV-28, SHV-5, TEM-
1A, TEM-1B, TEM-1D, VIM-27
Tobramycin aac(6')-Il, aadA1, aadA6, aadB, ant(2")-la, strA, strB,aac(3)-Id
Trimethoprim-
Sulfamethoxazole
dfrA1, dfrA12, dfrA14, dfrA15, dfrA17, dfrA29, dfrB5 OmpC2, OmpK35, OmpK36, OmpF
Non-indicated species. As required under 511A(b)(2)(C)(ii)(I) of the Federal Food, Drug and
Cosmetic Act, the following statement is included in the Precautions section of the device
labeling to address testing and reporting of non-indicated species:
Per the FDA-Recognized Susceptibility Test Interpretive Criteria Website, the safety and
efficacy of antimicrobial drugs, for which antimicrobial susceptibility is tested by this
AST device, may or may not have been established in adequate and well-controlled
clinical trials for treating infections due to microorganisms outside of those found in the
indications and usage in the drug label. The clinical significance of susceptibility
information in those instances is unknown. The approved labeling for specific
antimicrobial drugs provides the uses for which the antimicrobial drug is approved.
2. Matrix Comparison:
Not applicable.
K211748 - Page 41 of 43

[Table 1 on page 41]
Antimicrobial	Drug-Class Specific	Truncated Porins
Amikacin	aac(3)-IIa, aac(3)-Id, aac(6')-Il, aadA6, ant(2")-la, aph(3')-Ic, aph(3')-VIa, armA, strA, strB,aac(3)-Ia	
Amoxicillin-
Clavulanate	CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, CTX-M-2, KPC-2, KPC-3, NDM-1, NDM-5, NDM-7, OXA-1,
OXA-10, OXA-181, OXA-2, OXA-232, OXA-9, SHV-1, SHV-100, SHV-11, SHV-12, SHV-26, SHV-28, SHV-
30, SHV-83, TEM-1A, TEM-1B, VIM-1, VIM-27	OmpC2, OmpK35, OmpK36, OmpF
Ampicillin	CMY-42, CTX-M-15, KPC-3, NDM-5, OXA-1, OXA-9, SHV-12, TEM-1A, TEM-1B	
Ampicillin-
Sulbactam	CMY-4, CMY-6, CMY-42, CTX-M-2, CTX-M-15, KPC-3, NDM-1, NDM-5, NDM-7, OXA-1, OXA-10, OXA-
2, OXA-23, OXA-232, OXA-69, OXA-9, SHV-11, SHV-12, SHV-83, TEM-1A, TEM-1B, TEM-1D, VIM-27	OmpF, OmpK35, OmpK36
Aztreonam	carB-2, CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, KPC-2, KPC-3, NDM-1, NDM-5, OXA-1, OXA-2,
OXA-10, OXA-50, OXA-9, SHV-12, TEM-1A, TEM-1B, VEB-1, VEB-5	OmpF
Cefazolin	CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, CTX-M-2, KPC-2, NDM-1, OXA-1, OXA-10, OXA-181, OXA-
232, OXA-9, SHV-1, SHV-11, SHV-12, SHV-154, SHV-26, SHV-83, TEM-1A, TEM-1B, VEB-5	OmpF, OmpK35, OmpK36
Cefepime	ACT-7, ACT-16, carB-2, CMY-42, CMY-6, CTX-M-15, CTX-M-2, IMP-1, KPC-2, KPC-6, NDM-1, OXA-1,
OXA-10, OXA-181, OXA-2, OXA-232, OXA-50, OXA-9, PAO, SHV-1, SHV-100, SHV-11, SHV-12, SHV-26,
SHV-28, SHV-83, TEM-1A, TEM-1B, VEB-1, VEB-5, VIM-1	OmpC2, OmpK35, OmpK36, OmpF
Cefoxitin	CMY-4, CMY-42, CMY-6, CTX-M-15, CTX-M-2, KPC-2, NDM-1, NDM-7, OXA-1, OXA-10, OXA-181, OXA-
2, OXA-232, OXA-9, SHV-1, SHV-100, SHV-11, SHV-12, SHV-28, SHV-83, TEM-1A, TEM-1B	OmpC2, OmpK35, OmpK36, OmpF
Ceftazidime	ACT-7, ACT-16, ADC-25, CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, CTX-M-2, IMP-1, IMP-8, KPC-2,
KPC-3, KPC-6, NDM-1, NDM-5, NDM-7, OXA-1, OXA-10, OXA-181, OXA-2, OXA-23, OXA-232, OXA-24,
OXA-50, OXA-65, OXA-66, OXA-69, OXA-71, OXA-9, OXA-94, PAO, SHV-1, SHV-100, SHV-11, SHV-12,
SHV-26, SHV-28, SHV-30, SHV-5, SHV-83, SME-3, TEM-1A, TEM-1B, TEM-1D, VEB-1, VEB-5, VIM-1,
VIM-2, VIM-27	OmpC2, OmpF, OmpK35, OmpK36
Ceftazidime-
Avibactam	ACT-7, CMY-4, CMY-42, CMY-6, CTX-M-15, IMP-1, IMP-8, NDM-1, NDM-5, NDM-7, OXA-1, OXA-10,
OXA-101, OXA-181, OXA-2, OXA-232, OXA-50, OXA-9, PAO, SHV-100, SHV-11, SHV-12, SHV-26, SHV-
28, SHV-30, SME-3, TEM-1A, TEM-1B, VEB-1, VIM-1, VIM-2, VIM-2	OmpC2, OmpF, OmpK35
Ceftriaxone	ACT-7, CMY-2, CMY-4, CMY-42, CTX-M-15, CTX-M-2, KPC-2, NDM-1, NDM-7, OXA-1, OXA-10, OXA-
181, OXA-232, OXA-9, SHV-100, SHV-11, SHV-12, SHV-26, SHV-28, SHV-83, SME-3, TEM-1A, TEM-1B,
VEB-5, VIM-27	OmpC2, OmpK35, OmpK36, OmpF
Ciprofloxacin	QnrB1, QnrB7, QnrS1, oqxA, oqxB,QnrB34	OmpC2, OmpK35, OmpK36, OmpF
Eravacycline	tet(A), tet(D), tet(G), tet(R)	OmpC2, OmpK35
Ertapenem	ACT-16, ACT-7, CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, CTX-M-2, IMP-8, KPC-2, KPC-6, NDM-1,
NDM-5, NDM-7, OXA-1, OXA-10, OXA-181, OXA-2, OXA-232, OXA-9, SHV-1, SHV-100, SHV-11, SHV-
12, SHV-154, SHV-26, SHV-28, SHV-83, SME-3, TEM-1A, TEM-1B, VEB-5, VIM-27	OmpC2, OmpK35, OmpK36, OmpF
Gentamicin	aac(3)-IIa, aac(3)-IId, aac(3)-Id, aac(6')-IIa, aac(6')-IIc, aac(6')-Ian, aac(6')-Ib-cr, aac(6')-Il, aadA1,
aadA2, aadA5, aadA6, aadB, ant(2")-la, aph(3')-Ia, aph(3')-Ib, aph(3')-VI, aph(3')-XV, aph(6)-Id, armA,
rmtB, rmtC, rmtG, strA, strB,aac(6')-Ib	OmpC2, OmpK35, OmpK36, OmpF
Imipenem	ADC-25, OXA-23, OXA-24, OXA-65, OXA-66, OXA-69, OXA-71, SHV-5, TEM-1D	
Imipenem-
Relebactam	BCR1, CMY-4, CMY-42, CMY-6, CTX-M-15, IMP-1, KPC-2, KPC-3, NDM-1, NDM-5, NDM-7, OXA-1,
OXA-10, OXA-181, OXA-2, OXA-232, OXA-50, OXA-9, PAO, SHV-1, SHV-100, SHV-11, SHV-12, SHV-26,
SHV-28, SHV-30, TEM-1A, TEM-1B, VIM-1, VIM-2, VIM-27	OmpC2, OmpK35, OmpK36, OmpF
Levofloxacin	QnrB1, QnrB34, QnrB7, QnrS1, oqxA, oqxB,norA	OmpC2, OmpF, OmpK35, OmpK36
Meropenem	ACT-7, ADC-25, BCR1, carB-2, CMY-4, CMY-42, CMY-6, CTX-M-15, IMP-1, KPC-2, NDM-1, NDM-5,
NDM-7, OXA-1, OXA-10, OXA-101, OXA-181, OXA-2, OXA-23, OXA-232, OXA-24, OXA-50, OXA-65,
OXA-66, OXA-69, OXA-71, OXA-9, OXA-94, PAO, SHV-1, SHV-100, SHV-11, SHV-12, SHV-28, SHV-5,
SME-3, TEM-1A, TEM-1B, TEM-1D, VEB-1, VIM-2, VIM-27	OmpC2, OmpF, OmpK35
Meropenem-
Vaborbactam	CMY-4, CMY-42, CMY-6, CTX-M-15, KPC-2, NDM-1, NDM-5, NDM-7, OXA-1, OXA-10, OXA-181, OXA-
2, OXA-232, OXA-9, SHV-1, SHV-100, SHV-11, SHV-12, SHV-28, TEM-1A, TEM-1B, VIM-27	OmpC2, OmpK35, OmpK36, OmpF
Minocycline	tet(A), tet(A), tet(D), tet(K), tet(R),tet(38)	OmpK35
Piperacillin-
Tazobactam	ACT-7, ACT-16, ADC-25, carB-2, CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, KPC-2, KPC-3, KPC-6,
NDM-1, NDM-5, NDM-7, OXA-1, OXA-10, OXA-181, OXA-2, OXA-23, OXA-232, OXA-24, OXA-50, OXA-
65, OXA-69, OXA-71, OXA-9, OXA-94, SHV-1, SHV-100, SHV-11, SHV-12, SHV-26, SHV-28, SHV-5, TEM-
1A, TEM-1B, TEM-1D, VIM-27	OmpC2, OmpF, OmpK35
Tobramycin	aac(6')-Il, aadA1, aadA6, aadB, ant(2")-la, strA, strB,aac(3)-Id	
Trimethoprim-
Sulfamethoxazole	dfrA1, dfrA12, dfrA14, dfrA15, dfrA17, dfrA29, dfrB5	OmpC2, OmpK35, OmpK36, OmpF

--- Page 42 ---
C Clinical Studies:
1. Clinical Sensitivity:
Not applicable.
2. Clinical Specificity:
Not applicable.
3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):
Not applicable.
D Clinical Cut-Off:
Not applicable.
E Expected Values/Reference Range:
The FDA-recognized/approved susceptibility test interpretive criteria (breakpoints) for the
antimicrobials evaluated with the Selux AST System are listed in the table below.
Table 9. FDA-Approved or Recognized Interpretive Criteria1
Minimum Inhibitory
Antimicrobial Organism Concentration (μg/mL)
S I R
Amikacin Pseudomonas aeruginosa ≤16 32 ≥64
Amoxicillin-Clavulanate Enterobacterales ≤8 16 ≥32
Ampicillin Enterobacterales ≤8 16 ≥32
Acinetobacter spp.,
Ampicillin-sulbactam ≤8 16 ≥32
Enterobacterales
Aztreonam Enterobacterales ≤4 8 ≥16
Cefazolin Enterobacterales ≤1 2 ≥4
Cefepime Enterobacterales ≤2 4-8 ≥16
Cefoxitin Enterobacterales ≤4 8 ≥16
Ceftazidime Enterobacterales ≤4 8 ≥16
Enterobacterales,
Ceftazidime-Avibactam ≤8 - ≥16
Pseudomonas aeruginosa
Ceftriaxone Enterobacterales ≤1 2 ≥4
Ciprofloxacin Enterobacterales ≤0.25 0.5 ≥1
Ciprofloxacin Pseudomonas aeruginosa ≤0.5 1 ≥2
Eravacycline Enterobacterales ≤0.5 - -
Ertapenem Enterobacterales ≤0.5 1 ≥2
Enterobacterales,
Gentamicin ≤4 8 ≥16
Pseudomonas aeruginosa
Imipenem-Relebactam Enterobacterales ≤1 2 ≥4
Imipenem-Relebactam Pseudomonas aeruginosa ≤2 4 ≥8
K211748 - Page 42 of 43

[Table 1 on page 42]
Antimicrobial	Organism		Minimum Inhibitory							
			Concentration (μg/mL)							
			S			I			R	
Amikacin	Pseudomonas aeruginosa	≤16			32			≥64		
Amoxicillin-Clavulanate	Enterobacterales	≤8			16			≥32		
Ampicillin	Enterobacterales	≤8			16			≥32		
Ampicillin-sulbactam	Acinetobacter spp.,
Enterobacterales	≤8			16			≥32		
Aztreonam	Enterobacterales	≤4			8			≥16		
Cefazolin	Enterobacterales	≤1			2			≥4		
Cefepime	Enterobacterales	≤2			4-8			≥16		
Cefoxitin	Enterobacterales	≤4			8			≥16		
Ceftazidime	Enterobacterales	≤4			8			≥16		
Ceftazidime-Avibactam	Enterobacterales,
Pseudomonas aeruginosa	≤8			-			≥16		
Ceftriaxone	Enterobacterales	≤1			2			≥4		
Ciprofloxacin	Enterobacterales	≤0.25			0.5			≥1		
Ciprofloxacin	Pseudomonas aeruginosa	≤0.5			1			≥2		
Eravacycline	Enterobacterales	≤0.5			-			-		
Ertapenem	Enterobacterales	≤0.5			1			≥2		
Gentamicin	Enterobacterales,
Pseudomonas aeruginosa	≤4			8			≥16		
Imipenem-Relebactam	Enterobacterales	≤1			2			≥4		
Imipenem-Relebactam	Pseudomonas aeruginosa	≤2			4			≥8		

--- Page 43 ---
Minimum Inhibitory
Antimicrobial Organism Concentration (μg/mL)
S I R
Levofloxacin Enterobacterales ≤0.5 1 ≥2
Meropenem Enterobacterales ≤1 2 ≥4
Meropenem Pseudomonas aeruginosa ≤2 4 ≥8
Meropenem-
Enterobacterales ≤4 8 ≥16
Vaborbactam
Minocycline Enterobacterales ≤4 8 ≥16
Piperacillin-tazobactam Pseudomonas aeruginosa ≤16 32-64 ≥128
Tobramycin Pseudomonas aeruginosa ≤4 8 ≥16
Trimethoprim-
Enterobacterales ≤2 - ≥4
Sulfamethoxazole
S = Susceptible; I = Intermediate; R = Resistant; - = no interpretive criterion recognized
1 According to the FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria Website
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm4 10971.htm
VIII Proposed Labeling:
The labeling supports the finding of substantial equivalence for this device.
IX Conclusion:
The submitted information in this premarket notification is complete and supports a substantial
equivalence decision.
To support the implementation of changes to FDA-recognized susceptibility test interpretive
criteria (i.e., breakpoints), this submission included a breakpoint change protocol that was
reviewed and accepted by FDA. This protocol addresses future revisions to device labeling in
response to breakpoint changes that are recognized on the FDA STIC webpage
(https://www.fda.gov/drugs/development-resources/fda-recognized-antimicrobial-susceptibility-
test-interpretive-criteria). The protocol outlined the specific procedures and acceptance criteria
that Selux intends to use to evaluate the Selux AST System when revised breakpoints for the
following antimicrobials are published on the FDA STIC webpage: Amikacin, Amoxicillin-
Clavulanate, Ampicillin, Ampicillin-sulbactam, Aztreonam, Cefazolin, Cefepime, Cefoxitin,
Ceftazidime, Ceftazidime-Avibactam, Ceftriaxone, Ciprofloxacin, Eravacycline, Ertapenem,
Gentamicin, Imipenem-Relebactam, Levofloxacin, Meropenem, Meropenem-Vaborbactam,
Minocycline, Piperacillin-Tazobactam, Tobramycin, Trimethoprim-Sulfamethoxazole.
The breakpoint change protocol included with the submission indicated that if specific criteria
are met, Selux will update the device label to include (1) the new breakpoints, (2) an updated
performance section after re-evaluation of data in this premarket notification with the new
breakpoints, and (3) any new limitations as determined by their evaluation.
K211748 - Page 43 of 43

[Table 1 on page 43]
Antimicrobial	Organism		Minimum Inhibitory							
			Concentration (μg/mL)							
			S			I			R	
Levofloxacin	Enterobacterales	≤0.5			1			≥2		
Meropenem	Enterobacterales	≤1			2			≥4		
Meropenem	Pseudomonas aeruginosa	≤2			4			≥8		
Meropenem-
Vaborbactam	Enterobacterales	≤4			8			≥16		
Minocycline	Enterobacterales	≤4			8			≥16		
Piperacillin-tazobactam	Pseudomonas aeruginosa	≤16			32-64			≥128		
Tobramycin	Pseudomonas aeruginosa	≤4			8			≥16		
Trimethoprim-
Sulfamethoxazole	Enterobacterales	≤2			-			≥4		